





PULMONARY IMMUNE ENVIRONMENT DETERMINES 













A dissertation submitted to Johns Hopkins University in conformity with the requirements 









© 2015 Nathachit Limjunyawong 





The lung is a complex well-designed organ providing a large surface area for exchanging gas 
to provide oxygen to the body and eliminate carbon dioxide from the circulation. Because of 
its exposure to the environment, it is required to have active immunologic defense 
mechanisms to remove hazardous agents and maintain homeostasis. However, an aberration 
in this pulmonary immune environment can lead to several pathologic developments. 
Emphysema is characterized by progressive loss of alveolar surface area with a permanent 
airspace enlargement, and it is one of the major public health issues leading to serious 
morbidity and mortality. Disparities in individual immune responses interact with host 
genetic predispositions and environmental factors in a complex manner that impacts the 
susceptibility to develop emphysema. The overall goal of this thesis was to study 
immunological factors that are involved in determining the susceptibility to develop 
emphysema using a simplified elastase-induced murine model. First, we determined the 
susceptibility to develop emphysema in two common strains of mice. We found BALB/cJ 
mice to be much more sensitive to exogenous elastase compared to C57BL/6J mice. Based 
on gene expression analysis, we found different immunologic mechanisms that might 
underlie the differential progression of elastase-induced emphysema in these two mouse 
strains. In addition, MMP-producing macrophages (but not neutrophils or lymphocytes) 
were identified as the critical cells that mediate the extracellular matrix degradation in 
emphysema. Furthermore, we use genetically engineered mice to study the importance of 
several cytokine signaling pathways and transcription factors. We found important roles of 
IL-17A, IFN-, IL-33/ST2/MyD88, STAT6 and STAT3 in activating or modulating the 
macrophages to become more destructive. Lastly, we also showed that recent viral infections 
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could impact on the severity of emphysema following the acute elastase injury. In 
conclusion, the intricacy of genetic and environmental factors together influence immune 
responses in the lungs to determine the susceptibility to develop emphysema. This 
knowledge provides new insights into the cellular and molecular mechanisms that may be 
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The lung is a complex organ, comprised of a number of different cell types that form the site 
for gas exchange between oxygen (O2) in the air and carbon dioxide (CO2) in the circulation. 
This pivotal function provides O2 for cellular respiration, removes toxic CO2 and maintains 
whole body homeostasis.  
 
Due to the structure and function of the lung, an extensive area of this organ has to be in 
direct contact with the external environment, which subjects the conducting and respiratory 
surfaces to continuous exposure to a broad variety of particles, toxicants and infectious 
agents in the inhaled air. To limit the harmful consequences from these foreign materials, 
and to maintain the integrity of gas-exchange, the lung needs a tightly regulated defense 
mechanism, which is mainly derived from the pulmonary innate and adaptive immune 
system. Aberrant control of the immune system in response to these agents in genetically 
susceptible individuals is widely considered a major contributor to the pathogenesis of many 
pulmonary diseases, including chronic obstructive pulmonary diseases (COPD) characterized 
by bronchitis and emphysema. The basis of the regulation of pulmonary immunity, and the 
determination of susceptibility to the development of disease, are key to understanding the 
underlying mechanisms of disease pathogenesis and to develop novel treatments and 
interventions. 
  
The focus of the research presented here is to determine, using a mouse model, the 
immunological pathways responsible for susceptibility to the development and progression 
of emphysema. This study demonstrates that susceptibility to the development of severe 
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emphysema is dissimilar in different strains of mice. Furthermore, this susceptibility can be 
altered in different genetically modified mice, or by pre-exposure to microbial agents.  
 
This first chapter presents known basic background information on the structure and 
function of the respiratory system, human COPD and emphysema, animal models of 
emphysema, the assessments of emphysema in murine animals and the key questions on the 
disease which will be addressed in the remainder of this dissertation. 
 
1.2 Structure and Function of the Respiratory System 
The primary function of the mammalian respiratory system is to maintain the body’s 
homeostasis by conducting fresh oxygen-rich air to the alveoli and to facilitate the exchange 
of O2 and CO2 from erythrocytes. . To execute this exchange, air and blood must be brought 
into intimate contact. The function of the lung, as air conductor and gas exchanger, depends 
on its very complex structure. 
 
The airways and associated blood vessels are designed as tree-like structures, which branch 
in concert to reach into all regions of the lung parenchyma. The inspired air, after passing 
through the nasal passage or mouth, the pharynx, and the larynx (the upper airways), enters 
a series of dichotomous branching tracheobronchial tubular airways leading into the lungs 
(the lower airways). In humans, this branching airway tree begins with the trachea (the so-
called generation 0), bifurcating into bronchi (1st generation), bronchioles, terminal 
bronchioles, respiratory bronchioles, alveolar ducts, and alveolar sacs, in a total (on average) 




In human lungs, the number of branches doubles with each generation, to create 223 or 
about 8 million end branches [2]. In contrast, in the mouse, there is less airway branching, 
with only 13 - 17 generations, and no respiratory bronchioles [3].  
 
In humans, from the nose to the terminal bronchioles, the first 16 generations of airways do 
not participate in gas exchange. These generations form the conducting zone, constituting 
the anatomical dead space whose function is to filter, warm, moisten, and conduct the air 
into the deeper zone. The remaining 7 generations form the respiratory zone that contains 
the alveoli, which represent the smallest functional units of the lungs.  
 
The alveoli are surrounded by a dense pulmonary capillary network, fed by the pulmonary 
artery and drained by the pulmonary vein [4, 5]. This capillary network occupies about half 
the volume of the interalveolar septa, with a very thin wall between the air and blood [6].  In 
most areas of the respiratory zone, air and blood are separated only by the alveolar 
epithelium and the capillary endothelium - only about 0.5 m thick in humans, or one-
sixteenth the diameter of an erythrocyte. This narrow distance permits gas to diffuse 
between the air in the lungs and the erythrocytes in the capillaries (Fig. 1.1C-D). 
 
It is estimated that in the adult human being, there are 480 million alveoli, with a mean 
diameter of 200 m, (calculations derived from a direct, unbiased, point-counting 
stereological approach) [7]. These alveoli provide a total internal surface area of 25-70 m2, 
which is about the size of half a tennis court, or about 15-40 times greater than total body 
surface area (average of 1.7-1.9 m2) [8-10]. For mice, (adult 20-gram female C57BL/6), the 
mean alveolar number is estimated to be 2.3 million, which provide a total internal surface 
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area of 82.2 cm2 [11]. Alveolar number correlates closely with total lung volume, whereas 
alveolar size does not [7]. 
 
The wall of the alveolar membrane, the important site for gas exchange, consist of two types 
of epithelial cells. The primary cell type of the alveolar wall is thin, simple, squamous type I 
alveolar epithelial cells (type I pneumocytes), which have large cytoplasmic extensions 
that forms approximately 95% of the alveolar wall. Gas exchange occurs across the very 
large surface area formed by these type I pneumocytes, facilitated by their close apposition 
to the endothelial cells of the capillaries (Fig. 1.1D).  
 
Cuboidal type II alveolar cells (type II pneumocytes), also called septal cells, are 
interspersed among the type I alveolar epithelial cells. The type II cell represent about 60% 
of epithelial cells in the alveoli by number, even though they cover only 5% of alveolar 
surface area. Type II alveolar cells are recognized by abundant lipid-rich lamellar bodies in 
the cytoplasm and microvilli on the apical surfaces. The microvilli secrete interstitial fluid 
into the alveoli, thus moistening the surface between the cells and the air. This alveolar fluid 
contains pulmonary surfactant, a complex mixture of phospholipids and lipoproteins. The 
surfactant reduces the surface tension of alveolar fluid, thus decreasing the tendency of 
alveoli to collapse (atelectasis). Moreover, type II alveolar cells are also important in alveolar 
repair, being capable of both self-renewal, and of giving rise to type I cells through a process 
of transdifferentiation [12, 13], as well as several other physiologic activities [14, 15]. 
 
 
In addition to alveolar epithelial cells, there are underlying fibroblasts that produce 
extracellular matrix components including collagen, reticular and elastic fibers, which are the 
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main components of the basement membrane of the epithelium. The alveoli also contain a 
variety of other specialized cells, especially immune cells including macrophages, and a small 
number of dendritic cells, and lymphocytes (Fig. 1.2) [16, 17]. These cells are essential for 
pulmonary host defense and participate in both innate and adaptive immunity. During 
unhealthy states such as lung injury, inflammation or pulmonary infection, the amount, 
proportion and activation status of the immune cells can be markedly altered depending on 
the nature of the stimuli.  
 
At least three types of macrophages reside in the lung: (i) bronchial macrophages associated 
with the airway, (ii) alveolar macrophages or dust cells in the alveolar space, juxtaposed with 
type I or type II alveolar epithelial cells, and (iii) interstitial macrophages, in the interstitial 
space between the alveoli and the blood vessels. The macrophages function in the innate 
immune response, to clear fine dust particles, microorganisms, apoptotic cells and other 
debris from the lungs.  
 
Lung-resident dendritic cells, with many cellular projections, sample foreign antigens in the 
lumen of the alveoli and conducting airway, and initiate appropriate adaptive immune 
responses. Typically, dendritic cells that take up antigens in the lungs traffic to the lung-
draining lymph nodes (tracheobronchial) and activate B and T lymphocytes to respond to 
the challenge.  
 
These immune cells require very tight regulation through several mechanisms to balance 
between maintaining tissue homeostasis and responding to the harmful stimuli. A 
dysregulation of these responses can be dangerous, and is implicated in pathogenesis of 
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several common inflammatory lung diseases, including COPD, asthma, acute lung injury, 
and pneumonia. 
 
Although the best known function of respiratory system is its contribution to homeostasis 
by providing gas exchange, the respiratory system also plays a vital role in other functions 
such as regulating blood pH and body temperature, modulating blood pressure by secreting 

















Figure 1.1 Model and electron micrographs of human respiratory structure. (A) Model 
of airway branching hierarchy in human lung, (B) Scanning electron micrograph of terminal 
conducting airway which opens into alveoli, (C) Scanning electron micrograph showing thin 
alveolar barrier separating air and red blood cells in capillaries, (D) Transmission electron 
micrograph illustrating endothelial cell (EN) lining the capillary bounded by a type I alveolar 
epithelial cell (EP). Adapted by permission from Basel : EMH Swiss Medical Publishers Ltd.: 











Figure 1.2 Illustration showing structure of peripheral lung tissue and immune-
associated cells in the lungs. Reproduced with permission from Nature Publishing Group: 







1.3 Chronic Obstructive Pulmonary Disease (COPD) and Emphysema 
1.3.1 Public Health Significance 
Chronic obstructive pulmonary disease (COPD) leads to morbidity and mortality, and is 
a major public health problem, imposing a significant burden on society, the economy and 
health service resources throughout the world. The burden of COPD is anticipated to 
increase continually in the next decade, due to continued exposure to risk factors, and aging 
of the population. 
 
According to the World Health Organization (WHO), COPD became the 3rd leading cause 
of death globally in 2012, after only heart disease and cancer; (increased from the 4th leading 
cause of death globally in 2000) [18].  Currently COPD leads to 3 million fatalities per year in 
North America, which corresponds to 5% of all deaths [18]. Similarly, COPD was ranked as 
the 3rd leading cause of death in the US in 2011, according to the Centers for Disease 
Control and Prevention [19]. A further indicator of the public health importance of COPD 
is the years lost due to disability (YLD’s); globally, the rank for COPD has increased from 6th 
in 1990 to 5th in 2010, with COPD related disabilities affecting more than 60 million people 
[20]. In North America, the lifetime risk of physician-diagnosed COPD is estimated to be as 
high as 25% with elevated risk in the age range of 35-80 [21]. 
 
 The global spending on medicine for COPD, together with asthma, ranks the third highest 
(behind medicines for cancer and diabetes) [22, 23]. Costs are continually growing for 
managing this chronic disease among an ever larger patient population.  In 2010, the cost 
associated with COPD in the United States alone was estimated at US$50 billion, comprising 
$30 billion in direct health care costs (diagnosis, treatment, and rehabilitation), and $20 
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billion in indirect costs (the morbidity and mortality caused by the disease) [22]. In 2007 the 
market for COPD drugs was estimated to be valued at over US$5.5 billion worldwide [23]. 
However, there is still no effective treatment for COPD. None of the available drugs on the 
market can halt the decline in lung function, reduce the progression of the disease, or have 
substantial effect on exacerbations, which are the major cause of hospital admission of 
COPD patients [24]. 
 
1.3.2 Definition and Features 
COPD is an umbrella term used to describe a complex, heterogeneous and progressive, 
multi-systemic disease that develops in, and emanates from, the lungs. COPD is classically 
characterized by persistent airflow limitation measured during forced expiration by 
spirometry [25]. The disease is associated with an abnormal inflammatory responses in the 
lung, and is not completely reversible. The pathological characteristics underlying airflow 
limitation in COPD are: (i) an increase in the resistance of small airways due to chronic 
bronchitis or obstructive bronchiolitis (affecting the conducting airway), and (ii) an increase 
in lung compliance, or decrease in elastic recoil, due to emphysema (affecting the distal 
airway and respiratory zone) [25-27].  
 
Chronic bronchitis is defined clinically by a chronic cough that produces sputum for at least 
three months in each of two successive years, which often leads to fibrosis of the large 
conducting airway [28]. In contrast, emphysema is defined pathologically as progressive 
destruction of alveolar parenchymal wall, leading to a permanent enlargement of the 





The principal characteristic respiratory manifestations of COPD are long-lasting cough, 
sputum production, and breathlessness. The physiological manifestation of COPD is a 
restriction in airflow. The most reproducible and objective measurement of this airflow 
limitation is spirometry, which is extensively used for clinical diagnosis. This testing can be 
done by measuring the forced expiratory flow in one second (FEV1), and the forced 
expiratory volume (FVC). COPD is characterized by (i) a persistently low (< 80% of the 
predicted value) FEV1, and (ii) a low (< 70%) FEV1/FVC.  In COPD-mediated airflow 
limitation, low FEV1 and FEV1/FVC values are obtained despite the use of bronchodilator 
medication [30]. 
 
The most widely used classification of chronic obstructive lung disease is devised by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) [30, 31]. This classification 
uses FEV1 as the most important criterion by which to categorize the degree of COPD, and 
uses four levels: mild (I), moderate (II), severe (III), or very severe (IV) (Table 1.1). GOLD 
stage 0 refers to individual with cough, sputum and some history of exposure to risk factors 
for developing COPD, but without an abnormal FEV1 and FEV1/FVC ratio. 
 






0 at risk >70% 80% normal spirometry but with chronic symptoms 
(cough, sputum production) 
I mild <70% 80% with/without chronic symptoms 
II moderate <70% 50 up to <80 with/without chronic symptoms 
III severe <70% 30 up to <50 with/without chronic symptoms 
IV very severe <70% < 30 or
< 50 
FEV1 < 30 or 
FEV1 < 50 with the presence of respiratory 




Due to progressive course of the disease, COPD patients experience a gradual decline in 
lung function and health throughout their life [32]. The rate of this decline can be accelerated 
by smoking and aging [32]. While many patients seek health care attention only after 
substantial symptoms are present, most patients are diagnosed or treated for COPD in the 
early stage [33].  However, several recent studies show that COPD is commonly 
underdiagnosed, especially in the early, relatively asymptomatic stages [34-36]. Moreover, 
COPD is often associated with co-morbidities that may have an impact on prognosis 
[37].  In the United States, while more than 12.7 million adults have been diagnosed with 
COPD, there are an additional 24 million undiagnosed adults with impaired lung function 
consistent with COPD [38]. 
 
1.3.3 Risk Factors 
COPD is a preventable disease. The primary risk factor for COPD is cigarette smoke, 
including active, passive and second-hand exposure. Smoking and environmental tobacco 
exposure are the major causes of COPD deaths [39], accounting for more than 80 % of 
the risk of developing COPD [40, 41]. However, among individuals with the same 
smoking history, not all will develop COPD, suggesting that smoking behavior alone is 
not sufficient to explain all of the etiology of COPD.  
 
There is consistent epidemiological evidence that some non-smokers develop COPD 
[42]. Environmental risk factors, other than tobacco smoke, which are associated with the 
onset of COPD include indoor and outdoor air pollution, and occupational exposures 
(particularly to organic and inorganic dusts, and chemical agents). Differences in genetic 
predispositions remain important, but maternal smoking, respiratory infections (i.e. 
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pneumonitis), and other non-respiratory infections (including HIV) have also been linked 
to emphysema and COPD burden [43-46]. 
 
There is a strong, and ever growing, relationship between the increased prevalence of 
COPD and indoor pollution due to the use of biomass (such as woods, charcoal, crop 
waste, animal dung and coal) in cooking and heating, particularly in poorly ventilated 
spaces where there is a high amount of smoke produced [47-52]. For the year 2012, 
household air pollution caused by biomass fuel cooking was cited as causing 4.3 million 
deaths, which represent 22% of all deaths due to COPD [53]. This link between COPD 
and use of biomass fuel for cooking is highly relevant because of the large numbers of 
people affected. About 3 billion people worldwide are exposed to biomass fuel 
combustion, especially in low- and middle-income countries; thus the population at risk 
worldwide is very large [54] The numbers of biofuel users greatly exceeds the number of 
tobacco smokers, 3 billion versus 1 billion respectively.  
 
Genetic deficiency or mutation in some particular genes are also established etiologic 
factors for the development of COPD. For example, 1-2% of COPD patients carry 
homozygosity of the PiZ allele of the SERPINA1 gene (formerly known as Pi), a 
recessive trait common in Northern Europe [55-58]. This genetic condition results in a 
marked reduction in production of 1-antitrypsin (1-AT) [59-61].  1-AT, a serine 
protease inhibitor, is the major inhibitor of neutrophil elastase at steady state. Patients 
with an inherited deficiency in 1-AT have an elevated level of neutrophil elastase 
proteolytic activity in the pulmonary tissue, which leads to damage of the alveolar tissue 
and results in “genetic emphysema”.  
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The balance between proteases and anti-proteases in the lung is widely believe to be one 
of the common pathologic causes of emphysema, and will be further discussed in section 
1.4. Although a variety of other candidate gene loci have been linked to COPD [62-67], 
convincing evidence proving a genetic risk factor for COPD in humans has only been 
established for SERPINA1 gene.  Another potential risk factor is exposure to viral 
infections.  Many COPD exacerbations are associated with acute viral infections, and 
recovery from viral infections may also lead to increased sensitivity to other pathogenic 
triggers.  
 
Thus, the susceptibility to COPD likely results from a combination of multiple genetic 
and environmental factors. In this thesis, we employ an animal to provide insights into 
the enhanced susceptibility to emphysema due to both genetic background and to 
antecedent viral infection (Chapters 3 and 5). 
 
1.3.4 Pathogenesis of COPD/Emphysema 
Experimental and clinical studies have established that multiple types of cells and molecular 
mediators contribute to the complex pathogenesis of COPD/emphysema. However, there 
remain key gaps in our understanding of the connection between different events and 
mediators, the determinants of susceptibility, and identification of the final mediators that 
perpetuate tissue destruction in emphysema.  
 
The current paradigm holds that the pathophysiological changes in the COPD/emphysema 
lungs result from imbalance in four critical processes: (i) extracellular matrix proteolysis, (ii) 
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inflammation, (iii) oxidative stress, and (iv) cell death. Each processes is now reviewed in 
detail.  
 
1.3.4.1 Protease/antiprotease Imbalance and Extracellular Matrix Proteolysis 
The core definition of emphysema is the irreversible destruction of the alveolar wall. This 
damage has long been considered to be a consequence of proteolytic degradation due to 
either an abnormal increase in proteases, or a reduction in pulmonary antiproteases - 
proteins that protect the lung from local proteases [68]. Proteolytic degradation was 
proposed as a mechanism based on the occurrence of emphysema in humans who were 
deficient in alpha1-antitrypsin [61, 69] and on experimental animal models in which 
emphysema was induced by instillation of proteases (such as papain or elastase) into the lung 
[70, 71].  
 
The most important target of these proteolytic enzymes may be elastin in the connective 
tissue underlying the epithelium, since loss of lung elasticity is the common feature among 
COPD patients [72]. Desmosine, a cross-linking amino acid of elastin, and used as a 
biomarker for elastin degradation, is increased in the blood and urine of COPD patients, and 
its levels positively correlate with the severity of disease [73-76]. The major endogenous 
candidates accounting for this tissue degradation are neutrophil elastase (NE) and matrix 
metalloproteinases (MMPs).  
 
Neutrophil elastase (NE) is an abundant serine protease stored in azurophilic granules in the 
cytoplasm of the neutrophils, and expressed on the cell surface in response to cytokines [77]. 
The NE contributes to the regulation of immune responses by acting in combination with 
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oxygen radicals, to help degrade phagocytized microorganisms [78]. Once secreted in 
association with neutrophil extracellular traps (NETs), NE destroys virulence factors, kills 
bacteria, and facilitates the formation of NETs [79]. NE has a wide range of substrates, 
including most of the extracellular matrix proteins (i.e. elastin, Type III and IV collagens, 
fibronectin, laminin, and fibronectin). At homeostasis, NE can be inhibited by 1-AT, a 
serine proteinase inhibitor in the blood.  
 
Neutrophil elastase is considered to be the primary destructive enzyme in emphysema, 
because patients with inherited 1-AT deficiency develop pulmonary emphysema early in 
life. Evidence showing that NE (a normally occurring cognate proteinase) can cause 
emphysema was provided by animal models where human leukocyte elastase was instilled 
into the lungs of hamsters and dogs [80, 81]. Moreover, elastase was found to bind with 
connective tissue close to elastic fibers, but not with collagen in the damaged areas of the 
treated lungs [81]. This spatial association of NE with alveolar interstitial elastin in the 
emphysematous areas in the animal model was subsequently confirmed in humans [82]. 
Further evidence for a role for NE comes from the observation that in neutrophil-elastase-
null mice, the emphysema induced by chronic exposure to cigarette smoke is significantly 
less severe than in wild type mice [83]. Mice with reduced 1-AT also developed cigarette 
smoke-induced emphysema earlier than did wild-type mice [84, 85]. Although many studies 
have suggested neutrophil elastase as a therapeutic target for treating COPD/emphysema, 
and several neutrophil inhibitors have been developed and are in clinical trial [86-90], to date 




MMPs are a large groups of at least 28 zinc-dependent proteinases that can degrade a variety 
of matrix components, including collagen, laminin and elastin. The MMPs essentially 
function in tissue remodeling, repair, and development, as well as in inflammation. The 
MMP family can be categorized into six groups, based on substrate specificity, amino acid 
similarity and homology: (i) collagenases (MMP-1, -8, -13, -18), (ii) gelatinases (MMP-2, -9), 
(iii) stromelysins (MMP-3, -10, -11, -17), (iv) matrilysins (MMP-7, -26), (v) membrane-type 
MMPs (MT-MMPs, MMP-14, -15, -16, -17, -24, -25), and (vi) other MMPs [91].  
 
Multiple recent studies cite MMPs as the critical proteolytic enzymes involved in the 
pathogenesis of COPD (Table 1.2). There are increased levels of several MMPs in the blood 
and BAL from COPD patients. Among all MMPs, MMP-12 has been the most studied as a 
potential candidate protease associated with pulmonary emphysema, and as a potential target 
for COPD treatment.  
 
The increased level of MMP-12 in human patients with COPD in some clinical studies [92-
94], is supported by the up-regulation of MMP-12 expression in many experimental animal 
models of emphysema including cigarette smoke [95-103], elastase [104-106], ozone [107]  
and helminth infection [108]. Additionally, MMP-12 knockout mice are protected from 
developing emphysema after chronic exposure to cigarette smoke [102]. Orally bioavailable 
synthetic MMP-9/12 inhibitors decreased inflammation and alveolar destruction in tobacco-
exposed guinea pigs [109].  
 
Although strong data from animal models consistently have supported the role of MMP-12 
in emphysema, data from human patients is inconsistent. Some studies have failed to detect 
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elevation of MMP-12 in alveolar macrophages or lung tissue from patients with 
COPD/emphysema, or find a correlation between the level of MMP-12 with severity of 
disease [110-112]. Another point that should be taken into the consideration is that MMP-12 
also plays an important role in removing microbes from the respiratory tract, and mice 
deficient in MMP-12 have an increased burden of bacterial infection and increased mortality 
[113]. This raises a doubt on the benefit of MMP-12 inhibition in treating COPD.  
 
Table 1.2 COPD-associated MMPs and their relevance 
 
Class MMP Other name Substrate Relevance to COPD 
Collagenases MMP-1 Collagenase-1 Collagens (I–III, 





 Increased whole lung MMP-1 
mRNA and protein in human and 
guinea pig emphysema [110, 114, 
115] 
 MMP-1 overexpressing mice 
develop emphysema via 
degradation of collagen type III 
[116, 117] 
   




V, VII, VIII, X), 
gelatin, fibronectin
 Increased MMP-8 in BAL [118] 
and sputum which correlated with 
airflow obstruction [119] 
 Increased MMP-8 in patients 
with COPD exacerbation 
compared to stable COPD and 
controls [120] 
   
 MMP-13 Collagenase-3 Collagens (I–IV, 
IX, X, XIV), 
gelatin,  
pro- MMP-9 
 Increased MMP-13 expression in 
alveolar macrophages and epithelial 
cell type II in the COPD patients 
[121] 
  




 Increased MMP-2 expression and 
activity in the COPD patients [122] 
mainly in alveolar macrophages 
and airway epithelial cell [115] 
   Increased MMP-2 in both cigarette 
smoke-exposed mice [123, 124] 
and wood smoke-exposed mice 
[125] 





Table 1.2 COPD-associated MMPs and their relevance (continued) 
 
Class MMP Other name Substrate Relevance to COPD 
Gelatinases 
(contd.) 
MMP-9 Gelatinase-B Collagens (IV, V, 




9, pro-MMP-13,  
IL-1β 
 Increased MMP-9 protein and 
activity in neutrophils, serum, 
induced sputum of COPD 
paralleled with severity of the 
disease [115, 118, 119, 126-129] 
 Increased MMP-9 expression 
(mostly associate with increased 
MMP-12 expression) in both 
cigarette smoke- and elastase-
induced emphysema in murine 
model [104, 130-135] 
 Mice overexpressing human MMP-
9 in macrophages decrease alveolar 
wall elastin and develop early-onset 
emphysema [136] 
 MMP-9/MMP-12 inhibitor can 
attenuate smoke-induced 
emphysema in guinea pigs [109] 
 





 Increased MMP-10 gene 
expression in parenchyma with 
increasing GOLD stage [112] 
  








 Increased MMP-12 protein in 
BAL, induced sputum, bronchial 
biopsies of COPD [92-94] 
 Increased MMP-12 production and 
release in animal model of 
emphysema induced by cigarette 
smoke [95-103], elastase [104-106], 
ozone [107] and hookworm [108] 
 MMP-12 deficient mice have 
decreased numbers of 
macrophages in lungs and do not 
develop emphysema in response to 
long-term exposure to cigarette 
smoke [102] 
 MMP-9/MMP-12 inhibitor can 
attenuate smoke-induced 
emphysema in guinea pigs [109] 
 Some single-nucleotide 
polymorphisms in MMP-12 gene 
are associated with lower risk of 






Activity of MMPs can be physiologically inhibited by two main inhibitors: -2 
macroglobulin and tissue inhibitor of the matrix metalloproteinases (TIMP) family (TIMP-1, 
-2, -3, -4)]. To illustrate the hypothesis of protease/antiprotease imbalance in COPD 
pathophysiology, most studies observe only relative changes compared to their MMPs 
substrates. However, association of these inhibitors with COPD pathogenesis, and possible 
causal connections, are still unclear. A study in humans showed that alveolar macrophages 
isolated from patients with COPD produced less TIMP-1 than did the alveolar macrophages 
from healthy smokers and non-smokers [140]. However, in mice exposed to cigarette smoke, 
TIMP-1 levels were increased [141] or unchanged [142].  Some polymorphisms of the 
TIMP-2 gene have been identified in COPD patients [143]. Mice exposed to cigarette smoke 
for 10 days showed an increase MMP-12/TIMP-2 ratio compared to controls. Nonetheless, 
currently, no study describe the significance of these inhibitors in onset of emphysema in 
humans. 
 
1.3.4.2 Inflammation    
Pulmonary inflammation is a characteristic feature of the COPD patients. Several types of 
innate and adaptive inflammatory cells are recruited, and many inflammatory mediators are 
secreted with potential to cause alveolar destruction. The pathophysiological role of each of 
these types of cells and mediators are not yet fully understood.  
 
Potential role of innate immunity. An elevated number of neutrophils are found in 
sputum and bronchoalveolar lavage (BAL) fluid of patients with COPD compared to healthy 
individuals [144, 145]. Furthermore, the severity of pulmonary neutrophilic inflammation 
and the number of circulating neutrophils, correlate with an acceleration in lung function 
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decline, suggesting the role of neutrophils in progression of COPD [146, 147]. The elevation 
in neutrophil count follows the increase in neutrophil chemotactic molecules such as IL-8, 
growth related oncogene alpha (GROα; also known as CXCL1) and leukotriene B4 (LTB4) 
in the BAL fluid or in the sputum from COPD patients [148-151].  
 
Neutrophils are one of the candidate pathogenic cells in COPD because they are a rich 
source of a range of proteolytic enzymes [such as neutrophil elastase, cathepsin G, several 
MMPs (MMP-8, MMP-9)] and reactive oxygen species. Typically, activated neutrophils have 
a very short half-life (about 11.4 hours) [152], and then undergo apoptosis, and get removed 
by macrophages [153]. However, in COPD, the neutrophils’ half-life is prolonged and is 
associated with a decreased expression of pro-apoptotic genes and an increased expression 
of anti-apoptotic genes [154].  
 
However, the significance of neutrophils in development of COPD/emphysema remains 
ambiguous. In experimental animal models, mice depleted of neutrophils or mice deficient in 
the ability to synthesize the neutrophil chemoattractant LTB4 were protected from protease-
induced pulmonary emphysema [155]. However, in rats, depletion of neutrophils did not 
lessen the severity of cigarette-smoke induced emphysema [156].  
 
Macrophages are another class of effector cell that produces enzymes that could contribute 
to lung pathogenesis including MMP-2, MMP-9, MMP-12 (aka macrophage elastase), 
collagenase 1, and cathepsin K, L and S [93, 115, 157, 158]. The number of macrophages is 
markedly increased in the sputum, BAL fluid, airway wall and lung parenchyma in COPD 
patients [145, 159, 160].  The level magnitude of the increase in mononuclear cells is 
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positively correlated with the severity of COPD [161]. This accumulation of cells can derive 
from either local proliferation of alveolar macrophages [162, 163], or recruitment of 
peripheral monocytes into the lung in response to chemokines such as monocyte 
chemotactic protein 1 (MCP1; CCL2) and GROα [164, 165]. In a rat model of emphysema 
induced by cigarette smoke, both macrophage count and their elastolytic activity were 
elevated after 2 months of exposure, and remained elevated for 6 months and the counts 
and enzymatic activity correlated very strongly with the time course of the histopathological 
evolution of emphysema [166]. Further,  in rats where macrophage accumulation was 
prevented by neutralizing antibodies, the development of emphysema in cigarette smoke-
exposed animals was significantly attenuated [156]. 
 
Potential role of adaptive immunity. Adaptive immune response is also appears to be 
involved in the pathology of COPD/emphysema. Multiple studies have demonstrated an 
increased in a mix populations of both CD4+ helper T cells and CD8+ cytotoxic T cells in 
COPD patients. In the peripheral blood, airways, and lungs of COPD patients, lymphocyte 
polarization was directed towards T helper cell type I (Th1) and T cytotoxic cell type I (Tc1) 
phenotypes are the predominant CD4+ cells that accumulate [167-169], and there is also an 
elevated level of Th2 and Th17 cells [170, 171]. The basic features of each T helper cell 
subpopulation are expressed in Table 1.3. The Th1 cells produce mainly interferon- (IFN-
), which can induce macrophage activation to produce large amounts of pro-inflammatory 
cytokines [i.e. tumor necrosis factor-alpha (TNF-), and interleukin (IL)-1, IL-6] and 
inducible nitric oxide synthase (iNOS). Not surprisingly, levels of these pro-inflammatory 
cytokines, along with IFN-, were higher in lungs of patients with COPD than in healthy 




Transgenic mice overexpressing IFN- or TNF-, specifically in the lung, develop 
emphysema, possibly due to induction of MMP-12 or MMP-9 in macrophages [173, 174]. 
Moreover, mice in which there has been gene-targeted knockout of the TNF-receptor, IL-1-
receptor and IL-6 develop less severe emphysema than do wild-type mice [105, 175-177].  
 
Although Th2 cells do not predominate in patients with COPD, Th2 cytokines are linked to 
the pathogenesis of COPD because of their ability to activate proteolytic pathways. 
Inducible overexpression of IL-13, a potent Th2 cytokine, in transgenic mice activates a 
number of extracellular matrix degrading enzymes (MMP-2, -9, -12, -13, and -14 and 
cathepsins B, H, S, K, and L), and results in developing emphysema [178].  
 
There is increasing evidence that Th17 also plays a role in pathogenesis of COPD. Th17 
cells are characterized by secretion of IL-17, IL-21, and IL-22 cytokines, which induce the 
release of GROα, IL-8 and GM-CSF, and orchestrate neutrophilic inflammation [179, 
180]. Stable COPD patients have more T cells producing IL-17A+, IL-17F+and IL-22+ in 
their bronchial and lung biopsies than do control non-smokers [181-184]. Overexpression of 
IL-17A in lung epithelium in mice promotes lung inflammation, with an induction of MMP-
9 and shows a COPD-like phenotype [185]. Mice-deficient in IL-17A or the receptor for IL-
17A are protected from both cigarette smoke-induced emphysema and elastase-induced 




Collectively, the evidence regarding the role of adaptive immunity in COPD is mixed, with 
the association of multiple cell populations with COPD. However, the critical function of 
these cells in the pathogenesis of the disease has not been yet elucidated. 
 












Th1 IFN-, IL-12 Tbet, STAT1, 
STAT4, Runx3
IFN-, CXCR3 Response to intracellular pathogens 
and viral infections 
Th2 IL-4, IL-2 GATA-3, 
STAT6, STAT5
ST2, IL-4, IL-5, 
IL-13 
Response to extracellular parasites,
Involve in allergic response 
Th9 TGF-β, IL-4 PU.1 IL-9 Involve in tumor immunology or 
parasites 







Regulator of tissue inflammation, 
response to extracellular parasites 
and involved in autoimmunity 
Tfh IL-6, IL-21 Bcl-6, Ascl2 CXCR5, IL-21, 
PD-1 
Trigger the formation and 
maintenance of germinal centers 
iTreg TGF-, IL-2 Foxp3, STAT5 IL-10, TGF- Immune suppression, and involve 
in immune tolerance 
* Master transcription factors are shown in italic. 
 
Another possible contribution of adaptive immunity to the pathophysiology of 
COPD/emphysema has been suggested to be though an autoimmune mechanism [190, 191]. 
Lymphoid follicles with B cells, T cells and follicular dendritic cells are found in both 
bronchial wall and parenchymal tissue of patients with emphysema [192].  The possibility of 
the role of autoimmunity in COPD/emphysema was raised with the discovery, in the 
emphysematous lung, of Th1 and Th17 cytokines, the pivotal cytokine players in 
autoreactive inflammation [193]. Key evidence of the role of autoimmunity is, in COPD and 
emphysema patients, the presence of circulating antibodies (produced by B cells) against 
elastin fragment in COPD, and the responsiveness of CD4+ T cells isolated from COPD 
lungs to elastin [194]. However, these observations of anti-elastin cannot be reproduced by 
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other groups [195, 196]. Thus, the involvement of autoimmune response in the pathogenesis 
of emphysema remains uncertain. 
	
1.3.4.3 Oxidative Stress   
Oxidative stress occurs when the redox balance is disturbed by excess reactive oxygen 
species (ROS) in relation to antioxidant defense mechanisms. The ROS are chemically 
reactive and unstable molecules or free radicals containing oxygen, which are routinely 
generated in the cells as a byproduct of aerobic respiration or by oxidoreductase 
enzymes, and play important roles in intra- and inter-cellular signaling, cell cycle control, 
homeostasis and host cell defense mechanisms [197]. However, during times of 
environmental stress (i.e. UV or heat exposure, microbial infection), ROS levels can 
markedly increase. The imbalance of excess ROS can result in molecular, cellular and tissue 
damage.  
 
The lung, with its large surface area and dense vascularization, is especially vulnerable to 
environmental oxidative stress, because it is directly and constantly exposed to multiple 
foreign materials and pathogens containing oxidants.	In smokers and in patients with 
COPD,	there are increased levels of pulmonary and systemic oxidative stress markers in 
BAL fluid, lung tissue, exhaled breath condensate, serum and urine of smokers [198-204]. 
Increasing numbers of studies have strongly linked the oxidative stress burden to 
pathogenesis of COPD. 
 
Increased ROS in the lungs can derive from endogenous cellular activities, (especially release 
from activated inflammatory cells) and from exogenous oxidants in inhaled air. Cigarette 
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smoke is likely to be the primary source of oxidants in most cases of COPD. Cigarette 
smoke is a complex mixture of some 4,700 chemical compounds, which consist of more 
than 1,000 species of oxidants. In the gas phase there are approximately 1015 oxygen free 
radicals per puff, comprising a variety of organic radicals with different reactivities, such as 
nitrogen dioxide (NO2), nitric oxide (NO), hydrogen peroxide (H2O2), peroxynitrite 
(ONOO−), and peroxynitrate (O2NOO−). In addition, the particulate matter phase has more 
than 1018 free radicals per gram, which includes hydrogen peroxide (H2O2), hydroxyl radicals 
(•OH) and other organic compounds (e.g. semiquinone, hydroquinone, phenol) [205, 206]. 
Other gaseous pollutants such as ozone (O3), sulfur dioxide (SO2), NO2, diesel particulates 
and particulate matter <10 m (PM10), are also highly reactive and can also cause 
inflammation in the lung [207-209].  
 
Activated inflammatory cells, including neutrophils or macrophages, and other structural 
cells such as epithelial and endothelial cells, can be another significant source of ROS in 
COPD patients. Activated neutrophils or macrophages use the NADPH oxidase system 
(respiratory burst oxidase) to produce ROS e.g. O2•−, which is rapidly converted to H2O2 by 
superdioxide dismutase (SOD) [206]. The levels of ROS, such as O2•− and H2O2, 
spontaneously released from BAL macrophages or circulating neutrophils, are higher in 
smokers than in non-smokers [203, 210-212]. Similarly, neutrophil myeloperoxidase, which 
can metabolize H2O2 to the more reactive hypochlorous acid, accumulates in the lungs of 
patients with COPD [213]. Cigarette smoke can also activate the generation of oxidants (e.g. 
ONOO−) via inducible nitric oxide synthase in epithelial cells or endothelial cells, which has 
been linked to alveolar injury [214]. 
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These ROS are extremely active and can damage all tissues, particularly by oxidizing 
polyunsaturated fatty acids in cell membranes (lipid peroxidation). The oxidative stress 
induced by cigarette smoke can cause injury by decreasing cell adherence, and increasing 
detachment and cell death in human alveolar epithelial cells [215]. Moreover, oxidants can 
directly damage proteins including those in the lung matrix (such as elastin and collagen) 
[216], and indirectly through the process called protein carbonylation [217]. This protein 
modification can alter protein function, disrupting normal cell function and physiological 
mechanisms. A significant increase in the levels of protein carbonyls correlates with GOLD 
stage progression in COPD [218]. Particularly important for emphysema, The function of 
1-AT can also be inactivated by oxidation with semiquinone extracted from cigarette 
smoke [219], and the oxidized 1-AT is detectable in BAL fluid of cigarette smokers [220]. 
Importantly, higher amounts of oxidized DNA, indicated by 8-hydroxydeoxyguanosine in 
lung tissues, positively correlates with the number of cigarettes smoked per day [221]. 
Under normal circumstances, the level of oxidants is balanced by several endogenous 
(enzymatic or non-enzymatic) antioxidant mechanisms. Many classical antioxidant enzymes 
such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase can prevent 
initiation of the ROS reaction. Another group of enzymes, including heme oxygenases, 
peroxyredoxins, thioredoxins and glutaredoxins, neutralize ROS through redox cycle with 
other protein modifications [222, 223]. The non-enzymatic antioxidants include glutathione, 
ascorbic acid (vitamin C), -tocopherol (vitamin E), -carotene, uric acid, albumin, mucin, 
bilirubin and lipoic acid. The levels of these antioxidants in COPD patients compared to 
healthy controls vary among different studies possibly due to variables such as genetics, 
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smoking histories, severity of the disease, and time interval from last smoke to sampling time 
[224].  
 
Antioxidants are typically markedly increased in response to cigarette smoke and oxidative 
stress; however, a question is raised whether this induction of antioxidants is sufficient to 
deal with the excess of oxidant burdens, particularly in chronic exposure to oxidants. Studies 
have demonstrated that augmented antioxidant mechanisms, either by direct administration 
of antioxidant supplementation or by molecular manipulation of antioxidant genes, can 
ameliorate the severity of emphysema in animal models [217, 225-228]. However, no studies 
have shown that dietary supplementation with antioxidants results in clinical improvement, 
nor are the existing antioxidant therapies successful without intolerable side effects [229]. 
Despite these current significant limitations, development of novel antioxidant drugs and 
strategies for targeting oxidative stress continue to be pursued as a promising therapeutic 
approaches to treat COPD [230].  
 
 1.3.4.4 Cellular Senescence and Cell death 
Another mechanism postulated to result in alveolar wall destruction in emphysema involves 
failure of the lung maintenance and repair process following repeated injury from chronic 
exposure to toxicants such as those contained in cigarette smoke [231]. Both an increased 
number of apoptotic cells and an increase in cell proliferation, particularly septal epithelial 
and endothelial cells, have been reported in human emphysemic lungs [232-234]. This 
apoptosis of structural cells in emphysema might be partly due to reduced endothelial cell 
maintenance factors such as vascular epidermal growth factor (VEGF) [232], as confirmed in 
both in vitro and animal models [235-237]. Additional evidence that apoptosis could have an 
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important role in emphysema was provided by the results of experiments where transfection 
of active caspase-3 into the lung of mice resulted in alveolar wall apoptosis and destruction 
[238]. However, the exact underlying apoptotic pathway that drive the persistent alveolar 
destruction associated with emphysema has not yet been identified.   
 
Due to the repeated cell proliferation needed to maintain alveolar integrity during repair, 
cells with a limited ability to divide might undergo cellular senescence, defined as a loss of 
proliferative capacity which can be determined by a shortening of chromosomal telomeres, 
and increased expression of senescence-associated cyclin kinase inhibitors (such as 
p16INK4a and p21CIP1/WAF1/Sdi1) and SA-β-gal (senescence-associated-β-galactosidase) [239]. 
The apparent senescence phenotype of alveolar epithelial and endothelial cells, paralleled 
with increased levels of senescence markers in peripheral blood leukocytes, is accelerated in 
COPD patients especially those with emphysema [239, 240]. Some mutations in the essential 
telomerase (telomere-repeat synthesizing enzyme) genes has been identified as a risk factor 
of COPD [237]. The finding that genetically modified mice that have short telomeres have 
increased susceptibility to develop cigarette smoke-induced emphysema [241] also supports 
the potential importance of cell senescence in the development of emphysema. In 
vitro exposure of human epithelial cells to cigarette smoke results in increased expression of 
SA-β-gal [242]. Interestingly, lung fibroblasts isolated from patients with emphysema have 
higher expression of SA-β-gal and reduced proliferative capacity compared with those from 






1.3.4.5   Summary Overview of the Pathogenesis of COPD.  
Many cells and mediators act together in the pathogenesis of COPD (Fig. 1.3). The key steps 
are a loss in tissue homeostasis caused by imbalance of several maintenance programs in the 
lung, including an imbalance in protease/anti-protease activity, inflammatory/anti-
inflammatory response, oxidative/anti-oxidative system and regeneration/death or 
senescence (Fig. 1.4A). It is important to note that these imbalances are not separated 
entities, but constantly interacting with each other, contributing to the complexity of the 
progression of COPD (Fig. 1.4B).   
 
The traditional protease/anti-protease model for emphysema requires the recruitment and 
activation of inflammatory cells including macrophages and neutrophils. A recent study 
demonstrated a prominent increase of adaptive immune inflammation, (consisting of B cells, 
CD4+ and CD8+ T lymphocytes and lymphoid follicles) in emphysema patients with the 
deficiency of 1-AT, suggests that the mechanism underlying emphysema is more 
complicated than a simple elastase/anti-elastase imbalance [245].  Increased oxidative stress 
triggered by inhaled environmental toxicants can initiate various early inflammatory events in 
the lungs including those regulated through NF-B-dependent pathways [246]. In turn, 
inflammatory responses result in the production of more ROS, in addition to the alteration 
of the anti-protease system. Some anti-proteases are susceptible to oxidative damage. The 
1-AT activity can be inhibited by oxidation of certain essential methionine residues by 
H2O2, leading to loss of its ability to bind with neutrophil elastase [247]. As a consequence, 
relatively high levels of proteases are present in excess of the local concentration of their 
inhibitors.  Protease-generated elastin fragments have a chemotactic property for immune 
cells, and could result in a positive-feedback loop resulting in continuous destruction of 
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parenchymal tissue [248, 249]. High concentrations of ROS-generated oxidized 
phospholipids in the plasma membrane of alveolar macrophages can decrease their 
phagocytic capacity (efferocytosis), resulting in failure to clear microbial infections or 
apoptotic cells [250]. Impaired efferocytosis can lead to secondary necrosis, sustained 
inflammation, and inadequate tissue repair in COPD [251]. Apoptosis is notable in areas of 
high oxidative stress, and inhibiting apoptosis with a broad-spectrum caspase inhibitor 
markedly reduces expression of oxidative stress markers and inflammation [235, 252]. 
Caspase-3 activation was directly inhibited by 1-AT, suggesting an anti-apoptosis role of 
anti-protease protein [253]. Furthermore, senescence is usually increased by DNA damage 
which can be induced by oxidative stress. This cellular senescence can in turn amplify the 
oxidative stress, propagate proinflammatory phenotype, diminish repair capacity, and all 










Figure 1.3 Hypothesis of cellular and molecular events underlying pathophysiology 
of COPD. AEI and AEII: alveolar epithelial cells type I and II, EC: endothelial cells; IC: 
interstitial cells, AM: alveolar macrophages, PMN: polymorphonuclear cells (neutrophils), 
DC: dendritic cells, CD4+/CD8+: CD4+/CD8+ T lymphocytes. 
Reprinted by permission from the American Physiological Society: Physiological Reviews 






Figure 1.4 Imbalance and interplay model of COPD pathogenesis. (A) COPD is 
hypothesized to result from imbalances between proteases/anti-proteases, 
inflammation/anti-inflammation, oxidants/antioxidants and repair/apoptosis. (B) Interplay 
between protease activity, inflammation, oxidative stress and apoptosis in the overall 




1.3.5 Exacerbation in COPD/Emphysema    
COPD is often associated with exacerbations that are a common cause of hospitalization 
and lead to a large proportion of COPD-associated mortality [256-260]. An exacerbation, as 
defined by the respiratory physician working group at the Aspen Lung Conference in 1999, 
“is a sustained episode with acute onset in the natural course of the disease, that deviates 
from normal day-to-day variations, worsening the patient’s symptoms, and requiring a 
change in medication” [261].  
 
Exacerbations are a primary contributor to both the economic and sociological burdens 
associated with the management of patients with COPD. Although exacerbations are 
infrequent in the early stage of COPD, they occur twice a year on average in patients with 
moderate-to severe disease [262]. The frequency of severe exacerbation is positively 
correlated with mortality [256].  
 
According to the data from the Healthcare Cost and Utilization Project that studied all 
hospitalized COPD patients  40 years of age in the United States in 2008, more than 
500,000 patients were hospitalized with acute exacerbation, which cost approximately $3.8 
billion in aggregate (which is the main cost driver in this population) [263]. Another study 
addressed the issue of total annual health care costs and found that the price increased from 
$11,747 in patients without exacerbation to $14,188 in those with moderate exacerbation and 




One of the greatest concerns regarding exacerbations is their long-lasting impact on the 
speed of the progression and the severity of disease [260, 265]. Thus, one of the main goals 
of COPD management is to prevent the exacerbation events [31].  
 
Most COPD exacerbations, some 70 – 80%, are caused by bacterial and viral respiratory 
infections (which may coexist) [266, 267]. Bronchoscopic sampling reveals that more than 
50% of COPD patients with exacerbation have high concentration of bacteria in their lower 
airway, compared to 0-4% of healthy adults [268, 269]. Predominant in the bacterial samples 
from such patients are new strains of Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas 
aeruginosa and Streptococcus pneumoniae [270-274]. The “frequent exacerbators”, who experience 
two or more exacerbations per year, have increased airway colonization with H. 
influenzae and S. pneumoniae , more severe symptoms and increased sputum purulence during 
exacerbation [275].  
 
Employing different approaches studies have reported viruses to be present in one third to 
two thirds of COPD exacerbations [267, 276, 277]. Although rhinoviruses are the most 
common identified virus group in COPD patients during exacerbations, influenza virus is 
the most commonly associated with severe exacerbations requiring hospitalization [260]. 
Respiratory syncytial virus (RSV) and human metapneumovirus have also been reported as a 
cause of exacerbation [278, 279].   
 
Other important potential causes include exposure to environmental pollution such as 




Exacerbations profoundly affect the nature of the immune response in the lung, and 
markedly impact the progression of COPD through several mechanisms. During 
exacerbations, particularly in patients who have microbial colonization in the respiratory 
tract, there are often marked increases of inflammatory biomarkers including white blood 
cell counts, pro-inflammatory cytokines, i.e. TNF-, IL-6 or IL-8, leukotriene B4 (LTB4), C-
reactive protein (CRP) and chemokines. Exacerbations have also been linked increased 
production of ROS, as observed by a persistent increase in 8-isoprostane and hydrogen 
peroxide in the exhaled breath of COPD patients with exacerbation [202, 283, 284].  
There are also elevations of proteases such as neutrophil elastase, MMP-9, but a reduction in 
protease inhibitor TIMP-1 [285-292].   
 
A variety of conserved molecular motifs within bacteria or viruses, called pathogen-
associated molecular patterns or PAMPSs, can be initially recognized by a set of diverse host 
innate immune-sensor molecules termed “pattern recognition receptors (PRRs)”. The Toll-
like receptors (TLRs), for instance, are a class of PRRs that detect a broad range of PAMPs 
including peptidoglycan, lipopolysaccharide (LPS) and flagellin on the bacterial surface, or 
single-stranded (ss-) and double-stranded (ds-) RNA in the viral genome. The downstream 
cascade of activation of these receptors can activate multiple signaling pathways, especially 
the NF-B-dependent pathways, which activates transcription factors that results in 
transcription and translation of a spectrum of cytokines, chemokines, and other 
inflammatory mediators. In a murine model, polyinosinic-polycytidylic acid [poly (I:C)] - a 
molecule mimicking viral ds-RNA that can activate TLR3 signaling - can augment the effects 





Although the cellular and molecular mechanisms of exacerbation are still not well elucidated, 
most studies have shown that prolonged increases in COPD exacerbations amplify the 
inflammatory response, proteases, and oxidative stress in the respiratory system. These 
repeated events further shift the imbalance of COPD-associated mediators (as described in 






















Figure 1.5 Role of microbial infections in exacerbations of COPD.  




1.4 Animal Models of Emphysema 
The causes of COPD are not fully understood. Most studies of the pathogenesis of COPD 
in human patients derive from comparison of human lung tissue or cells between COPD 
patients with different stages of the disease vs non-COPD patients, or smokers vs non-
smokers. However, since COPD is a very complex disease, and usually accompanied by 
various co-morbidities, such studies have only shown an association of particular events to 
COPD, causal relationships cannot be determined. Moreover, because human COPD is a 
slowly progressive disease, it is difficult to follow all the changes in humans. Thus, several 
animal models of COPD/emphysema have been developed to recapitulate aspects of this 
disease process, and facilitate understanding of the underlying pathologic mechanisms of the 
disease. These models also raise the opportunity to test novel drugs and therapies before 
clinical trials in humans.  
 
One of the complexities of human COPD is that it comprises both chronic bronchitis in the 
conducting airway, and pulmonary emphysema in the parenchymal tissue. This results in 
difficulty in using animal models to study both regions of the lung simultaneously. In this 
thesis, we focus on understanding the pathogenesis of emphysema affecting the destruction 
of alveolar tissue.   
 
Many of the causative agents of emphysema, including several types of proteases, cigarette 
smoke, biomass fuels, air pollutants (i.e. ozone), and helminths have been used to induce 
emphysematous phenotypes in laboratory animals. These animal models play a critical role in 
our current understanding of emphysema pathogenesis. However, each attempts to model 
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different aspects of the human disease and have inherent advantages and disadvantages in 
terms of outcome and human relevance, which will now be reviewed.  
 
 1.4.1 Protease-induced emphysema model 
In 1965, Gross et al. established the first reproducible experimental animal model of 
emphysema, by intratracheal installation of papain proteinase (a plant protease) into the 
lungs of rats [71]. This success in developing an animal model closely resembling the human 
emphysematous phenotype happened shortly after the discovery of an association between 
1-AT deficiency and emphysema [58]. From these observations emerged the hypothesis 
that the development of emphysema was due to the imbalance between proteases and anti-
proteases in the lung. While protease activity of papain depends on its purity and source, 
several other proteases with the capacity to degrade the extracellular matrix in the alveolar 
wall enzymes have subsequently been used in attempt to induce emphysema in a variety of 
animal species. These proteases include porcine pancreatic elastase [294, 295], human 
neutrophil elastase [296, 297], collagenase [298], proteinase 3 [299] and cathepsin B [300]. 
 
In rodent models, the most common protease-based approach to induce emphysema is a 
one-time intratracheal instillation of porcine pancreatic elastase, because of low-cost, good 
availability, speed, consistency, and impressive airspace enlargement [301-303]. This 
intratracheal insult causes, in the first few days, edema, hemorrhage and a rapid influx of 
inflammatory exudates composed of neutrophils and macrophages, with a number of other 
inflammatory mediators [304]. Within a week after elastase treatment, the hemorrhage and 
inflammation are typically resolved [155]. One week after treatment, there is an increase in 
the numbers of adaptive immune cells (CD4+, CD8+ cells), and within 21 days of the insult 
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there is significant observable enlargement of airspaces [188]. Marked increases of ROS 
production, other proteases and apoptotic markers can be also detected in the lung after 
elastase administration [175, 305, 306]. 
 
The severity of emphysema progressively evolves for at least 26 weeks after a single insult of 
pancreatic elastase [70, 304], even though the activity of exogenous enzymes was inhibited 
by endogenous protease inhibitors within 24 hours following administration [307]. The 
administration of elastase inhibitors have a protective effect only when given immediately 
before, or immediately after, elastase challenge; they are not effective if given 4 or 8 hours 
after challenge [308-310].  
 
This persistent emphysematous change in the animal model corresponds to the 
characteristics of emphysema in human patients, in which emphysema remains progressive, 
even after cessation of smoking [311, 312]. Although the mechanism of this progressive 
changes is not certain, the data suggests that it is the endogenous host responses, triggered 
by elastase, that cause persistent damage in the lung. It has been suggested that only 20% of 
the loss of parenchymal tissue after elastase challenge is due to direct attack by instilled 
elastase: the remaining 80% of the loss results from the host inflammatory or remodeling 
response [175].  
 
This progressive feature of the elastase model provides a good opportunity to gain insights 
into the mechanisms underlying the progressive loss of alveolar tissue associated with 
emphysema and an opportunity to define the roles of repair and remodeling of tissue in 
response to injury as well as the relationship between altered structure and pulmonary 
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functions and mechanics in emphysema [188, 313-317]. Ultimately, this model can be a 
useful tool with which to explore potential drug and intervention therapy to stop 
emphysema progression [134, 228, 318]. 
 
Although instillation of proteases can induce useful and reproducible emphysema-like 
pathology, and provide valuable information about the mechanisms underlying the 
progressive phase of emphysema development, these models have several drawbacks. (i)  
They cannot provide information on upstream events prior to release of excessive proteases 
in human COPD, particularly when the disease is initially triggered by environmental agents. 
(ii)  It is difficult to explore the role of other proteases that might be involved in the 
pathogenesis of emphysema, because their proteolytic activities are obscured by the impact 
of elastase. The question is raised whether the emphysema phenotype induced by a single-
dose elastase insult is physiologically comparable to the emphysema in humans, which might 
involve many proteases and/or more mediators. (iii) Exogenous porcine pancreatic elastase, 
and endogenous neutrophil elastase, have different primary endogenous inhibitors (2-
macroglobulin for pancreatic elastase, but 1-AT for neutrophil elastase) [307]. Thus, it is 
crucial to note whether a particular exogenous inhibitor may not inhibit both of these 
enzymes. (iv) Unlike the common human emphysema induced by environmental smoke, in 
which there is development of centrilobular emphysema, elastase produces panacinar 
emphysema characterized by uniform loss of all portions of the acinus from the respiratory 
bronchiole to the alveoli, as is typical for inherited 1-AT deficiency emphysema patients 
[319].  (v) None of these models can totally mimic the entire phenotype seen in human in 
COPD, because inflammation in the airways and mucus hypersecretion, which might 
contribute to emphysema development in humans, are not seen in these models. The 
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extrapolation of the data generated by these models to human diseases therefore has to be 
done with care. 
 
 1.4.2 Cigarette smoke-induced emphysema model 
Due to cigarette smoke being the predominant risk factor for development of COPD, 
smoke-induced animal models have been developed for study of the pathophysiology related 
to the development of emphysema. Chronic exposure to cigarette smoke in rodents can 
mimic multiple features of COPD, including accumulation of inflammatory cells and 
mediators, elevation of oxidative stress, hypersecretion of mucus, decline in lung function, 
mild emphysema, airway remodeling, pulmonary hypertension, and increased pulmonary 
inflammation associated with exacerbation [320, 321]. In the rodent model, the cigarette 
smoke induced centrilobular lesions resemble that seen in human smokers where the 
pathology begins from the respiratory bronchioles and spreads peripherally [319, 322]. Thus, 
this experimental model has gained attention for its potential to yield mechanistic insights 
into the earlier stages of the pathogenesis of emphysema, particularly the roles of 
inflammation and oxidative stress. 
 
In 1981, Huber et al. provided the first description of the morphological and physiological 
alterations in smoke-induced emphysema in rats [323]. Subsequently, different laboratories 
have used variations of this system for cigarette smoke-induced animal model of emphysema 
and no standard exposure protocol is in place. For example, smoke exposure intervals range 
from 1 to 3 sessions per day, with different numbers of cigarettes smoked in each session (2 
to 40 cigarettes a day), 5 to 7 days per week, for 2 to 36 weeks [83, 102, 324-330]. Different 




To simulate passive smoking, most studies burn the cigarette and passively expose the whole 
body of the animal. In contrast, some studies use a nose-only smoke exposure system to 
deliver smoke to the respiratory system only, and avoid the confounding effects of orally-
exposed nicotine or tar substances during the animals’ self-grooming [328, 331, 332]. Both of 
these techniques involve using the side stream smoke generated by the burning end of a 
cigarette (similar to passive smoking) to induce emphysema.  To simulate active smoking, 
investigators have delivered to the animals, the mainstream smoke produced by suction and 
drawing back of cigarettes by pump or “puffing” [227, 333-335]. However, there are no 
studies comparing the degree of emphysema produced by these different methods.  The 
smoking chambers are also unique to each group, and not all studies include monitoring of 
the dose and composition of cigarette smoke to which the animals are exposed. Thus, it is 
very difficult to make any comparison between the results from different authors.  
 
Recently, a study claimed that multiple injections of cigarette-smoke extracts into the 
peritoneal cavity of animals resulted in a systemic inflammatory response and the induction 
of proteases and oxidative stress in lung tissues, which caused pulmonary emphysema within 
a month [336]. However, the relevance of this approach to human emphysema remain 
uncertain. 
 
Models of cigarette-smoke induced emphysema have recently been used to investigate the 
impact of exacerbation by bacterial or viral infection. For instance, mice exposed to cigarette 
smoke and then infected with influenza virus H1N1 or H3N1 had increased number of BAL 
immune cells, (especially virus-specific activated CD8+ T cells with altered key cytokine 
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profiles), compared to smoke or influenza infection only, and had a 10 fold increase in virus 
titers in the lung at day 3, compared to influenza only mice [337, 338]. Several studies have 
reported that exacerbation with bacteria (heat-killed non-typeable Haemophilus influenzae), 
virus (rhinovirus), or exposure to a TLR agonist (polyI:C) that mimics virus-induced innate 
immunity, can accelerate progression of cigarette smoke-induced emphysema in mice [293, 
339-341]. 
 
Besides the lack of consistency between protocols to induce emphysema by cigarette smoke, 
other major disadvantages of this model are its high-cost, the need for long-period of 
exposure to develop the phenotype and the difficulty in using the model to study new 
therapeutic drugs. Moreover, although the lesions produced in the rodent model are similar 
to the pathology in humans, the emphysema in the rodent model is only mild, and the 
emphysema in the rodent does not progress even after smoking ceases, whereas in humans 
there is progression in symptomatic patients at GOLD stage III or IV.  In the animal model, 
the emphysema from cigarette smoke is stable and non-progressive, with persistent or 
decreased inflammatory responses after the end of exposure [342-344]. Furthermore, the 
cigarette smoke-exposed animal model cannot totally explain the susceptibility of human 
emphysema, since almost all animals develop emphysema, but only 15 - 20% of human 
develop emphysema. Finally, similar to the elastase model, the cigarette smoke model cannot 
model the chronic bronchitis seen in human COPD. 
 
1.4.3 Biomass fuel-induced emphysema models 
Biomass smoke has been used to induce emphysema in laboratory animals to simulate 
human disease, particularly that affecting women in developing countries who are exposed to 
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indoor pollutants from cooking with biomass fuels. Hu and colleagues exposed rats to 
smoke either generated from 25 gram grain crust (typical biomass fuel used for cooking) or 
from 10 cigarettes, twice daily with a 4 hour interval, 7 days per week, for 14 weeks. They 
reported that biomass smoke could induce pulmonary inflammation, systemic oxidative 
stress and emphysematous damage at levels similar to that of cigarette smoke [345]. Similarly, 
emphysematous changes were shown to be induced by exposing rabbits to smoke from 
dried dung [346], and by exposing rats to smoke from cow dung daily for one month [347]. 
 
 1.4.4 Air pollutant-induced emphysema models 
Environmental factors, including gases and particulate matter in polluted air, are involved in 
the development of COPD. Ground-level ozone, (O3,) is one of the six commonly found 
pollutants worldwide (together with particulate matter, carbon monoxide, sulfur oxides, 
nitrogen oxides, and lead) [348]. In contrast to cigarette smoke, which contains several 
thousand chemical compounds with a number of ROS species, ozone is a powerful “single” 
reactive oxidant molecule present in environmental air pollution, which induces pulmonary 
oxidative stress and triggers adverse health effects. Exposure to high levels of ozone has 
been associated with worsening of symptoms in patients with asthma and COPD [349-352].  
 
Ozone has long been used in models for asthma, because it can induce neutrophilic lung 
inflammation and oxidative stress with airway hyperresponsiveness, which are critical 
features of human asthma [353-355]. Recently, Triantaphyllopoulos et al. demonstrated that 
chronic exposure of mice to ozone at a high concentration (2-3 ppm) for 6 weeks could 
induce disruptions in alveolar architecture, leading to emphysema-like airspace enlargement 
[107, 356]. There was increased oxidative stress, an inflammatory response (e.g. increased 
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BAL cell counts, IL-13, IFN-, TNF-α, IL-6 and IL-17), an up-regulation of MMP-12, and 
increased apoptotic markers (caspase-3 and apoptosis protease activating factor-1). The 
emphysema-like lesion, and deteriorated lung function did not resolve, even 3 weeks after 
cessation of exposure [357]. This pattern is similar to that seen in the animal model of 
cigarette smoke-induced COPD and in human COPD. Thus chronic ozone exposure might 
be a good model with which to study the role of oxidative stress in initiating the emphysema 
phenotype. Treatment with N-acetylcysteine (NAC), a therapeutic antioxidant and a 
mucolytic agent, both before and after the animals were exposed to ozone, could not reverse 
the ozone-induced emphysema, even though lung inflammation and airway 
hyperresponsiveness were attenuated [357]. 
 
 1.4.5 Parasite-induced animal emphysema models 
Another interesting novel murine model of emphysema is that in which the disease is 
induced by infection with the nematode Nippostrongylus brasiliensis, which is used in mice and 
rats as a model for human hookworm infections [358, 359].  The free-living third-stage (L3) 
larvae of N. brasiliensis penetrate, (or injected) the skin and migrate via the circulation to the 
lungs at around two days post-infection. In the lungs, the L3 larvae reside for 12-48 hours 
prior to molting to the fourth stage larvae (L4). The L4 migrate up the conducting airways 
and are swallowed into the small intestine, where parasites complete their develop into 
adults, mate, and produce eggs deposited in the environment when the rodent 
defecates [358].  N. brasiliensis infection in mice is self-limiting as the adult worms are 




Although N. brasiliensis larvae reside in the host’s lung only for two days, they induce a 
strong, long-lasting, type 2 immune response, characterized by increasing levels of Th2 cells, 
IL-4, IL-13, IgE, eosinophils, basophils, mast cells and Type 2 innate lymphoid cells 
(ILC2s), as well as alternatively-activated (M2) macrophages, which are thought to promote 
repair of the tissue damage caused by the worms [361-366]. In 2008, Kopf et al. showed that 
N. brasiliensis infection left behind a chronic inflammatory response in the lung, causing 
progressive destruction of alveolar walls, and a marked enlargement of the airspace size, 
resembling the emphysema phenotype in humans [108]. This prolonged nematode-induced 
lung damage was associated with hemosiderin positive macrophages, with an alternatively 
activated (M2) phenotype marked by the induction of Arg (Arginase), Retnla 
(Fizz1) and Chi3l3 (Ym1) expression. These M2 macrophages exhibited substantial up-
regulation of MMP-12, (a potential protease candidate that might cause tissue degradation 
in emphysema pathogenesis), for more than 150 days, suggesting a role of Th2 cells and M2 
macrophages in the development of emphysema.  
 
More evidence in support of the role of Th2 cells in this model was demonstrated by 
injecting N. brasiliensis into mice selectively deleted of transforming growth factor-beta 
receptor type II (TGFβRII) in myeloid cells (including monocytes and macrophages) [367]. 
This study show that the lack of macrophage-mediated suppressor signaling resulted in an 
elevation of pro-inflammatory cytokines, an increase in type 2 immunity, excess MMP 
activity, and a more severe emphysema phenotype. However, these results were in contrast 
to the findings that mice lacking the capacity to generate Th2 responses, such as mice 
deficient in the production of the IL-4 receptor, IL-5 receptor, IL-13 or MMP-12, were not 
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protected from N. brasiliensis-induced emphysema. Thus, the mechanism of induction of 
emphysema by N. brasiliensis is still not clear. 
	
1.5 Assessment of Emphysema in Animal Model 
A critical step in the investigation of the development of emphysema and the evaluation of 
the therapeutic interventions in animal models is an efficient and accurate quantitatively 
assessment of phenotype. The major characteristic features of human emphysema include a 
decline in lung function over time, alveolar wall destruction, and a loss of elasticity and recoil 
that results in elevated lung compliance (the change in volume for any given change in 
distending pressure). Such changes in structure and function need to be evaluated carefully 
to understand both the pathogenesis and the effects of interventions on the progression of 
the disease. Several of these pathophysiologic changes can be assessed in animal models 
using techniques that resemble those used in humans.  
 
1.5.1 Diffusing Capacity for Carbon Monoxide 
A test of the diffusing capacity of the lungs for carbon monoxide (DLCO) is one of the most 
common clinically valuable tests of lung function.  In humans it is both convenient and easy 
to perform.  DLCO measures the ability of the lungs to exchange gas, and is directly impacted 
by a loss of alveolar surface area.  It is assessed by measuring the partial pressure difference 
between inspired and expired carbon monoxide after a 10 second breath hold at the end of a 
deep inspiration. The uptake of gas during this time reflects ability of the lungs to transfer 
gas from inhaled air to the red blood cells in the pulmonary capillaries. Because the major 
pathology of emphysema is the destruction of alveolar membranes and loss of gas-exchange 
surface area, decreases in DLCO is an excellent index to quantify the anatomic extent of 
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emphysema.  The extent of the fall in DLCO correlates tightly with the degree of emphysema 
as assessed by a reduction of lung tissue density observed CT imaging [368, 369]. The DLCO 
also can help separate emphysema from chronic bronchitis in COPD because patients 
diagnosed with chronic obstructive bronchitis and airway obstruction (but not emphysema) 
have normal DLCO [370].  To assess this characteristic in mice, our laboratory developed a 
quick and simple single-breath diffusing capacity measurement which is closely related to the 
DLCO measurement in humans.  This has been shown to be sensitive enough to quantify 
structural changes in several different lung pathologies including emphysema [371, 372].  
The procedure is performed in an anesthetized mouse using a 9 second lung inflation with a 
gas mixture containing approximately 0.5% neon (tracer gas), 0.5% carbon monoxide.  As in 
humans the gas is then quickly withdrawn and the gas is analyzed for the concentrations of 
neon and carbon monoxide.  However, as there are a number of assumptions in the 
procedure in the mouse, we call this the diffusion factor for carbon monoxide (DFCO) to 
distinguish from DLCO in humans.  
 
1.5.2 Pressure-Volume Curve  
Lung volumes and lung capacities refer to the amount of air associated with different parts 
of the respiratory cycle (reviewed in Table 1.4). Measurement of lung volume is an important 
metric for understanding normal function of the lungs as well as the changes in disease 
states. Because of the permanent destruction of alveolar walls and the dilation of airspaces in 
emphysema, the lung loses elasticity and recoil which results in increased lung compliance 
(or decreased elastance—the reciprocal of compliance). More air can also be trapped within 
the lung at the end of spontaneous expiration because the peripheral airways tend to collapse 
in the expiratory phase due to the weakening of interdependent forces between airways and 
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alveoli. This results in a greater respiratory effort in order to repeatedly open collapsed 
airways [373-375]. This also leads to the chronic lung hyperinflation, which is manifested by 
increases in total lung capacity (TLC), functional residual capacity (FRC) and residual volume 
(RV). 
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In rodents, some of these changes in lung volume and lung compliance can be obtained by 
determining the quasi-static pressure-volume (P-V) relationship.  In our laboratory, this is 
accomplished by starting at a completely degassed (atelectatic) state and slowly inflating and 
deflating the lung over a volume range between –10 and +35 mH2O. An example of the 
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characteristic of P-V curve in mouse is shown in Fig. 1.6.  Since we cannot obtain the 
maximum lung volume by voluntary effort and the inflation limb of P-V curve never reaches 
a plateau, TLC has to be determined by using a consistent maximal pressure - we have 
chosen 35 cmH2O [376, 377]. The residual volume (RV) can be obtained from the volume of 
air trapped in the lung due to collapse of airways after the first deflation limb as shown in 
Fig. 1.6. Moreover, lung compliance (defined as a change in lung volume per unit change in 
pressure) can be easily phenotyped from the slope of any linear region of the P-V loop (in 
our laboratory we use the range between 3-8 cmH2O). In experimental animal models of 
emphysema, the P-V curve is shifted upward and leftward, resulting in an elevation of TLC, 






















Figure 1.6 Pressure-Volume Relationship. Characteristic P-V curves of naïve BALB/c mouse 






1.5.3    Stereological assessment 
Emphysema has been defined as the “abnormal permanent enlargement of the airspaces 
distal to the terminal bronchioles, accompanied by the destruction of their walls” [28].  Lung 
stereology — unbiased quantitative extraction of the geometry of the irregular three-
dimensional (3D) lung structures from microscopy-based two-dimensional (2D) histological 
section images— was promoted by a joint policy statement from the American Thoracic 
Society and the European Respiratory Society as the appropriate “gold standard” for 
assessment lung morphology [378].  A number of different stereological dimensional 
parameters starting from 0D (number of alveoli), 1D (length or thickness of alveoli), 2D 
(alveolar surface area), to 3D (alveolar volume or size) can be estimated using this 
stereological-based approach.  
 
Emphysema in rodent models is commonly quantified in histological samples in terms of the 
mean linear intercept length (Lm),  defined as the mean length of straight line segments 
(chords) on random test lines spanning the airspace between alveolar walls (Fig. 1.7) [378]. 
Lm actually derives from measurement of volume-to-internal surface area (V/S) ratio of lung 
parenchyma [379], but it is commonly used as an index of airspace size [380]. It can also be 
estimated by intersection and point counting using a suitable coherent stereological test grid 
[381]. However, it is critical to point out that using Lm to quantify airspace enlargement has 
several drawbacks. Firstly, Lm is effective only for measuring the convex particles (i.e., where 
a line traversing the particle can have only one intercept), but alveoli do not always meet this 
condition (as an example in Fig 1.7) [381]. Also, Lm is a parameter representing only a mean, 
it cannot give any information regarding the variation on airspace dimension throughout the 
lung, nor the heterogeneity of pathological changes in the lung that are often found in 
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pulmonary emphysema. Moreover, Lm is very sensitive to degree of inflation and tissue 
shrinkage during fixation and sample preparation [376, 382] - in control animals, larger Lm 
are observed simply with a higher degree of lung inflation [381]. Thus, post-mortem lung 
fixation must be standardized to ensure a similar inflation state for all samples using a high 
inflation pressure (20-30 cmH2O) with a rapid inflow. However, it is not sufficient to 
conclude that the airspace enlargement observed by increased Lm always means emphysema, 
unless there is evidence showing destruction of alveolar walls. It is easy to generate increased 
Lm by inflating a lung without destruction of alveolar walls. Thus, it is important to obtain an 
estimate of tissue destruction, such as a decrease in total alveolar wall volume, total alveolar 



















Figure 1.7 Two approaches to estimate mean linear intercept (chord) length (Lm).  
Direct method based on intercept distribution. The distance (chord length) between 
intercepts of two alveolar walls is measured. A: alveolar airspace, D: alveolar duct, *: blood 
vessel. 
Indirect method based on point and intercept counting. Lm can be estimated indirectly by 
simple point and intersection counting using a coherent test line system. Points overlying on 
alveolar air space (a), ductal air space (d), septal tissue (s), and blood vessel (*).  




1.5.4 Imaging-based techniques 
In clinical practice, although emphysema can typically be diagnosed by physical examinations 
and pulmonary function tests (PFTs), including DLCO, spirometry or P-V relationships, these 
PFTs have a low sensitivity to detect the early stages of emphysema.  Since they lack the 
ability to discriminate at the regional level, the PFT results are at the whole lung level and 
reflect the variable pathologic changes in all lung compartments – some of which may not be 
related to emphysema. Indeed, more than 30% of patients with emphysema have no 
detectable functional abnormalities [386]. However, imaging-based techniques, such as high-
resolution computed tomography (CT), are noninvasive and have sufficiently high resolution 
and sensitivity to depict the presence and characteristic of emphysema in vivo. In rodents, X-
ray micro-CT scanning on anesthetized animals has been used to study the progression of 
emphysema in vivo [387]. Vasilescu et al. applied the principles and methods of design-based 
stereology used for histological sections to the mouse lung parenchymal images obtained 
from micro-CT methods. They found no difference in most stereological parameters (i.e. 
volume fraction of parenchymal and non-parenchymal tissue, mean linear intercept, number 
of alveoli) between quantitative analysis of traditional histological sections and micro-CT 
images [388]. Recently, several types of magnetic resonance imaging (MRI) modalities such 
as proton MRI, and hyperpolarized 3He- or 129Xe-diffusion MRI, have been applied 
successfully for the detection of emphysema in animal models [389-393]. Moreover, Jobse et 
al. recently illustrated that the V/Q (ventilation/perfusion) SPECT (single-photon emission 
computed tomography) imaging can detect lung structural changes in mice exposed to 




While the technology for small animal imaging has been developing, each of these 
techniques have advantages and limitations. The ability to be non-invasive allows in vivo 
imaging, and this is an obvious advantage compared to ex vivo histological techniques, since it 
can preserve the integrity of lung tissue while allowing three-dimensional (3D) 
reconstruction of the anatomy, whereas histological-based techniques physically destroy the 
lung’s 3D structure during the fixation and sectioning processes [388]. However, these 
imaging techniques are costly, requiring expensive instruments and highly trained 
technicians. Also, the histological sections can be further analyzed for biological insight, 
particularly for differentiation of cell/tissue structure and immuno-staining, which is not 




1.6 Thesis Summary, Hypothesis and Specific Aims 
Emphysema is a fundamental component of COPD. Emphysema is characterized by a long-
term, progressive loss of alveolar tissue, and airspace enlargement. The studies that have 
been carried out to define the pathogenesis of emphysema suggest that the mechanisms 
underlying the development of the disease are very complicated, and not completely 
understood.  
 
Several key mechanisms contributing to the pathophysiology of emphysematous changes 
remain unsolved. (i) Although cigarette smoke is the primary risk factor for 
COPD/emphysema, only 15 - 20% of smokers develop the disease. This statistic suggests 
that beyond the factors in cigarette smoke that promote emphysema there are complex 
underlying genetic, environmental and biological factors that dictate susceptibility to the 
disease. In animal models, different species, and different strains within the same species, 
when exposed to the same emphysema-inducing factors, develop different degrees of 
emphysema. (ii) Even though smoking cessation is a recommended therapeutic intervention 
to slow the decline in lung function, in most cases cessation does not stop the progression of 
the disease. This continuous decline is also commonly seen in murine models. This data 
indicates that individual initiating factors, such as cigarette smoke, cannot fully explain the 
pathogenesis of the disease. Aberrant, self-perpetuating, inflammatory or repair mechanisms, 
perhaps enhanced or triggered by initiating factors, might play important roles in the 
progression of emphysema. However, the nature and regulation of the proposed aberrant 
mechanisms are still poorly understood. Thus, identification of the associated cellular and 
molecular processes driving the persistent development of the disease is still required. (iii) 
Many types of respiratory infections can exacerbate emphysema. However, there is scarce 
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literature exploring the mechanisms by which these infections can alter or promote the 
progression of emphysema in humans and experimental animals. Moreover, the studies that 
have considered the effect of infection on the severity of emphysema, none have 
investigated the impact that a history of viral infection has on the progression and severity of 
emphysema. 
 
To date, there are several animal models of emphysema, but none satisfactorily model all 
aspects of human emphysema. Even though arguably the cigarette smoke animal model has 
merit for its use of a proven risk factor, this model is costly, takes a long time and results in a 
weak and high variability outcome. For this research project, we selected the elastase-induced 
emphysema animal model because it has several advantages over the cigarette-smoking 
animal model. The elastase model is relatively simple, inexpensive to implement, disease 
development is rapid, consistent, reproducible and the results replicate several aspects of the 
human disease. The degree of emphysema can easily be controllable by changing the dose of 
the elastase enzyme, (in contrast, in the cigarette smoke model, it is difficult to control the 
severity of emphysema, or produce severe emphysema). Moreover, the elastase model shares 
many similar mechanisms with the cigarette smoke model, such as proteolytic damage, 
matrix remodeling, and inflammatory responses. Lastly, the elastase model allows us to study 
the mechanisms that define the key characteristics of human emphysema disease – the 
progressive loss of alveolar epithelium – an aspect of emphysema that is not reproduced in 
the cigarette smoke model. This should be beneficial for development of novel therapeutic 




The overall goal of the present research is to explore - using elastase-induced murine model - 
the factors, particularly the immunological factors that contribute to the susceptibility to, and 
the regulation of, the development of emphysema. The severity of the emphysematous 
outcomes will be assessed by a combination of approaches, including pulmonary function 
tests such as diffusion factor for carbon monoxide (DFCO), pulmonary mechanics tests (lung 
volume and compliance), and quantitative stereology on histological sections, as well as 
several inflammatory biomarkers.  
 
We hypothesize that: (i) the susceptibility to the develop elastase-induced disease is different 
in two strains of mice (Chapter 3); (ii) immune mechanisms mediate this difference (Chapter 
4); and (iii) the disease can be altered by pre-infection with viruses (Chapter 5). The results 
should provide insight into the pathogenesis of emphysema, and help determine the roles of 
each mediator in the disease mechanism, thus providing potential targets for novel 
therapeutic intervention.  
 
To test our three hypotheses, we have established three specific aims, each of which will be 
addressed in an individual chapter. 
 
Specific Aim 1: Compare the susceptibility to elastase-induced emphysema in two 
commonly-used mouse strains: C57BL/6 and BALB/c 
To identify a genetic basis for differential susceptibility to develop emphysema of two 
commonly-used strains of mice, C57BL/6 and BALB/c, were exposed to varying doses of 
elastase and at different time points. The levels of lung damage were assessed by performing 




Specific Aim 2: Explore the immunological responses that contribute to susceptibility 
to, and progression of, elastase-induced emphysema 
To determine the role of various immunological mediators in the development of 
emphysemic damage, genetically modified mice deficient in specific mediators were 
challenged with elastase and the degree of emphysema was assessed by performing 
functional tests, mechanical tests, and histology. 
 
Specific Aim 3: Determine the impact of viral infection on development of elastase-
induced emphysema 
To investigate the role of viral infection on emphysema development, two types of viruses, 
(vaccinia and influenza), were delivered at different time points either before or after elastase 
challenge. To determine the degree of emphysema, we performed the functional tests, 


































Male wild type (WT) BALB/cJ, wild-type C57BL/6J, RAG-1-/- (on both BALB/c and 
C57BL/6 genetic background) and MyD88-/- (C57BL/6 background) were purchased 
directly from The Jackson Laboratory (Bar Harbor, ME). Breeder pairs of IFN--/- (both on 
BALB/c and C57BL/6 background) and STAT6-/- (BALB/c background) mice were also 
obtained from The Jackson Laboratory. ST2-/- mice were originally generated and 
backcrossed onto a BALB/c background by Dr. Andrew McKenzie (Medical Research 
Council, United Kingdom) as previously described [395, 396] and provided to us by Dr. 
DeLisa Fairweather. IL17A-/- (BALB/c background) mice were generated by Dr. Yoichiro 
Iwakura (University of Tokyo, Japan) [397] and kindly donated by Dr. Noel Rose. 
Conditional deleted STAT3 in myeloid cells (Cre-Lyz/STAT3fl/fl) and in CD4 cells (Cre-
CD4/STAT3fl/fl) mice were gifts from Dr. Cynthia Sears (Johns Hopkins School of 
Medicine). All knockout mice were bred and housed under specific pathogen-free conditions 
at the Johns Hopkins School of Public Health.  The animals were provided filtered air (60-
70% relative humidity) at 22-26ºC and maintained on a 12-hour light/dark cycle with ad 
labitum access to autoclaved food and filtered water. All experiments were performed using 
adult 8-10 week-old male mice according to the Institutional Animal Care and Use 
Committee of the Johns Hopkins University’s guidelines for all procedures. 
 
2.2 Intratracheal Elastase Administration 
To induce pulmonary emphysema, mice were anesthetized with a mixture of ketamine (100 
mg/kg)/xylazine (15 mg/kg) via intraperitoneal (i.p.) injection and suspended supine on a 
15º sloped platform by their upper teeth using silk thread.  A small incision on the neck was 
made to visualize the trachea. A 20-gauge IV catheter (Jelco Optiva®, Smith Medical, 
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Dublin, OH) with a manually bent tip was inserted into the trachea by gently pulling out the 
tongue and inserting the cannula toward the ventral surface of the mouse. A single dose of 
either 1.5, 3, 6 or 9 units (U) of porcine pancreatic elastase (EC-134, Elastin Products 
Company, Owensville, MO) dissolved in 50 L of sterile 1X phosphate-buffered saline 
(PBS) was injected into the lung through the inserted catheter. To promote the distribution 
of the solution into the lung, mice were then immediately ventilated through the cannula for 
10 seconds with room air at 0.1 mL tidal volume and 150 strokes/minute using a MicroVent 
Ventilator (Model 848, Harvard Apparatus, Holliston, MA). Control animals obtained an 
equal volume of sterile PBS only. After removing the cannula, the incision was closed by 
applying a small amount of cyanoacrylate tissue adhesive (Vetbond™ 3M™). Mice were 
allowed to recover at least 2 days, and were studied at various time points (2 days up to 5 
months) after elastase challenge as indicated in each experiment. 
 
2.3 Vaccinia and Influenza Infections 
To test the role of viral infection on the susceptibility of emphysema progression, either 
vaccinia virus (VV) or influenza A virus (IAV) was used in this study.  Attenuated Modified 
Vaccinia Ankara (MVA) strain of VV was kindly provided by Drs. Maureen Horton and 
Jonathan Powell at the Johns Hopkins School of Medicine. The VV was generated and 
passaged as previously described [398]. This strain of VV was genetically modified to contain 
ovalbumin protein sequence in the construct for facilitating the antigen-specific anti-viral 
immune response, while lacking lytic ability.  Stock of VV at 1 x 108 plaque-forming units 
(pfu) was stored at -80ºC. To inoculate VV into mice, mice were anesthetized by inhalation 
of 3% isoflurane mixed in an oxygen vaporizer, and then administered intranasally (i.n.) with 
2 x 106 pfu. The mock vaccinated mice were given with 20 L of PBS. At 7 or 21 days after 
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immunization with vaccinia, the mice were challenged i.t. with either PBS or elastase (1.5, 3 
or 6 U) as described above. 
 
For IAV-infected mice, mouse-adapted influenza A virus, A/Puerto Rico/8/34 (PR8: 
H1N1), was obtained from Dr. Sabra Klein, who originally obtained it from Dr. Maryna 
Eichelberger at the Food and Drug Administration. Mice were anesthetized by i.p. injection 
of a mixture of ketamine-xylazine (100 mg/kg and 15 mg/kg, respectively) and then i.n. 
inoculated with 20 l of a sublethal dose of PR8 (50 TCID50 (50% tissue culture infective 
dose) units/mouse) diluted in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) 
[399]. This dose of PR8 was chosen based on preliminary experiments showing that this 
dose did not kill any animals at least for 5 weeks after infection. The mock infected mice 
received an equal amount of vehicle (DMEM). All mice were maintained in microisolater 
cages and handled using biosafety level 2 (BSL2) practices and procedures. Body weights of 
mice were measured daily throughout the experiments. At 14 days after infection, mice 
received either PBS or elastase as appropriate for each specific experiment. 
 
2.4 Pulmonary Functions and Structure Phenotyping 
2.4.1 Diffusion Factor for Carbon Monoxide (DFCO) Measurement 
The complete procedure for measuring DFCO in mice was described in our recent 
publication [372]. Briefly, on the harvest day, mice were anesthetized with a 
ketamine/xylazine mixture (i.p.) prior to tracheostomy with an 18G stub needle cannula. 
Then, mouse lungs were quickly inflated with 0.8 mL of gas mixture containing 
approximately 0.5% carbon monoxide (CO), 0.5% neon (insoluble inert tracer gas) and 
balance room air. After a 9 second breath hold, 0.8 ml was quickly withdrawn from the lung 
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and diluted to 2 mL with room air. The dilution to 2 mL was needed to ensure that the 
tubing connection in the system was cleared with the sample gas. The diluted exhaled gas 
was allowed to mix for at least 15 seconds and was then injected into a Micro GC gas 
chromatograph (INFICON, Micro GC Model 3000A, East Syracuse, NY) to measure the 
concentrations of Ne and CO. This process was repeated at least twice and the averages of 
these Ne and CO concentration were used to calculate the DFCO for each animal. The DFCO 
was calculated as 1– (CO9/COC)/(Ne9/NeC), where “9” subscript refers to gases after the 9 
seconds of being held by the animal and “C” subscript refers to the calibration gases [371]. 
 
2.4.2 Pulmonary Mechanics and Quasi-static Pressure-Volume Relationships 
After DFCO measurements, mice were paralyzed with an intramuscular injection of 
succinylcholine at a dose of 75 mg/kg body weight. Then, animals were immediately 
connected to a flexiVent™ ventilator (Scireq, Montreal, QC, Canada) which provided a 
constant-volume ventilation to the mice with 100% oxygen at a tidal volume of 10 mL/kg, a 
rate of 150 breaths per minute, and a positive end‐expiratory pressure (PEEP) of 3 cmH2O. 
Following at least 3 minutes of this ventilation, the lungs were inflated to 30 cmH2O for 5 
seconds and returned to normal ventilation for 1 minute. Measurement of respiratory 
mechanics was then performed under closed chest conditions by applying an oscillatory 
pressure (the forced oscillation technique (FOT)), to the animal’s lungs and measuring the 
flow responses to the applied pressures.  Before doing the FOT measurement, conventional 
single‐compartment mechanics was first measured with 2 seconds of a 2.5‐Hz sinusoidal 
oscillation (Snapshot-150) to obtain respiratory system resistance (Rrs), dynamic compliance 
(Crs) and elastance (Ers) [400]. Next, the broadband FOT maneuver (Quick prime-3) was 
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performed and analyzed using the constant phase model, which provided Newtonian airway 
resistance (Rn), tissue damping (G), and tissue elastance (H) [401].  
 
Following the FOT maneuver, the stopcock connected to the cannula was closed to seal the 
mouse’s lung for 4 minutes, which allowed the animal to absorb all gas from the lung. After 
complete degassing, the lung volume was zero, and quasi-static pressure-volume (P-V) 
curves were immediately generated with a system detailed in previous studies [377]. Briefly, 
the system consists of a 5 mL air-filled glass syringe with an initial volume set at 3 ml 
mounted on a dual infusion-withdrawal syringe pump (model 55-2226, Harvard Apparatus, 
Holliston, MA). Delivered air volume to the lung was measured with a linear displacement 
transformer (model 244-000, Transtek, Ellington, CT), while airway pressure was measured 
with a differential-pressure transducer (PX-137, Omega Engineering, Stamford, CT). Airway 
pressure and volume were measured and the generated P-V curve was recorded on a 
PowerLab digital data acquisition system (ADInstruments, Colorado Springs, CO). To avoid 
excessive pressures during initial recruitment of the degassed lung, the first inflation was 
acquired at a slow flow rate (1 mL/min). Until reaching the pressure of 35 cmH2O, the flow 
rate was increased to 3 mL/min and the pump was instantly reversed to deflate the lung till a 
pressure of -10 cmH2O. Then, two more sequential P-V loops between 0 – 35 cmH2O were 
performed to ensure no leak or obstruction in the system and in the lung. Total lung capacity 
(TLC) and residual volume (RV) of each mouse were defined as the volume at 35 cmH2O 
and –10 cmH2O respectively, and quasistatic compliance of the respiratory system (Cstat) 






2.4.3 Lung Harvesting and Fixed Left Lung Volume Measurement 
After finishing the pulmonary mechanics measurements, the chest wall and diaphragm were 
exposed and the right mainstem bronchus was tied off with suture. The four right lobes of 
the lung (cranial, middle, caudal including accessory lobes) were removed, snap frozen in 
liquid nitrogen and stored at –80°C for RNA and protein analysis. The left lobe was then 
inflated with zinc-buffered formalin (Z-Fix, 174, Anatech, Battle Creek, MI) at a constant 
pressure of 30 cmH2O for at least 10 minutes. Next, the trachea was tied, the heart and left 
lung en bloc were excised from the chest cavity and kept submerged in Z-fix for at least 24 
hours. Then non-lung tissues were removed, and the fixed left lung volume was measured by 
the water immersion technique (Archimedes principle) [402]. Finally, the left lung was stored 
in 70% ethanol for further histologic processing. 
 
2.4.4 Lung Histology and Morphometry 
To measure the quantitative stereologic parameters of the lung, the left lung was cut 
transversely to the long axis into three pieces and then embedded in paraffin. Five-micron-
thick sections were cut from each of the pieces, and the sections were stained with 
hematoxylin and eosin (H&E) to assess lung architecture and inflammatory cells. Photos of 
parts of these sections were taken using a systematic uniform random sampling method 
[378] with a Nikon Eclipse 80i (Nikon, Tokyo, Japan) at ×200 magnification.  Fifteen to 
twenty digital images were obtained from each of the 3 lung sections. Each of these images 
was then analyzed by overlaying them with a sample grid line using Nikon's NIS Elements 
software. The stereological metric of airspace size was determined by the mean linear 
intercept (Lm) and alveolar surface area (S). These quantitative assessments of 
emphysematous changes in the lung were performed with a traditional system of 
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quantification [381] using counts of the number of intercepts with alveolar walls, and 
identifying where the end points of each line fell. From this sampling data, we then 
calculated the following:   
  Alveolar surface area (S) = 4(Vp・Ialv) /(d・Pair);   
   Lm = 4Vp/S, 
where Vp = parenchymal volume (which can be calculated from parenchymal fraction (Fpar) 
x fixed lung volume (from water displacement method), 
Ialv = number intercepts with alveolar septal walls,   
d = length of a single test line,  
and Pair = number of points hitting air spaces in alveoli and ducts. 
 
2.5 Bronchoalveolar Lavage (BAL) 
 2.5.1 Collection of BAL 
To assess cellular and protein profiles in the interalveolar space, lungs were slowly lavaged 
three times with 0.8 mL of cold PBS containing complete protease cocktail inhibitor tablets 
(Roche Applied Science, Indianapolis, IN).  For each lavage, the withdrawn lavage was 
stored on ice. This process was repeated with a fresh 0.8 mL volume of cold PBS. The first 
recovered BAL fluids from each sample were centrifuged at 300 g at 4ºC for 10 minutes to 
pellet cells. The supernatant was collected and stored at -80ºC for later BAL total protein 
and cytokine measurement. The cell pellet from the first wash was pooled with the second 
wash and centrifuged. The supernatant was discarded, and the remaining cells were re-
suspended with 1 mL of cold PBS and aliquoted into two separate tubes (0.5 ml each). One 
aliquot was used to determine the hemoglobin content, whereas another was processed to 
identify total and differential cell counts. 
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 2.5.2 Hemoglobin Content 
To quantify hemorrhage from alveolar epithelium-endothelium leakage into the BAL, we 
indirectly determined hemoglobin [403], by spectrophotometric analysis. Hemoglobin shows 
maximum light absorbance peak between 400-420 nm and absorbance at 405 nm correlates 
linearly with amount of erythrocytes in both lysed and intact cell suspension form [404]. 
Thus, one aliquot of 0.5 mL BAL from each sample was centrifuged and the supernatant 
was discarded.  Cells in the pellet were lysed with 0.5 mL hypotonic distilled water for 5 
minutes. Absorbance measurements of 0.2 mL cell lysates in replicate were taken at 405 nm 
using an Epoch Micro-Volume Spectrophotometer (BioTek, Winooski, VT). 
 
2.5.3 Differential Cell Count 
Another BAL aliquot was centrifuged to pellet the cells. After removing the supernatant, 0.1 
mL of Ammonium-Chloride-Potassium (ACK) lysis buffer (118-156-721, Quality Biological, 
Gaithersburg, MD) was added to the pellet at room temperature to lyse erythrocytes for 5 
minutes. Then, 0.4 mL of cold 1X PBS was added to the lysates. Ten microliters of total 
white blood cells in BAL were stained with Turk’s solution (EMD Millipore) prior to 
counting on a hemocytometer (Cambridge Instruments, Buffalo, NY) using a 20X objective 
of a Nikon Eclipse 80i (Nikon, Tokyo, Japan). Cells were also adhered to a glass microscope 
slide by cytocentrifugation (Cytospin 2; Shandon Instruments, Pittsburg, PA), fixed, and 
stained with Hema3™ (Fisher Scientific, Waltham, MA).  BAL cells were identified and 






2.5.4 Protein Concentration Measurement 
Total protein in BAL supernatant was determined with a bicinchoninic acid (BCA) protein 
assay (Pierce Thermo Scientific, Rockford, IL) according to the manufacturer's protocol. In 
brief, 25 l of BAL fluid was added to 200 L of a mixture of alkaline cupric (Cu2+) solution 
and BCA, and incubated at 37ºc for 30 minutes. The absorbance of purple-colored reaction 
products of this assay was measured at 562 nm with Epoch Micro-Volume 
Spectrophotometer (BioTek). The total protein in BAL fluid was determined by calculating 
the optical density of samples using standard curves generated with serial dilutions of known 
concentrations of bovine serum albumin (BSA) and expressed as micrograms per milliliter. 
The limit of detection was 5 µg/mL. 
 
2.6 RNA Extraction, Reverse Transcription, and Real-Time PCR 
Small pieces of snap-frozen right lung tissue were homogenized at 4000 rpm for 30 seconds 
in 1 mL Trizol Reagent (Ambion RNA Life technologies, Carlsbad, CA) in pre-filled 
Zirconium Beads Tubes (Denville Scientific, South Plainfield, NJ) using a Bead Bug 
microtube homogenizer (Benchmark Scientific, Edison NJ). Then, RNA was extracted from 
the aqueous phase of a Trizol and 1-bromo-2-chloropropane (BCP) mixture, precipitated 
with 100% isopropanol, washed with 75% ethanol in Diethylpyrocarbonate (DEPC)-treated 
water, and suspended in 100-200 L of DEPC-treated water. Lung RNA concentration and 
purity were assessed by a ratio of absorbance at 260 nm and 280 nm using the Take3 session 
mode on the Epoch Micro-Volume Spectrophotometer (BioTek). This lung RNA was 




One g of total RNA from lung homogenates was reverse-transcribed into complementary 
DNA (cDNA) with oilgo-dT and random primers using an iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA) following the manufacturer’s instruction. Reaction tubes were incubated 
at 25°C for 5 minutes, then at 42°C for 60 minutes, and finally with stopped reaction at 
85 °C for 5 minutes. The cDNA was then used for amplification and real-time detection in a 
96-well format using the Applied Biosystems 7500 real-time PCR system with TaqMan Gene 
Expression Assays-On-Demand, and TaqMan Universal Master Mix (Life Technologies, 
Grand Island, NY) following the manufacturer’s recommendation. Briefly, 15 L reactions 
were used containing 2 L of cDNA, 0.5 l commercially available gene expression Taqman 
fluorogenic primer/probes set as mentioned in Table 2.1 (Life Technologies), 7.5 L of 
Taqman Universal Master Mix (Life Technologies), and 5 L of DEPC-treated water. The 
PCR reaction was performed with the following thermal profile: 50ºC for 2 minutes, 95ºC 
for 10 minutes, and then 40 cycles of 95ºC (15 seconds), followed by 60ºC (1 minute). 
Analysis of gene expression was performed using the Applied Biosystems 7500 system SDS 
software package (Life Technologies). The relative expression ratio (RER) of the real-time 
PCR products was calculated by the 2‐ Ct method [405] which represents the fold difference 
in gene expression normalized to a housekeeping gene control (Actb: -actin) from the same 
sample. The relative expression was compared to the average of naïve Day 0 or PBS/media 
control treated groups. The average CT value of control groups was arbitrarily assigned an 


















Actin, beta Actb 11461 Mm00607939_s1 
Interferon, gamma Ifng 15978 Mm01168134_m1
IL-1, alpha Il1a 16175 Mm00439620_m1
IL-1, beta Il1b 16176 Mm00434228_m1
IL-4 Il4 16189 Mm00445259_m1
IL-5 Il5 16191 Mm00439646_m1
IL-6 Il6 16193 Mm00446190_m1
IL-10 Il10 16153 Mm01288386_m1
IL-13 Il13 16163 Mm00434204_m1
IL-17A Il17a 16171 Mm00439618_m1
IL-18 Il18 16173 Mm00434225_m1
IL-23, alpha subunit p19 Il23a 83430 Mm01160011_g1 
IL-33 Il33 77125 Mm00505403_m1
Interleukin 1 receptor-like 1, ST2, T1/ST2 Il1rl1 17082 Mm00516117_m1
Amphiregulin Areg 11839 Mm00437583_m1
Epidermal growth factor receptor (EGfr) Egfr 13649 Mm00433023_m1
Foxp3 Foxp3 20371 Mm00475162_m1
Heme Oxygenase (decycling) 1 (HO-1) Hmox1 15368 Mm00516005_m1
Inducible nitric oxide synthase 2 (iNOS) Nos2 18126 Mm00440502_m1
Arginase, liver (Arg-1) Arg1 11846 Mm00475988_m1
Chitinase-like 3 (Ym1) Chil3 12655 Mm00475988_m1
Resistin like alpha (RELMa, Fizz1) Retnla 57262 Mm00445109_m1
Matrix Metalloproteinase 2 (MMP-2) Mmp2 17390 Mm00439498_m1
Matrix Metalloproteinase 9 (MMP-9) Mmp9 17395 Mm00442991_m1
Matrix Metalloproteinase 12 (MMP-12) Mmp12 17381 Mm00500554_m1
Alpha-1-antitrypsin (1-AT) Serpina1a 20700 Mm02748447_g1 
Alpha-2-macroglobulin A2m 232345 Mm00558642_m1
Tissue inhibitor of metalloproteinase 1 (TIMP-1) Timp1 21857 Mm00441818_m1
Tissue inhibitor of metalloproteinase 2 (TIMP-2) Timp2 21858 Mm00441825_m1
Tissue inhibitor of metalloproteinase 3 (TIMP-3) Timp3 21859 Mm00441826_m1
Tissue inhibitor of metalloproteinase 4 (TIMP-4) Timp4 110595 Mm01184417_m1
Signal Transducer and Activator of 
Transcription 3 (STAT3) 
Stat3 20848 Mm01219775_m1
CD200 antigen (OX2) Cd200 17470 Mm00487740_m1
CD200 receptor 1 Cd200r1 57781 Mm00491164_m1
Transformation related protein 63 (p63) Trp63 22061 Mm00495793_m1






2.7 Protein isolation and Enzyme-Linked Immunosorbent Assays (ELISAs) 
To isolate protein for ELISA analysis, all four right lobes of the lung  from each mouse were 
homogenized at 4000 rpm for 45 seconds in 1 mL cold PBS plus complete protease cocktail 
inhibitor (Roche Applied Science) in the pre-filled Zirconium Beads Tubes (Denville 
Scientific) using a Bead Bug microtube homogenizer (Benchmark Scientific). Homogenates 
were then centrifuged at 10,000g at 4ºC for 10 minutes. The supernatants were transferred to 
a new tube and stored at -80ºC until used. Levels of IFN- and IL-33 were determined in 
homogenized supernatant using Duoset® ELISA development system kits (R&D System, 
Minneapolis, MN) according to the manufacturer’s instructions. Level were expressed as 
pg/mL/right lung. The limits of detection were 15.6 pg/mL for IL-33, and 31.25 pg/mL for 
IFN- 
 
2.8 Western Blotting 
For Western blot analysis of STAT3 and STAT6 phosphorylation, pieces of snap-frozen 
right lungs were homogenized at 4000 rpm for 45 seconds in 0.5 mL ice-cold 1X radio-
immunoprecipitation assay (RIPA) lysis buffer (Sigma Aldrich, St. Louis, MO) containing 
protease cocktail inhibitors (Roche Applied Science), 100 mM phenylmethylsulfonyl fluoride 
(PMSF) solution, and both serine/threonine and tyrosine protein phosphatase inhibitors 
(Sigma Aldrich). Homogenates were then centrifuged at 10,000g at 4ºC for 10 minutes, and 
the lysates were stored at –20°C until required. Protein concentrations were determined by 
BCA protein assay (Pierce Thermo Scientific) as described in section 2.5.4. All samples were 
heated at 70°C for 10 minutes in 25 L NuPAGE® Lithium Dodecyl Sulfate (LDS) Sample 
Buffer containing NuPAGE® reducing agent (Life Technologies). Then, denatured protein 
(50 µg) was loaded and separated by electrophoresis on a pre-cast 4-12% Bis-Tris 
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polyacrylamide gel using Bolt® mini gel tank system (Life Technologies), and subsequently 
transferred onto 0.2 m polyvinyl difluoride (PVDF) membranes for 7 minute using iBlot® 
Dry Blotting system (Life Technologies, Grand Island, NY). Membranes were blocked in 
Odyssey® blocking buffer (Li-cor Biosciences, Lincoln, NE) overnight at 4°C. Afterwards, 
the membranes were incubated with the following primary antibodies (in 0.2% Tween-20 in 
blocking buffer) for 1 hour at room temperature (also see in Table 2.2): phospho-STAT3 
(Tyr705) (1:1500, Cell Signaling Technology, Beverly, MA), STAT3 (1:200, Santa-Cruz 
Biotechnology, Dallas, TX), phospho-STAT6 (Tyr641) (1:500, Santa-Cruz Biotechnology, 
Dallas, TX), STAT6 (1:500, Santa-Cruz Biotechnology), or anti--actin (1:1000, Cell 
Signaling Technology). Membranes were then washed four times with 1X PBS and 0.1% 
Tween® 20 (Sigma Aldrich) and incubated for 30 minutes at room temperature with 
appropriate IRDye® fluorescently-labeled secondary antibody (in 0.2% Tween® 20 plus 
0.02% SDS in blocking buffer at 1:10000 dilution, Li-cor Biosciences). Blots were washed 
again, rinsed with PBS and imaged using an Odyssey® Classic Infrared Imaging system (Li-
cor Biosciences). Densitometric analysis of the immunoreactive signal was analyzed with 
Image Studio Lite (Li-cor Biosciences). The data were expressed as a ratio between arbitrary 
units (A.U.) of phospho-protein and total STAT3 or STAT6 protein. 
 
2.9 Nuclear Protein Extraction and STAT3 Transcription Factor Activity Assay 
To quantify the activation and translocation of STAT3 into the nucleus, nuclear extracts 
from a piece of frozen right lung were prepared using a nuclear extract kit (Active Motif, 
Carlsbad, CA). Briefly, the tissue was homogenized in ice-cold 1X hypotonic buffer 
containing phosphatase and protease inhibitors supplemented with dithiothreitol (DTT) and 
detergent using a 7-mL dounce tissue grinder (Wheaton, Millville, NJ). The lysate was then 
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centrifuged at 850 g at 4°C for 10 minutes. The pellet containing cells was re-suspended in 
1X hypotonic buffer with detergent, vortexed at high speed, and centrifuged at 14000 g at 
4°C for 30 seconds to pellet the nuclear fraction. The supernatant with the cytoplasmic 
fraction was discarded, and the pellet containing the nuclear components was lysed in lysis 
buffer plus DTT and protease inhibitor cocktail, vortexed, incubated on ice for 30 minutes, 
and centrifuged at 14,000 g at 4°C for 10 minutes. The nuclear extract in this final 
supernatant compartment was aliquoted, and its protein content was measured using the 
BCA assay as mentioned above, and then store at -80°C until used. 
 
The lung nuclear extract was used to determine the specific binding of STAT3 to its 
respective consensus binding site (5’-TTCCCGGAA-3’) using TransAM® STAT3 
transcription factor activity assay kit (Active Motif). The colorimetric result was developed 
using anti-STAT3 primary antibody and an HRP-conjugated secondary antibody system, 
whose absorbance could be measured at 450 nm with a reference wavelength of 655 nm 
(Epoch Micro-Volume Spectrophotometer - BioTek). Nuclear extracts from human liver 
cancer Hep G2 cells treated with IL-6, a well-known STAT3 activator, were used as positive 
controls. Specificity was monitored by adding STAT3 binding competitors, using either wild-























-actin (8H10D10) Cell Signaling 3700 mouse mAb WB 1:1000 
Phospho-STAT3 
(Tyr705) (D3A7) 
Cell Signaling 9145 rabbit mAb WB 1:1500
STAT3 (C-20) Santa-Cruz sc-482 rabbit pAb WB 1:200
Phospho-STAT6 
(Tyr641) 
Santa-Cruz sc-11762-R rabbit pAb WB 1:500
STAT6 (D1) Santa-Cruz sc-374021 mouse mAb WB 1:500
Anti-rabbit IgG 
IRDye® 800CW 
Li-cor 926-32213 donkey 2° Ab WB 1:10000
Anti-mouse IRDye® 
680RD 
Li-cor 926-68070 goat 2° Ab WB 1:10000
SiglecF-PE BD Biosciences 552126 rat mAb FL 1:100 
CD11b-PerCP-Cy5.5 BD Biosciences 550993 rat mAb FL 1:100 
CD11c-APC Miltenyi Biotec 130-091-
844 
hamster mAb FL 
1:50 
CD4-FITC eBioscience 11-0042-82 rat mAb FL 1:100
CD8-PE eBioscience 12-0081-82 rat mAb FL 1:100
CD3-PerCP-Cy5.5 eBioscience 45-0031-82 hamster mAb FL 1:100
B220-APC BD Biosciences 553092 rat mAb FL 1:100
NKp46-FITC eBioscience 11-3351-82 rat mAb FL 1:100
CD49b-PE BD Bioscience 553858 rat mAb FL 1:100
NKG2D-APC eBioscience 17-5882-81 rat mAb FL 1:100
Ly6G-FITC eBioscience 11-5931-82 rat mAb FL 1:100
CD64-PE BD Biosciences 558455 rat mAb FL 1:100
Ly6C-APC BD Biosciences 560595 rat mAb FL 1:100
gdTCR-APC eBioscience 17-5711-81 hamster mAb FL 1:100
IL-10-PE eBioscience 12-7101-81 rat mAb FL 1:100
Isotype-PE eBioscience 12-4031-81 rat mAb FL 1:100
CD25-PE-Cy7 eBioscience 25-0251-81 rat mAb FL 1:100
Foxp3-AlexaFluor647 BD Biosciences 560402 rat mAb FL 1:100
IFN-g-APC eBioscience 17-7311-81 rat mAb FL 1:100
Isotype-APC eBioscience 17-4301-81 rat mAb FL 1:100
IL-33 propeptide R & D AF5010 sheep pAb IF 1:20
Prosurfactant protein C Abcam ab90716 rabbit pAb IF 1:200
Alexa Fluor® 555 
Anti-Sheep IgG  
Molecular Probes A21436 donkey 2° Ab IF 1:200
Alexa Fluor® 488 
Anti-Rabbit IgG  
Molecular Probes A11008 goat 2° Ab IF 1:200
*mAb indicates monoclonal antibody, whereas pAb indicates polyclonal antibody. 2° Ab = secondary antibody. 




2.10 Flow Cytometry Analysis 
Single-cell suspensions from whole lungs were generated as previous described [406]. Briefly, 
lungs were perfused with 10 mL of room temperature sterile Dulbecco’s PBS via the right 
ventricle of the heart, then carefully removed from the chest (excluding non-lung tissue), 
minced thoroughly into fine pieces, and digested in a 5 mL RPMI 1640 medium (Life 
Technologies) containing 1 mg/mL collagenase type II (1701-015, Life Technologies) and 30 
g/mL DNase I (10104159001, Roche Applied Science) at 37°C for 30 minutes. Minced 
tissues were then filtered through a 100-µm mesh nylon cell strainer (352360, BD Falcon, 
Bedford, MA) to form a single-cell suspension. These single-cell suspensions were pelleted at 
1500g at 4°C, washed and re-suspended in ACK lysis buffer (Quality Biological) at room 
temperature for 5 minutes to lyse any contaminating erythrocytes. The remaining cells were 
passed through a new cell strainer, washed twice in FACS staining buffer [1X PBS with 2% 
heated-inactivated fetal calf serum (35-011-CV, Mediatech, Inc., Manassas, VA)], and treated 
with anti-mouse CD16/CD32 Fc Block (553142, BD Biosciences, San Jose, CA) for 10 
minutes prior to incubating in the dark with appropriate fluorochrome-conjugated surface 
marker staining antibodies on ice for 20 minutes.  
 
If intracellular cytokine staining (ICS) was needed, prior to the blocking and surface staining, 
isolated cells were stimulated for 4 hours at 37ºC with 50 ng/mL phorbol 12-myristate 13-
acetate (PMA, P1585, Sigma-Aldrich), 1 µg/mL ionomycin (I0634, Sigma-Aldrich) in the 
presence of cytokine secretion blocker Brefeldin (00-4506, eBioscience). Then, these 
stimulated cells were blocked, surface stained as above, washed in FACS staining buffer, 
fixed and permeabilized with the BD Cytofix/Cytoperm™ solution kit (555028, BD 
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Bioscience),  and finally stained with fluorescently-labeled specific intracellular staining 
antibodies. Staining with control isotype antibodies was included in each sample. 
 
All stained samples were then washed twice and analyzed on a BD FACSCalibur flow 
cytometer equipped with CellQuest Pro software (BD Bioscience). Total live cell numbers 
were counted on a hemocytometer using standard tryphan blue (15250-061, Life 
Technologies) dead cell exclusion test. All flow cytometry data were analyzed and plotted 
with FlowJo software (TreeStar, Inc., Ashland, OR). 
 
2.11 Immunofluorescent histochemistry 
To localize IL-33 expressing cells in the lung, unstained formalin-fixed, paraffin-embedded 
histological sections of 5 µm thickness were deparaffinized with 3 soakings in xylene for 5 
minutes each, followed by rehydrating in a series of ethanol concentration (100%, 95%, 
70%) for 3 minutes each, and then placed in running distilled H2O. Antigen retrieval was 
then done by heating the slides in 10 mM citrate buffer (pH 6.0) (S2369, Dako, Carpentaria, 
CA) to 90°C in a microwave for 10 minutes. Tissue sections were outlined with a 
hydrophobic barrier Dako pen (Dako) and blocked in the mixture between 2.5% normal 
goat serum (S-1012, Vector Labs, Burlingame, CA) and 2.5% donkey serum (D9663, Sigma 
Aldrich) in PBS for 1 hour at room temperature. Then, primary antibodies, including sheep 
polyclonal anti-IL-33 propeptide antibody (1:20, R&D) and rabbit polyclonal anti-
prosurfactant protein C antibody (1:200, Abcam, Cambridge, MA) in blocking solutions, 
were added to the slides and incubated overnight at 4°C. Sections were subsequently rinsed 
three times with 1X PBS and 0.05% Tween® 20 (Sigma Aldrich) prior to incubating 1.5 
hours with secondary antibodies including Alexa Flour® 555 donkey anti-sheep antibody 
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(1:200, Molecular Probe, Grand Island, NY) and Alexa Flour® 488 goat anti-rabbit antibody 
(1:200, Molecular Probe) at room temperature. After 3 additional 5 minute washes, the 
sections were mounted with a medium containing the nuclear dye 4’,6-diamidino-2-
phenylindole (DAPI) (Vectashield® mounting medium, H-1200, Vector Labs). 
Epifluorescent images were taken with a Nikon Eclipse 80i fluorescent camera (Nikon, 
Tokyo, Japan). 
 
2.12 Statistical Analysis 
Data were analyzed using GraphPad Prism Software (GraphPad, La Jolla, CA) by either a 
two-tailed unpaired Student t test (two groups) or a two-way analysis of variance (ANOVA) 
for multiple group analysis following by a post-hoc Tukey’s multiple comparison test to 
compare differences between groups as specified in each figure legends. Comparisons of 
Kaplan-Meier survival curves between groups were analyzed with a log-rank test. All of the 
data were expressed and plotted as means ± standard error of mean (SEM). Statistical 




















BALB/cJ mice are more susceptible to 
develop elastase-induced emphysema 











Emphysema, one of the major components of COPD, is characterized by the progressive 
and irreversible loss of alveolar lung tissue. Even though more than 80% of COPD cases are 
associated with cigarette smoking, only a relatively small proportion of smokers develop 
emphysema, suggesting a potential role for genetic factors in determining individual 
susceptibility to develop emphysema.  Although strain-dependent effects have been shown 
in several animal models of emphysema, the molecular basis underlying this intrinsic 
susceptibility is not fully understood. In this present study, we investigated emphysema 
development using the elastase model in two commonly used mouse strains, C57BL/6J and 
BALB/cJ. The results demonstrate that mice with different genetic backgrounds show 
disparate susceptibility to the development of emphysema. BALB/cJ mice were found to be 
much more sensitive than C57BL/6J to elastase insults in both a dose-dependent and time-
dependent manner, as measured by a significantly higher mortality, greater body weight loss, 
greater decline in lung function and mechanics, as well as a greater loss of alveolar tissue. 
The more susceptible BALB/cJ strain also showed persistence of inflammatory cells in the 
lung, especially macrophages and lymphocytes. A comparative analysis of gene expression 
following elastase-induced injury showed BALB/cJ mice elevated levels of IL-17A and 
alternatively-activated macrophages (M2) markers, whereas the C57BL/6J mice 
demonstrated augmented level of IFN-. These findings suggest a possible role for these 
cellular and molecular mediators in modulating the severity of emphysema, and the 







Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the 
Unites States and its prevalence and mortality is also steadily increasing globally.  COPD is 
comprised of two key components, chronic bronchitis and emphysema, and both lead to 
persistent airflow limitation [18, 25]. Emphysema is anatomically defined as a condition with 
irreversible airspace enlargement along with a slow progression of the alveolar wall 
destruction [29]. The mechanistic basis underlying its pathogenesis is very complex, 
involving a combination of recurrent inflammation, oxidative stress, proteases, and cell 
death, and all of these can be modified by both environmental exposures and host genetics 
[222, 407]. Cigarette smoking has been identified to be the most important environmental 
risk factor in developing emphysema, accounting for more than 80% of the cases [39-41]. 
Although clinical studies have shown that all smokers demonstrate a degree of pulmonary 
inflammation, only 15 - 20% of smokers develop emphysema [408]. This underscores the 
importance of susceptibility factors, which are almost certainly controlled by host genetic 
predisposition.  
 
Experimental mice are now commonly used to study the pathogenesis of many diseases, and 
the availability of inbred strains has provided many insights into the genetic basis of 
resistance or susceptibility to developing a number of different human diseases including 
emphysema. It has been documented that the development of emphysema in cigarette 
smoke-exposed mice is strain-dependent [409, 410]. Another common way to establish 
experimental emphysema is the use of an intratracheal instillation of an elastolytic protease 
into the lung, although the genetic basis underlying the sensitivity to elastase-induced 
progressive emphysemic change has not been studied.  
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C57BL/6 and BALB/c are two well-characterized laboratory inbred murine strains that have 
been widely used to model a number of different human diseases, in addition to being used 
as background strains to generate many types of genetically-engineered mice. They have 
been shown to have different phenotypic outcomes under various experimental conditions, 
emphasizing the important role of genetic backgrounds in the susceptibility to diseases [411]. 
In terms of immune responses, it has been well documented that genetic differences in the 
regulation of type 1 and type 2 cytokine-mediated immune responses between C57BL/6 and 
BALB/c mice play key roles in determining the resistance or susceptibility to many diseases, 
ranging from microbial infections to asthma. BALB/c mice have been widely shown to 
exhibit strong Th2-biased immunity, with eosinophilia and high levels of IgE, IL-4, IL-5, and 
IL-13 in response to allergens or parasitic infection [412-414].  On the other hand, C57BL/6 
mice display Th1-based immunity, recognized by high levels of IgG2a, IFN- and TNF- in 
response to parasite infection (e.g. Leishmania major) and greater susceptibility to 
atherosclerosis or organ-specific autoimmune disease [415-418].  In addition to this 
differential T cell polarization, macrophages from C57BL/6 are much also more capable of 
producing nitric oxide as a result of classical activation (M1 activation) in response to IFN- 
and lipopolysaccharide (LPS) [419].  This contrasts with the preferential alternative activation 
(M2 activation) with a Th2 cytokine milieu in BALB/c mice [420, 421].  However, the 
pattern of the polarization of Th1/Th2 or M1/M2 phenotypes in these two mouse strains 
can vary widely depending on the specific type of infection or stimuli.  
 
In the present work we aimed to investigate whether these two common inbred mouse 
strains, (C57BL/6J and BALB/cJ) also show a differential in susceptibility to progressive 
emphysema induced by elastase instillation. Differences in the response of the two strains 
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could help identify candidate genes and pathways contributing to the discordant phenotypes, 
and such information might have implications for the design of the therapeutic intervention 
for human emphysema. 
 
3.3 Results 
3.3.1 Effects of elastase administration on the lifespan and body weight in 
C57BL/6J and BALB/cJ mice  
In order to obtain a measure of the differential sensitivity to elastase injury in C57BL/6J and 
BALB/cJ male mice, we intratracheally administered porcine-derived pancreatic elastase and 
observed survival as well as changes in body weight. Fig. 3.1 show the survival of the mice 
treated with elastase at doses of 6 (panel A) and 9 (panel B) enzymatic units (U). The 
proportion of surviving animals with elastase injury was significantly higher in male 
C57BL/6J mice than in male BALB/cJ mice. Approximately 40% of BALB/cJ mice 
challenged with 6U elastase (Fig. 3.1A) and more than 80% of those that received 9U 
elastase (Fig. 3.1B) failed to survive beyond 3 days after the elastase insult.  In contrast, there 
was only 50% mortality in C57BL/6J mice given 9U of elastase and less than 10% with 6U 
of elastase in the first three days. The differences in survival between the two strains were 
significant (p < 0.05) at both doses. No further mortality was found in either C57BL/6J or 
BALB/cJ mice beyond 3 days.  The early deaths of elastase-treated mice at these relatively 
high doses suggest marked acute lung injury that cannot be resolved in a certain fraction of 
the mice. No animals treated with 3U of elastase died at any time during the 21-day 




Fig. 3.1C-D shows the changes in body weight of mice receiving 3U or 6U of elastase.  No 
weight losses were found in the saline-treated control groups. During the first few days post-
elastase challenge the animals treated with 3U and 6U of elastase exhibited a marked weight 
loss in both C57BL/6J and BALB/cJ mice. As expected, the decrease in body weight of the 
mice from both strains treated with 6U of elastase (Fig. 3.1D) was greater than in the 3U 
groups. C57BL/6J mice tended to show an earlier recovery from this early weight loss 
compared to BALB/cJ mice. At 3U and 6U, the body weight of C57BL/6J mice recovered 
to the level of saline controls by day 5 (Fig. 3.1C) and by day 8 (Fig. 3.1D), respectively. In 
BALB/cJ mice body weight returned to baseline levels at 8 days with 3U elastase, but still 
hadn’t caught up with the controls by 21 days. BALB/cJ that received 6U of elastase had still 
not recovered to their starting weight by day 21 (Fig. 3.1D).  
 
These survival and weight loss data clearly indicate that the BALB/cJ mice are much more 
sensitive to acute lung injury caused by elastase and they recovered slower after elastase 
challenge compared to C57BL/6J mice. 
 
3.3.2 Effect of elastase on the development and severity of progressive 
emphysema in C57BL/6J and BALB/cJ mice 
To address the dose-responsiveness of elastase on the lungs of these two strains of mice, we 
measured several variables of pulmonary function as well as lung mechanics and lung 
histology. Mean values of lung gas exchange function assessed by the DFCO in control 
C57BL/6J and BALB/cJ mice were not significantly different. However, there were dose-
dependent declines in DFCO in the elastase-treated groups in both strains. The fall in DFCO 
was found to be significant at the lower dose of enzyme and to a greater degree in BALB/cJ 
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mice compared to C57BL/6J mice (Fig. 3.2A). These drops in gas exchange ability were 
supported by changes in lung mechanics assessed by air-filled pressure-volume measures of 
total lung capacity, residual volume and quasistatic compliance (Fig. 3.2B-D). Control 
BALB/cJ mice had larger lung volumes and compliance compared to C57BL/6J mice.  
Increasing doses of elastase resulted in dose-dependent increases in TLC, residual volume, 
and lung compliance in both strains, but the changes were much more pronounced in 
BALB/cJ mice than C57BL/6J mice. Similar patterns were also found in several dynamic 
mechanical measurements obtained from the Flexivent ventilator, including compliance 
(Crs), elastance (Ers), tissue damping (G), and tissue elastance (H) (Table 3.1). However, 
elastase did not alter either of the measurements of resistance [respiratory system (Rrs) or 
airway resistance (Rn)].  
 
To examine the structural changes in the lungs, we assessed the morphology of lung 
parenchyma with histological sections (Fig. 3.3). Microscopic examination of histological 
sections of lungs at day 21 post-challenge with 1.5U, 3U, 6U or 9U of elastase showed 
substantial enlargement of alveoli in both strains of mice. However, at each dose of elastase 
the changes in the BALB/cJ were much greater than those in C57BL/6J. 
 
3.3.3 Time course of elastase-induced emphysema development in C57BL/6J 
and BALB/cJ mice 
Based on the survival results (Fig. 3.1) and the dose-response effects of elastase (Fig. 3.2-
3.3), we selected a dose that induced minimal mortality in both mouse strains (3U) to be 




On the first day after instillation of 3U in both C57BL/6J and BALB/cJ mice we observed 
prominent hemorrhage consistent with acute lung injury. Much of the hemorrhage was 
resolved by the day 2 in C57BL/6J mice, but evidence of hemorrhage remained until day 4 
in BALB/cJ mice (Fig. 3.4). The degree of hemorrhage was quantified by colorimetric 
assessment of hemoglobin in BAL (Fig. 3.11A) andthe results confirmed that BALB/cJ had 
more severe and prolonged hemorrhage. In addition to sustaining elevated and persistent 
hemorrhage, starting at day 14, the overall size of the BALB/cJ lungs was visually larger than 
the C57BL/6J lung.  
 
Fig. 3.5 shows that both C57BL/6J and BALB/cJ mice treated with 3U of elastase exhibited 
a significant decrease in DFCO as early as day 4. However, the decrease in DFCO in BALB/cJ 
mice was much greater than in C57BL/6J mice, and a further gradual decline of DFCO after 
day 21 was found only in BALB/cJ mice. Much higher increases in TLC and RV in 
BALB/cJ mice mirrored what seen in DFCO (Fig. 3.6-3.7). More than 40% and 100% 
increases total lung capacity were observed in BALB/cJ mice on day 7 and day 96, 
respectively, compared to only approximately 10% and 20% increases in C57BL/6J mice at 
the same time points. Although BALB/cJ mice had significantly reduced quasistatic 
compliance during the first week after elastase challenge (likely due to edema and 
inflammation in the lung), the compliance recovered quickly. After this recovery, compliance 
was increased over control and the percent increases were found to be higher than in the 
C57BL/6J mice beyond the first month post-elastase (Fig. 3.8). The higher increase in Crs 
and greater decreases in Ers, G, and H in BALB/cJ mice compared to C57BL/6J mice 




Histologic assessment of the lung structure confirmed the more pronounced 
emphysematous changes in the BALB/cJ mice (Fig. 3.9). Quantitative morphometric 
analysis showed significant increases in Lm as early as day 2, and the Lm continued to 
progress rapidly, reaching a 360% increase by day 21 in BALB/cJ mice. In C57BL/6J mice a 
significant increase (30%) of Lm was not observed until day 21 (Fig. 3.10). 
 
3.3.4 Inflammatory cell influx into the lungs of C57BL/6J and BALB/cJ mice 
in response to elastase 
To determine the inflammatory response in the lungs of C57BL/6J and BALB/cJ mice in 
response to 3U of elastase, we assessed the number of total inflammatory cells in 
bronchoalveolar lavage fluid. As shown in Fig. 3.11B, the number of total cells in the BAL 
was significantly increased to the same degree in both strains 2 days after the acute elastase 
insult. However, the number of total BAL cell in C57BL/6J mice began to decline by day 4 
and returned to baseline level on day 7, whereas the number of cells in BALB/cJ mice 
remained elevated above baseline even at 21 days post-elastase challenge. These remaining 
BAL cells in BALB/cJ mice correlated with the increased hemoglobin levels (Fig 3.11A), 
suggesting an instability of the alveolar epithelial-endothelial barrier, consistent with the 
increased acute damage of pulmonary tissue seen in this strain. To further characterize the 
cellular content of the BAL, we performed differential cell counts using Diff-Quik staining. 
The number of macrophages in BAL was increased after elastase administration in both 
strains. The macrophages were significantly increased by day 2 in BALB/cJ mice compared 
to day 4 in C57BL/6J, and this increase persisted above baseline in the long-term only in 
BALB/cJ mice (Fig. 3.11C).  We observed a huge influx of neutrophils on day 2 in both 
strains, however these were cleared from the BAL in the first week, and no significance was 
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found between two strains of mice (Fig. 3.11D). Interestingly, as illustrated in Fig. 3.11E, the 
elastase insult recruited lymphocytes into the lung, and there was a markedly higher number 
of recruited lymphocytes in the first week after the insult in BALB/cJ mice compared to 
C57BL/6J mice. On the other hand, the number of eosinophils tended to be higher in 
C57BL/6J mice than BALB/cJ mice after elastase administration, but this increase in 
eosinophil count did not reach a significance level of 0.05 compared to naïve animals in 
either strains (Fig. 3.11F).   
 
We characterized the lymphocyte population in whole lung tissue using cell surface marker 
staining (NK cells: CD3-CD49b+, NKT cells: CD3+ CD49b+NKp46+, CD4+ cells: 
CD3+CD4+CD8- and CD8+ cells: CD3+CD4-CD8+), and analysis by flow cytometry. 
BALB/cJ had more of NK cells and CD4+/CD8+ lymphocytes even at baseline (Fig. 3.12). 
Both NK cells and CD8+ cell numbers were further elevated in response to elastase by day 
14 in both strains, whereas there was an increase in NKT cells from day 14 to 21 only in 
BALB/cJ mice.  No significant changes in the number of CD4+ cells was detected after 
elastase either strain. 
 
3.3.5 Levels of IFN- and IFN--producing cells in C57BL/6J and BALB/cJ 
mice after elastase instillation 
In order to characterize the pathways underlying the difference in sensitivity to developing 
emphysema in C57BL/6J and BALB/cJ mice, we first compared levels of IFN- expression 
following elastase injury. The rationale is that C57BL/6J mice are well-known to be biased 
toward Th1 responses with high production of IFN- [417]. The mRNA expression level of 
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Ifng in whole lung tissue was significantly increased after day 7 and remained elevated at day 
21 after elastase challenge in C57BL/6J mice (Fig. 3.13A). This increase in mRNA correlated 
with an increase in its protein level by day 21 (Fig. 3.13B). In contrast, BALB/cJ mice 
showed no changes in either IFN- mRNA or protein expression over the 21-day sampling 
period. To identify the cells that produce IFN- in response to elastase, we performed 
intracellular staining of IFN- in combination with several surface markers of potential IFN-
-producing cells and analyzed the cells by flow cytometry. The results showed that, 
although both mouse strains have increases in total IFN--positive cells in the lungs at day 
14 following elastase challenge, the increase was significantly greater in C57BL/6J relative to 
BALB/cJ (Fig. 3.13C). This disparity in the number of IFN-+ cells at this time point was 
mainly due to greatly increased expansion of IFN-+ NK cells in C57BL/6J mice (Fig. 
3.14A-B). While there were increases of IFN-+ NKT cells and IFN-+ CD8+ cells in 
BALB/cJ mice at day 14, these were not significantly different from the increased levels in 
documented in C57BL/6J mice (Fig. 3.14C, E). No significant increases in the number of 
IFN-+ CD4+ cells were noted in either strain (Fig. 3.14D). 
 
3.3.6 Gene expression profiles of other T cell-associated genes in C57BL/6J 
and BALB/cJ mouse lungs following an elastase insult 
While C57BL/6J mice are Th1-biased, BALB/cJ mice are Th2-biased and associated with 
production of IL-4, IL-5 and IL-13 [412]. We thus looked for differences in gene expression 
of Th2 cytokines. Although there was a gradual upregulation of Il4 and Il5 expression in 
both C57BL/6J and BALB/cJ mice after instillation of elastase, we did not find any 
significant differences in Il4, Il5, and Il13 mRNA expression between the two strains (Fig. 
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3.15A-C). The same profile was also observed with expression of Il10 and Foxp3, two genes 
associated with regulatory T cells, lymphocytes with the ability to suppress other immune 
response (Fig. 3.15D-E). However, BALB/cJ mice did show a much greater increase in 
expression of Hmox1, gene encoding for heme oxygenase I, particularly at day 4 (Fig. 3.15F). 
Increased expression of heme oxygenase I (a stress-inducible enzyme with ability to catalyze 
the degradation of heme with potential anti-inflammatory effects) in BALB/cJ mice might 
be associated with the increased levels of iron from erythrocytes needing to be recycled after 
the increased hemorrhage in this strain (Fig. 3.15F) [422]. 
 
Interestingly, on days 7 and 14 following elastase treatment, expression of the Il17a gene 
encoding for IL-17A was nearly 20-fold higher in BALB/cJ mice relative to C57BL/6J mice 
(Fig. 3.16A). This increase was accompanied by higher mRNA expression of Il6 (in the early 
days), Il1b (at a various time points) and Il18 (at the same times). These are genes encoding 
cytokines that are known to drive Th17 differentiation and promote IL-17A production (Fig. 
3.16C- E) [423, 424].  Thus, the data suggest a possible role for the IL-17A signaling 
pathway in modulating the severity of elastase-induced emphysema. Complicating this 
picture, however, is that finding that mRNA levels of IL-23a (important for Th17 
maintenance) was higher in C57BL/6J mice at day 1, and no alteration in STAT3 expression 
(an induced transcription factor involved in Th17 differentiation) was seen in either strain 






3.3.7 Macrophage activation in C57BL/6J and BALB/cJ mice following 
elastase challenge 
Macrophages are key cells in the immune response, and our results have shown that they are 
the only immune cell type that persists in the BAL at days 14 and 21 following elastase 
challenge (Fig. 3.11). For this reason, we sought to further characterize the activation status 
of macrophages. Generally, classical activation of macrophages (M1) is recognized by 
increased production of inducible nitric oxide synthase, and this activation is involved mainly 
in type I inflammation that can kill intracellular pathogens [425]. In contrast, alternatively 
activated macrophages (M2) which can be divided into several subtypes with different 
stimuli, play a role in type II inflammation, which includes immunoregulation, wound 
healing, and tissue remodeling. Our gene transcriptional profiles of whole lung tissue 
indicate that the majority of genes in BALB/cJ affected by elastase are involved in M2 
macrophage activation (Arg1, Chil3, Retnla, Mmp2 and Mmp12) (Fig. 3.17). There was a 15-
fold induction of Arg1 and a 20-fold induction of Retnla at day 2. There was also a 4-fold 
increase of Mmp2 and a 40-fold increase of Mmp12 at 7 and 21 days post-elastase 
administration in BALB/cJ. On the other hand, Chil3 and Mmp2 expression were 
significantly up-regulated in C57BL/6J lungs only at day 7 (Fig. 3.17B, D). Although 
BALB/cJ had greater expression at baseline of the M1 activation marker, Nos2, compared to 
C57BL/6J mice, the overall trend of its expression following elastase instillation was not 
different between the two strains (Fig. 3.18A).  
 
CD200 is a receptor that is highly expressed on the surface of alveolar macrophages.  CD200 
ligands can be found on a variety of cells, with notably elevated expression especially on 
alveolar epithelial cells [426]. An engagement of CD200 receptor with the CD200 ligand has 
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been shown to inhibit classical macrophage activation and is likely is likely to play a role in 
the induction of alternatively activated macrophages [427]. We observed a drop in 
expression of Cd200 in BALB/cJ mice, which may reflect increased epithelial cell death.  
Related to this decreased in CD200, we found increased expression of Cd200r1 at the later 
time points, where the tissue repair function of M2 macrophages is likely increased (Fig. 
3.18B-C). Overall, these data implicate a role for M2 macrophages in causing the differential 
severity of emphysema in these two mouse strains. 
 
3.3.8 Cell proliferation and alarmin-associated gene expression in C57BL/6J 
and BALB/cJ mice following elastase challenge 
To determine if there was proliferation of cells in the lung after elastase injury, we assessed 
the expression level of Mki67, a marker of cell proliferation. The data show that both 
C57BL/6J and BALB/cJ mice had increases in this cell proliferation marker within the first 
week. A greater level, however, was observed in BALB/cJ mice suggesting more robust 
repair response in this strain (Fig. 3.17D). Moreover, we also determined the level of p63 
expression, which was recently shown to be an essential marker of stem cells in the lung 
parenchyma [428]. We did not detect any changes in p63 expression in either strain (Fig. 
3.18E). 
 
We also assessed the expression of a subset of epithelial cell alarmins, a group of 
constitutively produced molecules released in response to cellular stress or injury and with an 
ability to promote immune responses to restore tissue homeostasis [429]. Elastase injury 
resulted in a sudden increase in expression of Il33, followed by Il1rl1 (the gene encoding for 
IL-33 receptor; aka ST2), but these increases were similar between the two strains (Fig. 
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3.19A-B). To further pursue the effects of IL-33, we looked at its downstream signaling 
pathway.  In the first week Areg, which codes for amphiregulin, was significantly up-
regulated, while Egfr (the Areg receptor) was down-regulated (Fig. 3.19D-E). Interestingly, 
the baseline level of Il1a was about 6-fold higher in BALB/cJ mice when compared to 
C57BL/6 (Fig. 3.19C). Il1a transcription levels rebounded by day 4 and remained elevated to 
day 21 (Fig. 3.19C). Intriguingly, there was no change in Il-1a expression in the lungs from 
C57BL/6J mice (Fig. 3.19C). 
 
3.3.9 Expression profile of anti-proteases in C57BL/6J and BALB/cJ mice 
following elastase challenge 
Since anti-proteases are a pivotal component in the protease/anti-proteases mechanism that 
can protect tissue destruction by ablating proteolytic activity, we measured the level of 
several anti-protease genes (Fig. 3.20). Serpina1a, encoding for 1-antitrypsin (1-AT), was 
significantly higher in naïve BALB/cJ relative to naïve C57BL/6J, but the levels were 
decreased in both strains after the mice received elastase. In contrast, naïve C57BL/6J mice 
had higher levels of A2m, which encodes for 2-macroglobulin, but the level of A2m was 
elevated in response to elastase in both strains. No differences in Timp1, Timp2, Timp3, or 
Timp4 were found in C57BL/6J and BALB/cJ mice at baseline. Only Timp1 levels rapidly 
increased after elastase insult to a much greater degree in BALB/cJ mice. In contrast, Timp2, 
Timp3, and Timp4 levels dropped during first few days in BALB/cJ mice, but not in 
C57BL/6J mice, and the level gradually increased after these early days. However, we did not 






A single intratracheal administration or aerosol inhalation of porcine-derived pancreatic 
elastase has long served as an effective approach to rapidly induce acute lung injury leading 
to subsequent pulmonary emphysema in a wide variety of experimental animals. One 
proposed mechanism for the development of emphysematous changes involves the concept 
of a protease/anti-protease imbalance. This notion emerged following studies of emphysema 
patients with severe alpha1-antitrypsin deficiency [58]. Most of the older animal studies were 
performed in Syrian golden hamsters, and it was thought that this species developed severe 
emphysema following elastase because of its relatively low 1-antitrypsin level, low acute 
lung injury response, and depletion of glutathione-related antioxidant enzymes in the early 
phase [430-432]. Recently, mice C57BL/6 have been used to model elastase-induced 
experimental emphysema. Most of the work has been carried out in C57BL/6 mice taking 
advantage of the fact that complete information on its genome is known and many 
genetically engineered strains have been produced on this genetic background. However, as 
noted in the mouse model for allergic asthma [433], there is likely to be important strain 
difference in the response to elastase. In the present work, our aim was to compare the 
emphysematous phenotype in C57BL/6J mice and another commonly used mouse strain in 
immunologic studies, BALB/cJ mice. The hypothesis is that these differential responses 
could be used to provide new insights on the cellular or molecular processes contributing to 
the pathogenesis of the progressive stage of the disease. 
 
To this end we assessed various phenotypic endpoints, including mortality, body weight, 
pulmonary function, lung mechanics, and lung structure in both strains exposed to 
intratracheal elastase. Our data clearly show that at a given exposure level BALB/cJ mice are 
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more susceptible to elastase-induced pulmonary emphysema. Our results are consistent with 
the previous observation of differential susceptibility to emphysema induced by 
Nippostrongylus brasiliensis hookworm infection between BALB/c and C57BL/6 strains [108]. 
The strain-dependent effect has also been demonstrated in cigarette smoke-induced 
emphysema [84, 131, 410, 434, 435]. In these studies, C57BL/6 mice were considered as a 
“moderately sensitive” strain to develop emphysematous lesions after smoke exposure, 
because this strain of mouse showed more pathologic changes in response to cigarette 
smoke compared to the less sensitive mouse strains studied, the outbred ICR strain and 
inbred NZW strain. However, cigarette smoke only caused mild pathologic emphysema in 
the C57BL/6 strain as evidenced by only a 13-18% increase in mean linear intercept after 5-6 
months of exposure. This increase was less than in other more sensitive strains studied, i.e., 
AKR, SJ/L, A/J, and C3H. Only one study [434] compared the effect of cigarette smoke 
exposure on the C57BL/6J and BALB/cJ strains we studied here. They found that smoke-
exposed BALB/cJ mice did not show a significantly greater mean linear intercept, but they 
did find significantly more blood vessel muscularization compared to smoke-exposed 
C57BL/6J mice [434]. Similar levels of emphysematous injury between C57BL/6 and 
BALB/c mice were also observed in a chronic ozone-induced emphysema model [107].  
Nevertheless, these models of emphysema induced by chronic exposure to cigarette smoke 
or ozone cause only relatively very mild damage in alveolar tissue, which is not enough to 
magnify the inter-strain differences that can be observed with elastase or hookworm 
infection. 
 
The differential susceptibility between C57BL/6 and BALB/c mice that has been shown in a 
variety of other disease models can be attributed to differences in the immune responses. 
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Therefore, we sought to identify the differences in the immune milieu in response to elastase 
injury between the two strains. Our temporal evaluation of BAL cells showed that BALB/cJ 
mice had more lymphocytes in the first two weeks after elastase treatment and more 
persistent macrophages throughout the three weeks after the insult. These results suggest a 
potential role of these two cell types in determining susceptibility. Therefore, we also 
measured the alteration of several cytokines and activation markers associated with 
lymphocytes and macrophages. The instillation of elastase in the lungs recruited more IFN- 
producing cells, particularly NK cells with higher IFN- expression in C57BL/6J mice when 
compared with BALB/cJ mice. This result agrees with a number of published studies 
showing that C57BL/6 mice are Th1-prone and have the ability to produce elevated IFN- 
[416, 417]. However, elastase-treated BALB/cJ mice did not demonstrate the greater Th2 
response (IL-4, IL-5 and IL-13) that was shown in allergic or the parasitic infection model 
[413, 414]. Interestingly, in BALB/cJ mice there was a 20-fold upregulation of IL-17A, 
which was not found in C57BL/6J mice. Moreover, there was higher expression of IL-18 in 
BALB/cJ mice relative to C57BL/6J, both at baseline and after elastase administration. 
While mice overexpressing either IFN- or IL-18 specifically in the adult lung displayed an 
emphysema-like phenotype accompanied with high level of proteases such as MMP-12 and 
cathepsins [173, 436], it was also reported that IL-17A-deficient mice developed less 
pulmonary inflammation with reduced severity of emphysema after 3.5U elastase [188]. 
Moreover, transgenic IL-18-overexpressing mice had enhanced expression of IFN- and IL-
17A together with elevated numbers of IFN- and IL-17A positive cells in the lung [436]. 
These studies suggest a potential role of these cytokines in causing emphysematous damage 
triggered by elastase, but the mechanism remains unclear. Collectively, we hypothesize that 
101 
	
C57BL/6J and BALB/cJ mice have different mechanisms underlying the initial destruction 
of the alveolar tissue, and that the higher inductions of IL-17A and IL-18 are involved in the 
mechanism that results in an increased susceptibility to develop emphysema in BALB/cJ 
mice.  
 
Another potentially important difference in elastase-treated BALB/cJ mice and C57BL/6J 
mice is the prolonged presence of alternatively activated macrophages (M2 phenotypes) in 
the lung BAL. Such M2 macrophages participate in the resolution of inflammation, wound 
healing and tissue remodeling by producing a broad array of extracellular matrix proteases 
such as MMP-2, MMP-9 and MMP-12 (macrophage elastase) [425, 437]. To maintain tissue 
homeostasis, the activation of these macrophages has to be tightly regulated. In chronic 
inflammatory states, persistent activation of macrophage-derived MMPs is involved in 
remodeling the extracellular matrix, to the extent that such excessive stimulation can lead to 
subsequent loss of matrix integrity and mechanical failure as seen in periodontal disease or 
arthritis [438-440]. Several studies that have indicated a significant contribution of MMP-12 
protease in degradation of extracellular matrix in alveolar walls, and this is supported by a 
study that showed mice lacking MMP-12 have an attenuated severity of cigarette smoke-
induced emphysema [102]. Therefore, MMP-12 is commonly measured in experimental 
emphysema models to correlate with the severity of the pathology. Consistent with previous 
studies, we showed that the susceptible BALB/cJ mice had a greater elevation and 
prolonged production of MMP-12 in the lung in response to elastase injury than the resistant 
C57BL/6J strain. The polarization of macrophages toward M2 phenotypes with MMP-12 
elevation has also been observed in the hookworm infection model of emphysema [108], the 
acute ozone exposure model [441], the mouse cigarette smoke model [442, 443], and 
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possibly in human emphysema patients [444]. Interestingly, in addition to the expression 
signature for M2 macrophages, we also found the higher expression of inducible nitric oxide 
synthase (iNOS), a typical marker for classical activated macrophages (M1 phenotype) at 
baseline and after elastase insult in the BALB/cJ strain. This data is similar to several 
previous human studies showing the increased expression of iNOS in alveolar macrophages 
and lung tissue from COPD patients [445-447]. This classical activation of macrophages 
have been linked to the increase in production of reactive oxidation species (ROS) and nitric 
oxide (NO) as well as the enhanced release of several proinflammatory cytokines (e.g. IL-1, 
IL-6, IL-8 and TNF-) which have been shown to be important contributors to the 
pathogenesis of COPD [133, 448-450]. We also reported higher elevated expression of both 
IL-1 and IL-6, possibly due to greater M1 activation in BALB/cJ mice following to elastase 
challenge than C57BL/6J mice. Deficiency of either IL-1 or IL-6 were shown to protect 
the elastase-induced emphysema in mice [105, 176]. Overall, similar to the data from human 
COPD patients, our present work displayed mixed M1/M2 activation of macrophages in 
elastase-induced emphysema animals. The mixed M2/M1 phenotype could reflect a unique 
fixed activation status of the lung macrophages, a plastic phenotype that is dependent on 
changes in the local lung environment or it could represent the presence of multiple distinct 
populations of macrophages. It is possible that genetic factors contribute significantly to the 
changes in the lung environment that in turn influences a dynamic activation and metabolic 
phenotype of macrophages that ultimately promotes the progression of emphysema 
 
To completely understand the impact that a protease has on the progression of emphysema, 
also it is important to considered the expression dynamics of the endogenous and inducible 
inhibitors that regulate the overall level of protease activity in the lungs. Our results 
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illustrated that the control BALB/cJ mice have lower expression levels of 2-macroglobulin, 
a major endogenous anti-protease that can bind to porcine pancreatic elastase. Thus, if the 
up-regulation in the lung tissue after elastase was smaller in BALB/cJ mice relative to 
C57BL/6J mice, it could account for the increased emphysema in the BALB/cJ. However, 
2-macroglobulin is produced mainly by hepatocytes in the liver, and only in small amounts 
by cells in the lungs [451]. Moreover, a primary role of 2-macroglobulin is to rapidly trap 
excess proteinases, but not to inactivate them, so proteases can still be released after binding 
2-macroglobulin [307, 452]. Unlike 2-macroglobulin, 1-AT is more likely to be a 
physiological inactivator of elastase. Interestingly, our data showed a greater level of 1-AT 
in BALB/cJ mice when compared to C57BL/6J mice. This data is consistent with 
Martonana et al. who reported that there was higher mRNA levels of 1-AT expression in 
the liver tissue of BALB/c than C57BL/6 and pallid mice, corresponding with higher serum 
1-AT level and more elastase inhibitory capacity [453]. The pallid mice, which have a 
marked reduction in 1-AT levels, were shown to spontaneously develop an emphysema-
like phenotype at early ages of life, as well as having an increased susceptibility to develop 
more emphysema when exposed to the neutrophil chemotactic peptide FMLP [453, 454]. 
The fact that BALB/cJ mice have higher levels of 1-AT suggests that the increased 
susceptibility of this strain to progressive emphysema is more likely a result of other 
mechanisms, rather than anti-proteases activities. 
 
One of the outstanding questions regarding the pathogenesis of emphysema is the role of 
persistent chronic inflammation, and how it may lead to the continual alveolar tissue 
destruction in the lungs. In addition, there is often a gradual decline in lung function in 
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human patients, even in the absence of the risk factors as seen in smokers who have quit yet 
emphysema continues to progress [311]. This observation implies that the mechanisms 
underlying the initiation phase of human emphysema might be different from the 
mechanism driving the progression phase. This progression of immune-mediated pathology 
in humans cannot be reproduced in animals exposed to chronic cigarette smoke. This aspect 
of the human disease is perhaps better modeled in the BALB/cJ model of elastase-induced 
experimental emphysema, especially in BALB/cJ mice. A single insult that quickly heals 
leads to progressive tissue destruction over many months. Originally, as mentioned earlier, 
the hamster was reported to be susceptible to the development of emphysema induced by 
elastase presumably because of its low level of serum 1-antitrypsin and in low elastase 
inhibitory capacity [430]. Nevertheless, the hamster was shown to still have the ability to 
eliminate the exogenous elastase from the lung within 24 hours [307]. This situation is 
mimicked in our mouse model as evidenced by exogenous elastase-associated acute lung 
injury (e.g. mortality, hemorrhage, massive neutrophil infiltration) only in the first few days 
post challenge. Although this is a simple insult to produce, the model is clearly not 
mechanistically simple. The mechanism requires other endogenous mediators that may have 
many similarities to the human situation. Due to the fact that many emphysema patients are 
typically not diagnosed until they are symptomatic and in a relatively late stage of the disease 
[34, 36], studies utilizing the elastase-induced emphysema in BALB/cJ mice might turn out 
to be very beneficial for studying the mechanisms that are associated with progression of the 
disease at early stages, for evaluating potential therapeutic interventions to slow or stop the 




In conclusion, differences in strain-associated susceptibility to develop elastase-induced 
emphysema is documented here. We provided data in support of the hypothesis that the 
disparity in immune responses between the two strains studied results in part from 
differences in production of IFN-, IL-17A and alternative activation of macrophages. 
However, more experiments have to be performed to elucidate the mechanistic linkage 
between this immune response and the susceptibility of emphysema. 
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Figure 3.1 Survival rate and body weight of C57BL/6J and BALB/cJ mice following 
elastase challenge. (A-B) Survival after intratracheal instillation of C57BL/6J and 
BALB/cJ mouse lungs with 6 units (A) or 9 units (B). (C-D) Weight loss after intratracheal 
instillation of C57BL/6J and BALB/cJ mouse lungs with 3 units (C) or 6 units (D). (n  12 
mice per group). † = p < 0.05 by log-rank test (A-B) or one-way ANOVA (C-D) comparing 
BALB/cJ with C57BL/6J at the same dose. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 by 














Figure 3.2 Diffusion capacity and PV parameters in C57BL/6J and BALB/cJ mice 
following increasing doses of elastase. (A) Diffusion factor for carbon monoxide; (B) 
Total lung capacity; (C) Residual volume and (D) Quasistatic compliance of C57BL/6J and 
BALB/cJ mice after intratracheal challenge with elastase at the doses of 1.5, 3, and 6 units. 
(n = 5-14 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001 comparing elastase-treated group to PBS. † = p < 0.05, †† = p < 0.01, ††† = p < 







Table 3.1 Baseline values for lung mechanics parameters in both mouse strains before elastase and at 21 days after different time points 
after 1.5. 3U, or 6U elastase. Parameters measured are: respiratory system resistance (Rrs), elastance (Ers), compliance (Crs), 



















C57BL/6J 0.821 ± 0.058 0.038 ± 0.0004 26.369 ± 0.263 0.450 ± 0.039 4.503 ± 0.144 25.669 ± 0.570 
BALB/cJ 0.819 ± 0.075 0.052 ± 0.0004††† 19.190 ± 0.165††† 0.549 ± 0.059 3.528 ± 0.094††† 18.573 ± 0.404 
    
Elastase 1.5U    
C57BL/6J 0.691 ± 0.029 0.042 ± 0.0010 24.117 ± 0.529** 0.361 ± 0.028 4.186 ± 0.238 21.600 ± 0.722*** 
BALB/cJ 0.621 ± 0.019 0.072 ± 0.0037††† 13.944 ± 0.694***††† 0.358 ± 0.022 2.935 ± 0.120*††† 10.983 ± 0.957***†††
    
Elastase 3U    
C57BL/6J 0.767 ± 0.044 0.052 ± 0.0015*** 19.464 ± 0.508*** 0.441 ± 0.033 4.098 ± 0.123* 15.311 ± 0.507*** 
BALB/cJ 0.717 ± 0.033 0.080 ± 0.0014***††† 12.603 ± 0.219***††† 0.435 ± 0.030 2.916 ± 0.062**††† 8.900 ± 0.281***††† 
    
Elastase 6U    
C57BL/6J 0.697 ± 0.036 0.059 ± 0.0013*** 16.999 ± 0.359*** 0.398 ± 0.028 3.741 ± 0.093*** 12.620 ± 0.502*** 
BALB/cJ 0.889 ± 0.090 0.080 ± 0.0009***††† 12.561 ± 0.150***††† 0.579 ± 0.071 2.872 ± 0.041***††† 8.654 ± 0.161***††† 
    
    
 
Results are expressed as mean ± SEM (n = 5-14 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 







Figure 3.3 Photomicrographs of C57BL/6J and BALB/cJ lung parenchyma after 
treatment with 1.5, 3, and 6U elastase or vehicle. Representative H&E-stained lung 
sections from C57BL/6J (left panel) and BALB/cJ (right panel) mice before elastase and at day 




Figure 3.4 Gross appearance of C57BL/6J and BALB/cJ lungs following elastase 
challenge. Representative gross pathology of air-inflated lungs from C57BL/6J (left panel) 
and BALB/cJ (right panel) mice at days 1, 2, 4, 7, 14 and 21 post-elastase (3 units) challenge 














Figure 3.5 Time course of decline in diffusion capacity between two mouse strains 
following 3U elastase. (A) Diffusion factor for carbon monoxide and (B) Percentage 
change of DFCO in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, 21, 48 and 96 following 
3 units elastase. (n = 5-10 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p 
< 0.01, *** = p < 0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† 

































Figure 3.6 Time course of increase in total lung capacity between two mouse strains 
following 3U elastase. (A) Total lung capacity and (B) Percentage change of TLC in 
C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, 21, 48 and 96 following 3 units elastase. (n 
= 5-10 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = 










Figure 3.7 Time course of increase in residual volume between two mouse strains 
following 3U elastase. (A) Residual volume and (B) Percentage change of RV in C57BL/6J 
and BALB/cJ mice at days 2, 4, 7, 14, 21, 48, and 96 following 3 units elastase. (n = 5-10 
mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = p < 











Figure 3.8 Time course of increase in lung quasi-static compliance between two 
mouse strains following 3U elastase. (A) Quasi-static compliance and (B) Percentage 
change in Cstat from C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, 21, 48, and 96 
following 3 units elastase. (n = 5-10 mice per group). Two-way ANOVA analysis: * = p < 
0.05, ** = p < 0.01, *** = p < 0.001 comparing elastase-treated group to naïve animals. † = p 
< 0.05, †† = p < 0.01, ††† = p < 0.001 comparing BALB/cJ with C57BL/6J at the same 




Table 3.2 Baseline values for lung mechanics parameters in both mouse strains at different time point following 3U elastase. Parameters 
measured are: respiratory system resistance (Rrs), elastance (Ers), compliance (Crs), airway resistance (Rn), tissue damping (G), 















Naive   
C57BL/6J 0.756 ± 0.041 0.040 ± 0.0007 25.345 ± 0.432 0.449 ± 0.033 4.262 ± 0.144 24.922 ± 0.535
BALB/cJ 0.806 ± 0.074 0.054 ± 0.0009††† 18.767 ± 0.268††† 0.534 ± 0.056 3.540 ± 0.132††† 17.995 ± 0.524†††
Day 2   
C57BL/6J 0.723 ± 0.029 0.041 ± 0.0005 24.521 ± 0.315 0.360 ± 0.0019 4.468 ± 0.084 21.011 ± 0.469***
BALB/cJ 0.753 ± 0.048 0.053 ± 0.0033†† 19.753 ± 1.333†† 0.427 ± 0.036 3.760 ± 0.270† 15.303 ± 1.445††
Day 4   
C57BL/6J 0.703 ± 0.088 0.043 ± 0.0017 23.724 ± 1.223 0.298 ± 0.027 4.676 ± 0.262 18.028 ± 0.570***
BALB/cJ 0.639 ± 0.038 0.059 ± 0.0007††† 16.882 ± 0.195††† 0.365 ± 0.033 3.493 ± 0.197†† 12.589 ± 0.538***†††
Day 7   
C57BL/6J 0.633 ± 0.026 0.047 ± 0.0009** 21.438 ± 0.400*** 0.361 ± 0.036 4.029 ± 0.122 17.597 ± 0.812***
BALB/cJ 0.785 ± 0.047† 0.063 ± 0.0015***††† 15.906 ± 0.372*††† 0.485 ± 0.054 3.319 ± 0.062††† 10.917 ± 0.300***†††
Day 14   
C57BL/6J 0.721 ± 0.030 0.054 ± 0.0023*** 18.880 ± 0.922*** 0.420 ± 0.032 3.952 ± 0.131 15.149 ± 1.065***
BALB/cJ 0.703 ± 0.032 0.075 ± 0.0013***††† 13.312 ± 0.225***††† 0.423 ± 0.035 2.998 ± 0.063††† 9.070 ± 0.163***†††
Day 21   
C57BL/6J 0.815 ± 0.067 0.053 ± 0.0023*** 19.224 ± 0.755*** 0.483 ± 0.049 4.155 ± 0.194 15.047 ± 0.759***
BALB/cJ 0.717 ± .0033 0.080 ± 0.0014***††† 12.603 ± 0.219***††† 0.435 ± 0.030 2.916 ± 0.062††† 8.900 ± 0.281***†††
Day 48   
C57BL/6J 0.813 ± 0.075 0.048 ± 0.0023* 20.885 ± 1.057** 0.411 ± 0.056 4.219 ± 0.215 17.126 ± 1.193***
BALB/cJ 0.719 ± 0.080 0.084 ± 0.0012***††† 11.939 ± 0.177***††† 0.447 ± 0.080 2.878 ± 0.047††† 8.334 ± 0.153***†††
Day 96   
C57BL/6J 0.676 ± 0.050 0.053 ± 0.0024*** 19.004 ± 0.804*** 0.385 ± 0.022 4.024 ± 0.207 15.209 ± 0.663***
BALB/cJ 1.090 ± 0.180 0.090 ± 0.0021***††† 11.129 ± 0.267***††† 0.820 ± 0.159**†† 2.600 ± 0.097*††† 8.350 ± 0.071***†††
 
Results are expressed as mean ± SEM (n = 5-10 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = p < 0.001 comparing BALB/cJ with C57BL/6J at 




Figure 3.9 Representative photomicrographs of C57BL/6J and BALB/cJ lung 
parenchyma after treatment with 3U elastase at different time points. H&E-stained 
lung sections from C57BL/6J (left panel) and BALB/cJ (right panel) mice prior to and at days 








Figure 3.10 Time course of increase in mean linear intercept between two mouse 
strains following 3U elastase. (A) Mean linear intercept and (B) Percentage change of Lm 
in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, 21, 48, and 96 following 3 units 
intratracheal elastase. (n = 5-10 mice per group). Two-way ANOVA analysis: * = p < 0.05, 
** = p < 0.01, *** = p < 0.001 comparing elastase-treated group to naïve animals. † = p < 









Figure 3.11 Analysis of bronchoalveolar lavage from C57BL/6J and BALB/cJ mice 
following 3U elastase. (A) Hemoglobin content; (B) Total cell counts; (C) Macrophage and 
monocyte counts; (D)Neutrophil counts; (E) Lymphocyte counts; and (F) Eosinophil counts 
from BAL of C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, and 21 following 3U elastase. 
(n = 4-5 mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 
0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = 









Figure 3.12 Flow cytometry analysis of NK, NKT and T cells from whole lung of 
C57BL/6J and BALB/cJ mice following 3U elastase. Number of (A) NK cell; (B) NKT 
cells; (C) CD4+ cells; and (D) CD8+ cells per lung in C57BL/6J and BALB/cJ mice at days 7, 
14, and 21 after challenge with 3U elastase. (n = 5 mice per group). Two-way ANOVA 
analysis: * = p < 0.05, *** = p < 0.001 comparing elastase-treated group to naïve animals. † 
= p < 0.05, †† = p < 0.01, ††† = p < 0.001 comparing BALB/cJ with C57BL/6J at the 













Figure 3.13 Expression of IFN- and number of IFN--producing cells from 
C57BL/6J and BALB/cJ mice following 3U elastase administration. (A) Real-time RT-
PCR; (B) ELISA analyses of IFN- mRNA and protein levels; and (C) Flow cytometry 
analysis of the number of IFN- positive cells per lung in C57BL/6J and BALB/cJ mice 
following intratracheal challenge with 3U elastase at days 2, 4, 7, 14 and 21. (n = 4-5 
mice/group). Two-way ANOVA analysis: * = p < 0.05, *** = p < 0.001 comparing elastase-
treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = p < 0.001 comparing 
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Figure 3.14 Pulmonary sources of IFN- in C57BL/6J and BALB/cJ mice following 
3U elastase administration. (A) Representative flow plot showing the percentage of IFN-
+ cells gated on CD3-NKp46+ (NK cells) and number of IFN-+ ; (B) NK cells; (C) NKT 
cells; (D) CD4+ cells; and (E) CD8+ cells per lung in C57BL/6J and BALB/cJ mice at days 7, 
14 and 21 after challenge with 3U elastase. (n = 5 mice per group). Two-way ANOVA 
analysis: * = p < 0.05, *** = p < 0.001 comparing elastase-treated group to naïve animals. † 




















Figure 3.15 Th2- and Treg-associated gene expression profiles in the lungs obtained 
from 3U elastase-treated C57BL/6J and BALB/cJ mice. Real-time PCR analysis of lung 
mRNA levels of (A) IL-4, (B) IL-5, (C) IL-13, (D) IL-10, (E) Foxp3, and (F) Heme 
oxygenase I in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14, and 21 after challenge with 
3U elastase. (n = 4 mice per group). All data are compared with naïve C57BL/6J group and 
normalized to -actin expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 






Figure 3.16 Th17-associated gene expression profiles in the lungs obtained from 3U 
elastase-treated C57BL/6J and BALB/cJ mice. Real-time PCR analysis of lung mRNA 
levels of (A) IL-17a, (B) IL-23a, (C) IL-6, (D) IL-1β, (E) IL-18, and (F) STAT3 of C57BL/6J 
and BALB/cJ mice at days 2, 4, 7, 14 and 21 after challenge with 3U elastase. (n = 4 mice 
per group). All data are compared with naïve C57BL/6J mice and normalized to -actin 
expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = p < 
























Figure 3.17 M2 macrophage-associated gene expression profiles in the lungs obtained 
from 3U elastase-treated C57BL/6J and BALB/cJ mice. Real-time PCR analysis of lung 
mRNA levels of (A) Arginase1, (B) Ym1, (C) Fizz1, (D) MMP-2, (E) MMP-9, and (F) MMP-
12 in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14 and 21 after challenge with 3U elastase. 
(n = 4 mice per group). All data are compared with naïve C57BL/6J group and normalized to 
-actin expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 0.01, ††† = p < 






Figure 3.18 M1 macrophage and stem cell proliferation-associated gene expression 
profiles in the lungs obtained from 3U elastase-treated C57BL/6J and BALB/cJ mice. 
Real-time PCR analysis of lung mRNA levels of (A) iNOS, (B) CD200, (C) CD200r1, (D) 
Ki67 and (E) p63 in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14 and 21 after challenge 
with 3U elastase. (n = 4 mice per group). All data are compared with naïve C57BL/6J group 
and normalized to -actin expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 
0.01, *** = p < 0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p 






































Figure 3.19 Alarmin-associated gene expression profiles in the lungs obtained from 
3U elastase-treated C57BL/6J and BALB/cJ mice. Real-time PCR analysis of lung 
mRNA levels of (A) IL-33, (B) ST2, (C) IL-1, (D) Amphiregulin, and (E) Epidermal growth 
factor receptor in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14 and 21 after challenge with 
3U elastase. (n = 4 mice per group). All data are compared with naïve C57BL/6J mice and 
normalized to -actin expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001 comparing elastase-treated group to naïve animals. † = p < 0.05, †† = p < 






Figure 3.20 Anti-protease gene expression profiles in the lungs obtained from 3U 
elastase-treated C57BL/6J and BALB/cJ mice. Real-time PCR analysis of lung mRNA 
levels of (A) 1-antitrypsin, (B) 2-macroglobulin, (C) TIMP1, (D) TIMP2, (E) TIMP3, and 
(F) TIMP4 in C57BL/6J and BALB/cJ mice at days 2, 4, 7, 14 and 21 after challenge with 
3U elastase. (n = 4 mice per group). All data are compared with naïve C57BL/6J mice and 
normalized to -actin expression. Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001 comparing elastase-treated groups to naïve animals. † = p < 0.05, †† = p < 
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Prominent inflammatory infiltrates in the alveolar space are often recognized as one of the 
major features during development of emphysema in both human patients and experimental 
animals. This involves the recruitment and activation of several types of inflammatory cells, 
particularly neutrophils, lymphocytes and macrophages. However, the relationship between 
the activation status of these cells and the destruction of alveoli and enlargement of airspaces 
resulting in emphysema are not well understood. In this chapter, we investigated the effects 
of inhibiting immune cell recruitment and activation on the severity of emphysema induced 
by elastase. We found that although a marked increase in the number of neutrophils and 
lymphocytes in the BAL was observed following elastase administration, the absence of 
these cells did not alter the severity of emphysema progression. These findings do not 
support the hypothesized potential role of neutrophils and lymphocytes in the pathogenesis 
of emphysema at least in this elastase experimental model. However, deficiency of IFN- or 
IL-17A mitigated the severity of elastase-induced emphysema. Moreover, the hindrance of 
alternative activation of macrophages by either abrogate of STAT6, STAT3 or IL-33 
signaling pathway diminish the progression of emphysema as well. From these data, we 
conclude that macrophages which are alternatively activated via these pathways in response 
to elastase-induced injury as well as IFN- and IL-17A contribute to the development of 
emphysema in this model, whereas neutrophils and lymphocytes do not. Given the 
persistent presence of these activated macrophages in injured lungs, they might serve as a 







Persistent pulmonary inflammation is one of the prominent features of chronic obstructive 
pulmonary disease (COPD). Inflammation has been hypothesized to make a critically 
important contribution to the pathophysiological process of emphysema, a primary 
component of COPD.  A persistent elevation of certain inflammatory cells together with 
increased expression of a number of inflammatory mediators including cytokines, 
chemokines, inflammatory enzymes, and adhesion molecules in BAL, sputum and lung 
tissue have been shown to associate with the severity of the disease [145, 146, 148, 150, 151]. 
However, most studies have only established a firm correlation between this immunological 
phenotype and the severity of disease. Some aspects of this emphysema-associated immune 
responses can be seen in animal models of emphysema including cigarette smoke inhalation, 
elastase-induced experimental emphysema, ozone exposure, hookworm (Nippostrongylus 
brasiliensis) infection and various models of gene overexpression and gene deficiency.  While 
these models have provided partial insight into the immunopathologic mechanisms 
underlying the disease [107, 108, 455], a coherent cellular and molecular mechanism that 
accounts for the pathogenesis of emphysema is yet to be defined.  
 
Neutrophils or polymorphonuclear cells (PMNs), macrophages and T-lymphocytes are the 
most common inflammatory cells proposed to be involved in the pathogenesis of 
emphysema, as they are typically elevated in the lungs of patient with emphysema [456]. 
Neutrophil infiltration is often an early response following pulmonary injury. Emphysema is 
one of the most studied diseases that exhibits a marked pulmonary neutrophilia [457]. The 
rapid influx of circulating neutrophils into the lungs has been demonstrated in most animal 
models of emphysema as well [107, 155, 458]. Neutrophils are attractive candidates for 
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contributing to tissue destruction in emphysema because of their capacity to produce a 
variety of potential effector molecules that can damage tissue, particularly proteases (e.g. 
neutrophil elastase, cathepsins and several matrix metalloproteinases MMPs) and reactive 
oxygen species (ROS) [457]. However, neutrophils have been shown to play an important 
role in wound healing and tissue repair [459, 460].  The phagocytic capacity of neutrophils 
removes necrotic cells generated during tissue injury to limit further damage and facilitate 
proper repair [461, 462]. Also, recent studies have shown that neutrophils can also release 
neutrophil extracellular traps (NETs), extracellular web-like fibril matrices which are able to 
trap infectious agents and scavenge cellular debris [463]. Thus, the role of neutrophils in the 
pathogenesis of emphysema remains unclear. 
 
Similar to neutrophils, macrophages are another major effector cell in innate host defense 
and can release a number of tissue-damaging mediators, predominantly MMPs and 
collagenase [115]. There is mounting evidence that an increase in the number of 
macrophages in the BAL fluid, sputum, alveolar space and lung parenchymal tissue in 
COPD patients, due in part to an increased macrophage proliferation and prolonged 
macrophage survival [145, 159, 160, 464, 465]. Interestingly, macrophages are also found at 
the site of alveolar tissue destruction in patients with emphysema [466, 467]. It is likely that 
the pulmonary immune environment during COPD development drives the differentiation 
of a heterogeneous population of macrophages that display characteristics of both 
classically- (M1) and alternatively- (M2) activated cells. This mixed phenotype is represented 
by the simultaneous elevation of inducible nitric oxide synthase (iNOS) and arginase activity, 
typical markers of M1 and M2, respectively [468-470]. While M1 macrophages express high 
levels of pro-inflammatory genes relevant to innate and adaptive cell-mediated immunity, M2 
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polarization is typically associated with wound-healing, tissue remodeling and 
immunoregulatory function [420, 425]. Both populations of macrophages might play a role 
in the development of emphysema, however, a better understanding of the relative 
contribution of these M1 and M2 macrophages is likely to enhance our understanding of the 
pathogenesis of progressive stage of emphysema. 
 
Cells of the adaptive immune response are also associated with emphysema. There is an 
infiltration of multiple subsets of T-lymphocytes into the airways and lung parenchyma of 
patients with COPD accompanied by their canonical cytokines and chemokines [168, 170, 
464, 471]. IFN--producing type 1 T helper (Th1) CD4+ and type 1 cytotoxic (Tc1) CD8+ 
cells are predominant among all population of lymphocytes [167]. Indeed, studies in 
experimental animals demonstrated that cigarette smoke-exposed CD8-deficient mice fail to 
develop emphysema, whereas IFN--overexpressing mice develop spontaneous emphysema 
at an early age [173, 472]. While cigarette smoking has been shown to induce IFN--
producing Th1 or Tc1 responses, it also appears to promote IL-17A-producing Th17 or 
Tc17 responses in mice [187, 473]. Moreover, a recent study revealed the persistence of 
elevated IFN- in the BAL and an increase in the number of Th17/Tc17 cells in the lung 
tissue of 24-week cigarette smoke-exposed mice; changes that were maintained even after 12 
weeks of smoking cessation [474]. A number of other publications have identified the 
presence of IL-17A-producing Th17, Tc17 and  cells in COPD subjects [181-184, 475]. 
The IL-17 cytokine can induce other pro-inflammatory cytokines and chemokines from 
several cell types and in turn recruit neutrophils to the site of inflammation, which might 
enhance pathologic outcomes associated with neutrophils [476]. Moreover, either IL-17A or 
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IL-17 receptor deficiency in mice resulted in a mitigated degree of smoke-induced 
pulmonary inflammation and emphysema. In contrast, lung epithelial cell-specific 
overexpression of IL-17A in transgenic mice exaggerated the effects of cigarette smoke [186, 
187]. Antigen-presenting cells isolated from the lungs of patients with emphysema stimulated 
T lymphocytes to secrete significant amounts of IFN- and IL-17A, but not IL-4, in co-
culture experiments [477]. Data presented in Chapter 3 demonstrates that IFN- and IL-17A 
are also elevated in the elastase-induce experimental emphysema model.  Overall, these 
studies reveal the potential role of IFN- and IL-17A in emphysema, but the exact function 
of these cytokines in the mechanism that results in the destruction of alveolar walls has not 
been fully explored yet. 
 
Here, the goal was to test the role of neutrophils, macrophages as well as the IFN- and IL-
17A signaling pathways in the elastase-induced experimental emphysema model. In contrast 
to the cigarette-smoke induced emphysema model, the intratracheal elastase model causes 
progressive immune-mediated emphysema which allows for a more accurate means to tease 
out the underlying mechanisms involved in the development of alveolar tissue destruction 
and airspace enlargement. 
 
4.3 Results 
4.3.1 IFN- deficiency alters the development of elastase-induced emphysema 
Drawing on our data demonstrating that C57BL/6J mice had higher expression of IFN- 
following the elastase injury than BALB/cJ mice (Fig. 3.13 – 3.14), we sought to determine 
the role of IFN- in the pathogenesis of emphysema by utilizing IFN--deficient mice on 
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both C57BL/6 and BALB/c backgrounds. The elastase-treated IFN--/- mice on C57BL/6 
background (IFN--/- B6) had improved pulmonary function as shown by a higher diffusion 
capacity than elastase-treated C57BL/6J WT animals (Fig. 4.1A). Although no statistically 
significant differences were detected, which might be due to the IFN--/- B6 mice having 
larger lungs at the baseline, the elastase insult resulted in a less than 10% increase in total 
lung capacity in IFN--/- B6 mice compared to almost a 50% increase in WT mice (Fig. 4.1B). 
A slightly smaller increase in residual volume and compliance in IFN--/- B6 mice were also 
observed (Fig. 4.1C-D). We attempted to confirm these data with IFN--/- mice on a 
BALB/c background (IFN--/- BALB). The absence of IFN- in BALB/c mice also protected 
them from elastase-induced emphysema, as evidenced by significantly lower TLC, RV and 
compliance values. These results implicate IFN- contributing to the development of 
elastase-induced emphysema. 
 
4.3.2 IL-17A contributes to the severity of elastase-induced emphysema in a 
neutrophil-independent fashion 
As opposed to the IFN- up-regulation in C57BL/6J mice, the susceptible BALB/cJ mice 
had almost a 20-fold higher induction of IL-17A expression in the lung after challenge with 
elastase (Fig. 3.16A). To evaluate whether IL-17A is involved in dictating the severity of 
elastase-induced emphysema, BALB/c mice deficient in IL-17A production, were used for 
this study. Twenty one days after elastase treatment, significantly higher DFCO accompanied 
by lower TLC, RV and compliance were found in IL-17A-/- BALB mice compared to BALB/cJ 
WT mice, highlighting a reduction of elastase-induce emphysema in the knockout animals 
(Fig. 4.3). These results were confirmed by histological analysis that demonstrated 
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significantly less alveolar destruction and airspace enlargement in the lungs from IL-17A-/- 
BALB mice compared to the WT controls (Fig. 4.4). 
 
IL-17A has been shown to mediate inflammation by enhancing the recruitment of 
neutrophils into the inflammatory site [476]. In addition, we found marked migration of 
circulating neutrophils into the lung after elastase injury (Fig. 3.11). To investigate the role of 
neutrophils in the elastase-induced experimental emphysema model, an antibody-mediated 
depletion strategy was employed. Fig 4.5A-B shows that a single intraperitoneal injection of 
500 mg of an anti-Ly6G (Clone 1A8) antibody successfully depleted neutrophils within the 
peripheral blood within 24 hours and that the percentage of circulating neutrophils relative 
to total leukocytes remained constantly low for at least 6 days following injection. Moreover, 
1A8 treatment could also mitigate the infiltration of neutrophils into the lungs following to 
the elastase insult (Fig. 4.5B). These results indicated that our approach could successfully 
block neutrophil infiltration within the window of regular neutrophil influx observed after an 
elastase insult. The number of macrophages and lymphocytes in the BAL were not 
appreciably changed in response to neutrophil depletion by 1A8 treatment (data not shown). 
However, neutrophil depletion failed to influence the severity of elastase-induced pulmonary 
emphysema, as no significant alterations to DFCO, TLC, RV, compliance or a quantitative 
histological assessment of airspace enlargement were observed in 1A8-treated BALB/cJ 






4.3.3 T and B cells do not significantly alter the severity of elastase-induced 
emphysema 
We next sought to explore the importance of adaptive immune cells, particularly T and B 
cells, in the progression of elastase-induced emphysema by utilizing mice lacking functional 
recombination activation gene-1 (Rag-1). The RAG-1 protein mediates immunoglobulin and 
T cell receptor V(D)J recombination, which is required for B and T lymphocyte 
development. As such, RAG-1 knockout mice are entirely devoid of T and B cells [478]. We 
treated RAG-1-deficient mice on both C57BL/6 (RAG-1-/- B6) and BALB/c (RAG-1-/- BALB) 
backgrounds with 3U elastase. RAG-1-/- B6 mice developed the same degree of emphysema 
observed in WT animals (Fig. 4.8). While the absence of T and B lymphocytes in RAG-1-/- 
BALB mice can significantly lessened the TLC elevation caused by elastase, no significant 
changes in DFCO, RV and compliance were observed between WT and the genetically-
modified mice (Fig. 4.9). Of note, both RAG-1-/- B6  and RAG-1-/- BALB mice had slightly 
smaller lungs than the WT control animals as indicated by lower TLC values, an observation 
that has yet to be described in the literature. Furthermore, assessment of lung histology 
showed that there was no significant difference in extent of airway damage (Fig. 4.10A) or 
Lm values (Fig. 4.10B) between the elastase-challenged RAG-1-/- BALB mice and their WT 
controls.  
 
4.3.4 Macrophage activation during the development of elastase-induced 
emphysema 
Owing to the failure to diminish the severity of elastase-induced emphysema in mice lacking 
either neutrophils or lymphocytes, we hypothesized that macrophages might be the key 
effector cells causing emphysematous damage in our model.  We have previously shown a 
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correlation between the persistent increase in macrophage number recovered from the BAL, 
sustained alternative activation of macrophages (M2 phenotype) and the progression of 
emphysema in the sensitive BALB/cJ strain in Chapter 3. Therefore, we sought to test the 
hypothesis that blocking the ability of macrophages to develop an M2 activation phenotype 
diminishes the severity of emphysema. Signaling though the Signal Transducer and Activator 
of Transcription (STAT) 6 protein has been shown to be essential for the differentiation and 
proliferation of alternatively-activated macrophages [479], as STAT6-deficient mice have 
displayed defective M2 expansion in a variety of studies [480, 481]. In this way, we compared 
the extent of emphysematous changes in the lungs in response to intratracheal elastase 
administration between STAT6-/- mice and WT BALB/cJ controls. Fig. 4.11 illustrates that 
the absence of STAT6 significantly diminishes the severity of pulmonary emphysematous 
changes at 21 days post-elastase administration as assessed by all of the pulmonary function 
and mechanics measurements. In agreement with these physiological findings, intratracheal 
elastase caused noticeably fewer emphysematous lesions in histological sections obtained 
from STAT6-/- mice compared to WT controls by gross inspection (Fig. 4.12A) and 
quantified by mean linear intercept (Fig. 4.12B). 
 
In addition to STAT6-dependent M2 activation, STAT3 signaling downstream of IL-6 or IL-
10 receptor-engagement has been reported to up-regulate the expression of several genes 
associated with M2-like phenotypes [482, 483]. We first examined whether STAT3 was 
activated via phosphorylation in response to elastase injury. Immunostained Western blots 
demonstrated that there was a significant increase in phosphorylation of the tyrosine-705 
residue of STAT3, an indication of STAT3 activation, in the lungs during first 4 days after 
elastase challenge, while there was no change in total STAT3 levels (Fig. 4.13A-B). Since 
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phosphorylated STAT3 can translocate into the nucleus and bind to STAT3-responsive 
elements in the promoter regions of its target genes, we next confirmed its activation by 
extracting the nuclear protein fractions from the lung tissue of mice receiving elastase at 
different time points and evaluating their ability to bind to oligonucleotides containing the 
STAT3 consensus binding site. Similar to the patterns observed by the immunostained 
Western blots, intratracheal elastase administration led to a significant elevation of STAT3 
DNA binding activity in the lung from day 1 to day 4 post-elastase treatment (Fig. 4.13C).  
Due to the fact that whole body STAT3 deletion is embryonic lethal, we assessed the 
significance of STAT3 activation in our model using conditional knockout mice where the 
STAT3 gene is specifically ablated in either myeloid cells (Cre-LyZ/Stat3fl/fl) or CD4 cells 
(Cre-CD4/Stat3fl/fl) on a C57BL/6 background. These mice were challenged with elastase in 
comparison to Stat3fl/fl control animals. Only myeloid-specific STAT3-deficient mice, not 
CD4-specific mice, showed a reduction in elastase-induced lung damage as seen by the lower 
values for lung function and airspace enlargement (Fig. 4.14 – 4.15).  
 
4.3.5 Blocking the IL-33 signaling pathway can attenuate the progression of 
elastase-induced emphysema 
IL-33 is an innate cytokine that is rapidly released following damage to the mucosal 
epithelium [484]. It functions via binding to a heterodimeric membrane receptor complex of 
ST2 and IL-1 receptor accessory protein (IL-1RAcP), which is constitutively expressed or 
inducible on a variety of cell types including IL-13-secreting type 2 innate lymphoid cells and 
macrophages [485-487]. As such, IL-33 has been shown to enhance the polarization of 
macrophages towards the M2 phenotype [488]. We first attempted to identify the cellular 
source(s) of IL-33 by immunofluorescence staining assay, and we found it to be primarily co-
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localized with cells expressing pro-surfactant protein C, suggesting that a major source of IL-
33 in our model is alveolar type II cells in the lungs (Fig. 4.16) [489]. Based on its known 
function and these findings, it was interesting to test if targeted disruption of the IL-33 
signaling pathway can modulate the development of elastase-induced lung injury. As shown 
in Fig. 4.17, higher DFCO was associated with lower TLC, RV, and compliance suggesting 
significantly abrogated elastase-induced emphysematous damage in ST2-/- mice compared 
with WT mice. Similarly, quantitative histomorphometric assessment indicated that deletion 
of the IL-33 receptor significantly inhibited the increase in Lm typically observed for 
BALB/cJ mice (Fig. 4.18). Furthermore, mice lacking MyD88, an essential adaptor protein 
downstream of IL-33 receptor engagement and key for the signaling cascade, also developed 




Emphysema is well-known to correlate with an increased number of inflammatory cells in 
the pulmonary system, predominantly neutrophils, macrophages and lymphocytes. 
Controversy remains whether neutrophil or macrophages are involved in the destruction of 
alveolar tissue seen in emphysematous lung since both of them can secrete a number of 
elastolytic enzymes associated with the pathology. Mixed subsets of T lymphocytes are 
found in human emphysema subjects and can produce different mediators that modulate the 
function of neutrophils and macrophages. In light of the existing evidence, our goal here was 
to address the impact of these cells in a model of protease-induced loss of lung tissue. 
In an attempt to clarify the impact of neutrophils, we used a 1A8 antibody to systemically 
deplete neutrophils. This 1A8 antibody is an antibody against Ly6G which is specifically 
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expressed on neutrophils and has been successfully used to deplete neutrophils from the 
circulating blood [490]. In our hands, a single dose of intraperitoneal injection of 1A8 
antibody was sufficient to significant reduce the number of neutrophils in both the 
peripheral blood and to limit the recruitment of neutrophils into the lung even in the context 
of elastase-induced inflammation. We did not see a rebound in neutrophil counts for at least 
for 6 days after elastase administration, suggesting efficient depletion at least during the 
period when we typically observe the marked influx of neutrophils during the response to 
elastase. In our hands, neutrophil depletion did not alter the degree of elastase-induced 
emphysematous damage in the lung. This result is consistent with the study from Ofulue and 
Ko showing no effects of neutrophil depletion on cigarette-smoke induced emphysema 
[156]. However, our data is conflicting with work by Shim et al. demonstrating that 
emphysema induced by elastase could be ameliorated by alleviating neutrophil inflammation 
[155]. One possibility that might lead to these contrary results is a potential difference in the 
antibodies used to deplete neutrophils. While our antibody treatment with the 1A8 anti-
Ly6G clone selectively depletes neutrophils, and we did not observe any changes in other 
leukocyte counts, Shim and colleagues’ study specified only that they used an anti-Ly6G 
antibody from BioXCell, which could include the 1A8 Clone we utilized or the RB6-8C5 
Clone as both are anti-Ly6G antibodies. However, the RB6-8C5 antibody clone not only 
recognizes Ly6G but also binds with low affinity to Ly6C, which also results in the depletion 
of blood-derived inflammatory monocytes [490-492], plasmacytoid dendritic cells (pDCs) 
[493, 494], and CD8+ T cells [495, 496]. In addition, intranasal elastase markedly increased 
lung volume, compliance and chord length in their study, and the effects of neutrophil 
depletion on these parameters of emphysema were minimal (less than 10% reduction of lung 
volume and chord length). Together, it is reasonable to speculate that the minor protective 
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effect observed in their study might be a result from non-specific depletion of monocytes or 
other immune cells.  
 
Historically, based on observations in patients with severe 1-antitrypsin (1-AT) 
deficiency, neutrophils were suggested to be a potential candidate for driving the 
pathogenesis of emphysema [58]. Lacking enough functional 1-AT, these patients exhibited 
high levels of neutrophil elastase activity which correlated with the extent of their 
emphysema [497]. Also, mice with low levels of 1-AT (such as pallid mice) display a certain 
degree of airspace enlargement at 12-months of age and develop smoke-induced emphysema 
earlier than wild-type mice [84, 85, 453]. However, it is worth noting that 1-AT does not 
only function to inhibit neutrophil elastase activity, since some studies have shown a 
suppressive effect of 1-AT on the number of inflammatory cells in the BAL as well as 
TNF- and MMP-12 production by alveolar macrophages following cigarette smoke 
exposure [101, 498]. Moreover, although neutrophils have the ability to secrete a number of 
enzymes causing elastolytic damage, emphysema was not detectable in other pulmonary 
diseases such as cystic fibrosis where chronic neutrophil inflammation is even more apparent 
[72]. Additionally, neutrophils are short-lived and are present only in the first few days after 
elastase administration, whereas the tissue damage progresses over months. In this regard, 
we suspect that increased number of recruited neutrophils seen in the lung shortly after 
elastase challenge is only the consequence of the elastase-induced tissue damage, which 
compromises the integrity of the alveolar-capillary barrier, increases microvascular 
permeability, and induces the release of neutrophil chemotactic factors. Nevertheless, we did 
not see an appreciable role of neutrophils per se in the degradation of alveolar tissue in this 
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model. This does not necessarily mean that neutrophils have no effect on the development 
of emphysema in COPD patients, who display chronic inflammation with persistent 
presence of neutrophils in the lungs. Moreover, neutrophils might have even bigger roles 
during microbial infection-induced exacerbation in these patients because neutrophils can 
release several other mediators (e.g. highly reactive oxygen species, proteases, etc.) in order 
to destroy invading microorganisms. However, these mediators might be deleterious to the 
host tissue as well. 
 
Next we sought to evaluate the involvement of lymphocytes in the pathogenesis of 
emphysema. Experimentally, both cigarette smoke and elastase models of emphysema show 
significant elevation of lymphocyte counts in the lungs [104, 344] (also shown in Chapter 3). 
However, our data from RAG-1-/- mice showed that lymphocytes are not required for the 
progression of disease in the elastase-triggered airspace enlargement. This is in agreement 
with D’hulst and colleagues who showed that severe combined immunodeficiency (scid) 
mice, which also lack functional B and T lymphocytes, developed pulmonary emphysema at 
comparable levels to WT mice when exposed to cigarette smoke [499]. Our assumption is 
that the elevation of lymphocytes observed might be in response to foreign antigen derived 
from the exogenously-administered porcine elastase and/or modified self-antigens derived 
from damaged host proteins after elastase-induced injury, but in any case these responses do 
not appear to have a significant impact on progressive alveolar tissue destruction per se. 
These observations do not support the notion for a causal role for the adaptive immune 
response in the progression of emphysema as well as the suggestion that chronic emphysema 




Having been unable to determine a clear role for neutrophils and lymphocytes in our 
elastase-induced experimental emphysema model, we then hypothesized that macrophages 
could play a significant role in the progression of this disease. Ofulue and Ko showed that 
while depletion of neutrophils did not protect the lung from cigarette-smoke induce 
emphysema in rats, the depletion of macrophages/monocytes clearly did [156]. Moreover, 
several recent studies strongly support the impact of macrophages in mouse models of 
smoke-induced emphysema, for example, mice lacking macrophage elastase (MMP12) did 
not develop emphysema [102]. Together with our data in Chapter 3, macrophages appear to 
be the only inflammatory cell type in BAL that remains elevated even two weeks after the 
initial elastase insult, a time frame that corresponds with ongoing tissue destruction and 
progressive emphysema. This suggests that macrophages, rather than neutrophils, may be 
the effector cells causing alveolar tissue degradation in this model. However, we have yet to 
definitively show the effects of macrophage depletion on elastase-induced emphysema, but 
these studies are currently ongoing. A member of our group, Dr. Daniel Lagassé, attempted 
to selectively deplete macrophages in the lungs using intratracheal administration of 
clodronate-loaded liposomes. Although he could successfully deplete about 90% of 
macrophages in naïve animals, the efficacy of depletion fell to only 40 – 60% when the 
animals had previously received elastase.  
 
While troubleshooting our approach to macrophage depletion, we instead decided to 
validate the importance of macrophages in the development of emphysema by focusing on 
their activation status using knockout mice which possess altered expression of interesting 
genes relevant to macrophage activation. In terms of activation status and phenotype, 
macrophages display a high level of plasticity depending on the dictates of their 
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microenvironment [500]. Classical pro-inflammatory M1 macrophages versus alternative M2 
macrophages were originally distinguished from each other based on the Th1/Th2 cytokines 
mediating their activation in vitro [501, 502]. However, a number of recent studies have 
illustrated that macrophage polarization in vivo is much more complex [503]. M2 
macrophages are of particular interest to the work herein since prior global gene expression 
analyses of alveolar macrophages isolated from COPD smokers, healthy nonsmokers and 
healthy smokers revealed the up-regulation of immunomodulatory and repair-associated M2-
related genes but a deactivation of M1-related pro-inflammatory genes [469].	For example, 
the expression of MMP12, which is associated with extracellular matrix remodeling and has 
been repeatedly linked to emphysema progression in mice, was shown to be favored by M2 
activation [504]. Interestingly, helminth parasitic infection, which is also marked by a heavily 
Th2/M2-skewed immune response, results in the development of progressive emphysema as 
well [108]. In Chapter 3, we also found an elevation of M2 markers (Arg1, Chil3, Retnla and 
Mmp12) together with Il4 (a major driver of M2 phenotype) in response to elastase injury. 
We further investigated the role of alternatively activated macrophages using STAT6-
decifient mice, since STAT6 is a transcription factor that responds to IL-4 and IL-13 
signaling and is essential to skew towards the M2 phenotype [480, 481, 505]. We found that 
deficiency in STAT6 decreased the severity of elastase-induced emphysema, a result that is 
consistent with the spontaneous development of an emphysema-like phenotype 
accompanied by elevated MMP-12 expression in mice overexpressing IL-13 [178]. This IL-
13-mediated pulmonary emphysema could be rescued by eliminating MMP-12 [506].  
 
In addition, ST2 receptor knockout mice and MyD88 knockout mice, genes involved in the 
IL-33 signaling pathway, that is known to amplify IL-13-dependent M2 activation both in 
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vitro and in vivo [488], also exhibited reduced progressive damage of alveolar tissue. As shown 
in Chapter 3, the expression of IL-33 mRNA was significantly increased during the first 
week after elastase insult, which was then followed by the concurrent up-regulation of ST2 
and MMP12 mRNA on days 7 and 21(Fig. 3.18 – 3.19). We hypothesize that IL-33 is 
released from injured epithelial cells following elastase injury, becomes subsequently 
activated by proteases in the inflamed lung, and ultimately binds to ST2 on the surface of 
macrophages to push them towards the M2 phenotype. Also, type 2 innate lymphoid cells 
(ILC2), which are resident in the lung and are known to express the ST2 receptor, might 
respond to IL-33 by releasing IL-13 [507]. The released IL-13 from ILC2 can in turn drive 
the M2 activation of alveolar macrophages via STAT6 [508]. Of note, Couillin and his group 
showed that both IL-1R1-/- mice and MyD88-/- mice are protected from elastase-induced 
emphysema [176]. However, we could only reproduce their results in MyD88-/- mice but not 
in IL-1R1-/- mice. Furthermore, MyD88 is an adaptor protein shared by a number of Toll-
like receptor (TLR) and IL-1 receptor family members including ST2 [509]. Thus, we suspect 
the protective effect of MyD88-/- might be due to the lack of IL-33 signaling, rather than the 
loss of IL-1 signaling, as speculated in their study. Overall, given the sustained presence of 
alternatively activated macrophages in elastase-treated lungs, these cells may in fact 
perpetuate the degradation of extracellular matrix components and promote chronic 
emphysema progression. 
 
In addition to STAT6, STAT3 phosphorylation is also predominant in alternatively 
activation macrophages [505]. Again, we obtained a protective effect in mice which had the 
STAT3 gene conditionally deleted in myeloid cells. STAT3 is the key transcription regulator 
of both IL-6 and IL-10. Fernando and colleagues demonstrated that IL-6 can enhance the 
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expression of several M2 markers (Arg1, Retnla, Chil3) in bone marrow derived macrophages 
when co-treat with IL-4/IL-13 [483]. This enhancement of M2 phenotype by IL-6 was 
shown to be STAT3-dependent. Furthermore, IL-6 can stimulate the expression and the 
release of IL-10 [510]. IL-4/IL-13-induced M2 macrophages treated with IL-6 
spontaneously produce significant amount of IL-10 [483]. IL-10 derived from M2 
macrophages themselves can also induce STAT3 activation and can drive and perpetuate M2 
polarization [482]. Again, we showed in Chapter 3 that there was an up-regulation of IL-4 
expression following elastase insult. This increased IL-4 can skew macrophage toward an M2 
phenotype, which would be enhanced by IL-6- and IL-10-mediated STAT3 activation. Thus, 
depletion of STAT3 in macrophages can block the IL-6/IL-10/STAT3 axis and in turn 
diminish the alternative activation and ultimately abrogate the tissue destruction.  
 
Based on the observation that IFN- expression was higher in the less susceptible C57BL/6J 
strain of mouse, and the fact that IFN- is known to skew towards the M1 macrophage 
phenotype and away from the potentially pathogenic M2 phenotype, we hypothesized that 
IFN- may be a protective molecule in our system. Instead, we found that IFN- deficiency 
resulted in an attenuation of elastase-induced emphysema in both C57BL/6 and BALB/c 
mice, implicating IFN- in the pathogenesis of the disease. Although contrary to our 
hypothesis, these results are consistent with data from Wang et al. who reported that IFN- 
overexpressing transgenic mice displayed spontaneous airspace enlargement and larger lung 
volume [173]. In addition, Ma et al. showed an amelioration of the emphysema-like 
phenotype induced by cigarette smoke in IFN--null mice [511]. In Fig.3.14, we showed 
increases in the number of both IFN-+ NK cells and IFN-+ CD8+ cells following elastase 
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administration. However, since emphysema remained unchanged in the absence of T 
lymphocytes including CD8+ cells in RAG1-/- mice, NK cells are potentially the critical 
source of IFN- in our model. Interestingly, transgenic overexpression of IFN- significantly 
increased the number of macrophages in the BAL as well as the expression of a number of 
proteases including MMP-12, MMP-9 and cathepsins, possibly via up-regulation of 
chemokine receptor CCR5 and its ligands [173, 511]. However, the mechanisms by which 
IFN- modulates the function of macrophages and the release of these elastolytic enzymes 
particularly during progression of emphysema are not well understood. 
 
Having observed a much greater increase in the expression of IL-17A in the elastase-
susceptible BALB/cJ strain (data shown in Chapter 3), we also explored the role of IL-17A 
by using IL-17A-/- mice on a BALB/cJ background. The data show that deletion of IL-17A 
could ameliorate the extent of elastase-induced emphysema. This result resembles a recently 
published study done with IL-17A-/- mice on C57BL/6 background by Kurimoto et al. [188]. 
However, it is critical to note that a past study in our laboratory failed to find this protective 
effect in IL17A-deficient mice on C57BL/6J background following elastase treatment. In 
both the previous study and our present work, IL-17A was undetectable in the BAL fluid, 
and the level of IL-17A in lung tissue was not significantly altered from saline controls. This 
raises some doubt about whether C57BL/6 mice mount a substantial IL17A response to 
elastase injury. In looking at other animal models of emphysema, protection from 
emphysema development was also found in cigarette smoke-exposed IL-17A and IL-17 
receptor knockout mice, and conversely, overexpression of IL-17A in lung epithelial cells 
was found to enhance the severity of emphysema from cigarette smoke [186, 187]. However, 
knockout of IL-17R (C57BL/6 strain) did not mitigate the extent of ozone-induce 
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emphysema [512]. This contradiction likely reflects different underlying mechanisms in the 
pathogenesis of emphysema between a complex mixture of substances (cigarette smoke) and 
a single oxidizing molecule (ozone). With regards to its function, IL-17A is well-known to 
mediate inflammation by promoting neutrophil chemoattractant chemokines and cytokines 
[476, 513]. The number of neutrophils was attenuated in the BAL of IL-17A-/- mice exposed 
to either or cigarette smoke and elastase when compared to that of wild-type animals [187, 
188]. Nevertheless, unlike deficiency in IL-17A, the depletion of neutrophils did not 
significantly impact the extent of emphysema in either cigarette smoke or elastase models. 
This suggests that IL-17A modulates the development of emphysema in a neutrophil-
independent fashion. Shan and colleagues showed that the receptor for IL-17A was 
expressed on the surface of lung macrophages and treating lung macrophages with 
recombinant IL-17A induced the expression of macrophage-specific MMP-12 [477]. 
Interestingly, cigarette smoke-exposed or elastase-treated IL-17A-/- mice did not exhibit a 
reduced influx of neutrophils, but did have fewer macrophages and lower expression of 
MMP-12 compared to exposed wild-type mice [187, 188]. Moreover, overexpression of IL-
17A in the lung increased the number of macrophages and enhanced the expression of 
MMP-12 in response to cigarette smoke [187]. Collectively, we suspect that IL-17A 
modulates the severity of emphysema via the activation of macrophages.  
 
Another important outstanding question is the cellular source of IL-17A during the 
development of emphysema. Although IL-17A was initially reported to be predominantly 
expressed in activated CD4+ Th17 cells [514], our results in RAG-1-/- mice suggests that 
these cells are not likely to be the critical source of IL-17A in our model. Furthermore, 
STAT3 is known to be required for the differentiation of naïve CD4+ cells into Th17 cells 
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[515], and yet mice specifically deleted of STAT3 in CD4 cells developed the same degree of 
pulmonary emphysema as wild-type animals receiving elastase. All of this evidence suggests 
cells other than Th17 cells are the important source of IL-17A in our system. Recently, some 
innate non-lymphoid cells such as monocytes, NK cells, NKT cells and lymphoid tissue 
inducer (LTi)-like cells have been shown to have the capacity to rapidly produce IL-17A 
[516], and further investigations into these cells is warranted. 
 
In summary, data from the present study strengthen the critical role of MMP-secreting 
macrophages, rather than neutrophil and lymphocytes in the pathogenesis of emphysema. 
The function of these macrophages can be modified by a variety of cytokines, including 
IFN-, IL-17A, and those that signal through STAT6 and STAT3, all of which we have 
shown can alter the severity of elastase-induced emphysema. Furthering our knowledge 
towards understanding the mechanisms associated with macrophage polarization in the 
context of the emphysemic lung might be beneficial for identifying macrophage-targeted 
diagnostic and therapeutic manipulations of this disease. 
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Figure 4.1 Properties of lungs from IFN--deficient (C7BL/6 background) and 
C57BL/6J mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system of IFN--/- and wild-type (WT) 
C57BL/6J mice on Day 21 after intratracheal administration of 3U elastase. (n = 4-6 mice 
per group). Two-way ANOVA analysis: N.S. = not significant, * = p < 0.05, ** = p < 0.01, 
*** = p < 0.001 comparing elastase-treated group to PBS-treated animals on the same 












Figure 4.2 Properties of lungs from IFN--deficient (BALB/c background) and 
BALB/cJ mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system of IFN--/- and wild-type (WT) 
BALB/cJ mice on Day 21 after intratracheal administration of 3U elastase. (n = 4-6 mice per 
group). Two-way ANOVA analysis: N.S. = not significant, * = p < 0.05, *** = p < 0.001 
comparing elastase-treated group to PBS-treated animals on the same genotype. †† = p < 





















Figure 4.3 Properties of lungs from IL-17A-deficient (BALB/c background) and 
BALB/cJ mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system of IL-17A-/- and wild-type (WT) 
BALB/cJ mice on Day 21 after intratracheal administration of 3U elastase. (n = 9-10 mice 
per group). Two-way ANOVA analysis: N.S. = not significant, * = p < 0.05, *** = p < 0.001 
comparing elastase-treated group to PBS-treated animals on the same genotype. † = p < 













Figure 4.4 Histologic assessment of lungs from IL-17A-deficient and BALB/cJ mice 
following 3U elastase. Representative H&E-stained lung sections from wild-type (WT) 
BALB/cJ (left panel) and IL-17A-/- (right panel) mice on day 21 after 3U elastase or PBS 











Figure 4.5 Neutrophil depletion with 1A8 antibody in BALB/cJ mice. (A) Schedule of 
treatment with 1A8 antibody, elastase challenge and tissue harvesting.  (B) Percentage of 
neutrophils in peripheral blood, and (C) number of neutrophils at different time points in 
BAL fluid after 1A8-mediated systemic neutrophil depletion following 3U elastase. (n = 3 
mice/group). Unpaired t-test: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 for 1A8 treated 






Figure 4.6 Effect of systemic neutrophil depletion on the development of emphysema 
induced by 3U elastase in BALB/cJ mice. (A) Schedule of treatment with 1A8 antibody, 
elastase challenge and tissue harvesting. (B) Diffusion capacity. (C) Total lung capacity. (D) 
Residual volume, and (E) Compliance of respiratory system of BALB/cJ mice treated with 1A8 
antibody or untreated one day prior to giving 3U elastase or PBS. All data were collected on day 
21 after administration of 3U elastase or PBS. (n = 5 for PBS-treated group, n = 15 for 
elastase-treated group). Two-way ANOVA analysis: * = p < 0.05, *** = p < 0.001 comparing 
elastase-treated group to PBS-treated animals. N.S. = no significant different were found 






Figure 4.7 Histologic assessment of lungs from either neutrophil-depleted or non-
depleted BALB/cJ mice following 3U elastase. (A) Representative H&E-stained lung 
sections from untreated (left panel) and 1A8-treated (right panel) BALB/cJ mice on day 21 after 
3U elastase or PBS control. Original magnification x40. Scale bar = 500 m. (B) Mean linear 
intercept of histological sections from untreated and 1A8-treated BALB/cJ mice. Two-way 
ANOVA analysis: *** = p < 0.001 comparing elastase-treated group to PBS-treated animals. 






















Figure 4.8 Properties of lungs from RAG-1-deficient (C57BL/6 background) and 
C57BL/6J mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system in RAG-1-/- and wild-type (WT) 
C57BL/6J mice on Day 21 after intratracheal administration of 3U elastase. (n = 2-5 mice 
per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 














Figure 4.9 Properties of lungs from RAG-1-deficient (BALB/c background) and 
BALB/cJ mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system in RAG-1-/- and wild-type (WT) 
BALB/cJ mice on Day 21 after intratracheal administration of 3U elastase. (n = 2-4 mice per 
group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 comparing 
elastase-treated group to PBS-treated animals on the same genotype. ††† = p < 0.001 



















Figure 4.10 Histologic assessment of lungs from RAG-1-deficient and BALB/cJ mice 
following 3U elastase. (A) Representative H&E-stained lung sections from wild-type (WT) 
BALB/cJ (left panel) and RAG-1-/- (right panel) mice on day 21 after 3U elastase or PBS 
control. Original magnification x40. Scale bar = 500 m. (B) Mean linear intercept of 
histological sections from RAG-1-/- and wild-type (WT) BALB/cJ mice. Two-way ANOVA 
analysis: N.S. = no significant different were observed comparing between elastase-treated 











Figure 4.11 Properties of lungs from STAT6-deficient (BALB/c background) and 
BALB/cJ mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system of STAT6-/- and wild-type (WT) 
BALB/cJ mice on Day 21 after intratracheal administration of 3U elastase. (n = 9-13 mice 
per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
comparing elastase-treated group to PBS-treated animals on the same genotype. † = p < 









Figure 4.12 Histologic assessment of lungs from STAT6-deficient and BALB/cJ 
mice following 3U elastase. (A) Representative H&E-stained lung sections from wild-type 
(WT) BALB/cJ (left panel) and STAT6-/- (right panel) mice on day 21 after 3U elastase or PBS 
control. Original magnification x40. Scale bar = 500 m. (B) Mean linear intercept of 
histological sections from STAT6-/- and wild-type (WT) BALB/cJ mice. (n = 5 mice per 
group). Two-way ANOVA analysis: N.S. = not significant, *** = p < 0.001 comparing 
elastase-treated group to PBS-treated animals on the same genotype. †† = p < 0.01 

















Figure 4.13 Time course of STAT3 activation in lung tissue from C57BL/6J mice 
following 3U elastase. (A) Representative western blot images for expression level of p-
STAT3, STAT3 and -actin (B) Graph showing the ratio of the relative density of p-STAT3 
and STAT3 and (C) Level of STAT3 DNA binding activity in the lungs of C57BL/6J mice 
at various time points following administration of 3U elastase or PBS control. (n  6 mice 
per group). One-way ANOVA analysis: * = p < 0.05, ** = p < 0.01*** = p < 0.001 









Figure 4.14 Properties of lungs from STAT3-deficient in either myeloid or CD4 cells 
mice and C57BL/6J mice following 3U elastase. (A) Diffusion capacity (B) Total lung 
capacity (C) Residual volume and (D) Compliance of respiratory system of Cre-LyZ/Stat3fl/fl, 
Cre-CD4/Stat3fl/fl and wild-type (WT) C57BL/6J mice on Day 21 after intratracheal 
administration of 3U elastase. (n = 4-10 mice per group). Two-way ANOVA analysis: * = p 
< 0.05, ** = p < 0.01, *** = p < 0.001 comparing elastase-treated group to PBS-treated 
animals on the same genotype. †† = p < 0.01, ††† = p < 0.001 comparing STAT3-









Figure 4.15 Histologic assessment of lungs from STAT3-deficient in either myeloid 
or CD4 cells mice and C57BL/6J mice following 3U elastase. Representative H&E-
stained lung sections from wild-type (WT) C57BL/6J (upper panel), Cre-LyZ/Stat3fl/fl (middle 
panel) and Cre-CD4/Stat3fl/fl (lower panel) mice on day 21 after 3U elastase or PBS control. 













Figure 4.16 Localization of IL-33 protein in the lungs of BALB/cJ mice. (Upper panel) 
Representative immunofluorescence stained lung sections for pro-IL-33, pro-surfactant protein 
C and DAPI (nuclear stain) of BALB/cJ mice. (Lower panel) Composited images showing co-
localization of pro-IL-33 and pro-surfactant protein C. Original magnification 20x or 40x 
















Figure 4.17 Properties of lungs from ST2-deficient (BALB/c background) mice and 
BALB/cJ mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity (C) 
Residual volume and (D) Compliance of respiratory system of ST2-/- and wild-type (WT) 
BALB/cJ mice on Day 21 after intratracheal administration of 3U elastase. (n = 10-17 mice 
per group). Two-way ANOVA analysis: *** = p < 0.001 comparing elastase-treated group to 
PBS-treated animals on the same genotype. ††† = p < 0.001 comparing ST2-defeicient mice 









Figure 4.18 Histologic assessment of lungs from ST2-deficient and BALB/cJ mice 
following 3U elastase. (A) Representative H&E-stained lung sections from wild-type (WT) 
BALB/cJ (left panel) and ST2-/- (right panel) mice on day 21 after 3U elastase or PBS control. 
Original magnification x40. Scale bar = 500 m. (B) Mean linear intercept of histological 
sections from ST2-/- and wild-type (WT) BALB/cJ mice. (n = 10-14 mice per group). Two-
way ANOVA analysis: N.S. = not significant, *** = p < 0.001 comparing elastase-treated 
group to PBS-treated animals on the same genotype. ††† = p < 0.001 comparing ST2-/- mice 










Figure 4.19 Properties of lungs from MyD88-deficient (C57BL/6 background) mice 
and C57BL/6J mice following 3U elastase. (A) Diffusion capacity (B) Total lung capacity 
(C) Residual volume and (D) Compliance of respiratory system of MyD88-/- and wild-type 
(WT) C57BL/6J mice on Day 21 after intratracheal administration of 3U elastase. (n = 1-3 
mice per group). Two-way ANOVA analysis: * = p < 0.05, ** = p < 0.01 comparing 
elastase-treated group to PBS-treated animals on the same genotype. † = p < 0.05 comparing 














Viral infection alters the sensitivity to 












Viral infection-induced exacerbation is common in COPD, and it critically impacts the 
progression of the disease. This viral infection potentially can modulate both the innate and 
adaptive immune responses in several ways, but little is known how these changes in the 
immune response impact the severity of emphysema outcomes. In the present study, we pre-
infected both C57BL/6J and BALB/cJ mice with either vaccinia virus, influenza A virus, or 
their appropriate vehicle, followed by intratracheal challenging with elastase at 7 days (for 
vaccinia virus) or 14 days (for influenza virus) after viral inoculation to induce 
emphysematous changes in the lung. Our results showed that while vaccination with vaccinia 
one week prior to induction of emphysema exaggerated the extent of elastase-induced 
alveolar tissue destruction in C57BL/6J mice, it abrogated the disease in BALB/cJ mice. 
Examining the effect of pre-exposure of influenza A virus, we found no differences in the 
degree of emphysema caused by elastase between influenza-infected and non-infected in 
C57BL/6J mice.  However, pronounced reduction in the severity of emphysema was 
observed in BALB/cJ animals exposed to influenza virus prior to elastase. Also, we found 
that this viral infection effect on susceptibility to emphysema was dependent on altered 
immune responses in certain critical time periods, with minimal effect outside of these 
critical periods.  Overall, this study reveals that exposure to viral infection can modulate the 
pulmonary immune environment and subsequently impact the development of emphysema. 








Chronic obstructive pulmonary disease (COPD) is characterized by progressive and usually 
irreversible airflow limitation and is a major cause of chronic morbidity and mortality world-
wide [517]. Clinically, patients with COPD usually experience pathologic characteristics of 
both chronic inflammation in the airway (chronic bronchitis) and proteolytic destruction of 
alveolar wall tissue leading to permanent airspace enlargement (emphysema) [28, 29]. One of 
the major complications affecting the accelerated progression of COPD is acute 
exacerbation from bacterial or viral respiratory infections [266, 267].  Such exacerbations 
impact the nature of the pulmonary immune environment, which can subsequently affect the 
progression of COPD. Robust increases of inflammatory biomarkers (e.g. white blood cell 
counts, pro-inflammatory cytokines, chemokines and proteases) have always been detectable 
during such exacerbations. However, little is known about the underlying mechanisms 
linking the immune system changes induced by these infectious agents to the pathologic 
effects driving the progression of emphysema. Here, we selected two types of viruses, 
vaccinia and influenza A virus to study the role of viral infection on the progression of 
emphysema. 
 
Vaccinia virus is a prototype member of the Orthopoxvirus genus, which is a group of large 
enveloped DNA viruses with ability to reproduce entirely within the cytoplasm of host cells 
[518]. Vaccination with vaccinia virus was used to eradicate human smallpox, another human 
pathogenic virus in the same genus. Recently, vaccinia has been employed as a promising 
viral vector to deliver immunotherapetics for targeting cancer cells including lung cancer 
[519-523]. Intranasal infection with modified vaccinia virus Ankara (MVA) strain has been 
shown to be able to effectively induce pulmonary immune responses, particularly Th1 effects 
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[524]. Pre-vaccination can induce Th1 responses and promote M1 macrophages. It also 
mitigates Th17 and M2 phenotypes in the lungs, resulting in a protective effect for 
bleomycin-induced pulmonary fibrosis [525]. Because of this effect on fibrosis, we sought to 
investigate if pre-exposure to vaccinia can similarly modulate the development of 
emphysema. 
 
In contrast to vaccinia virus, influenza A viruses are in the group of Orthomyxoviruses and 
contain a negative-sense strand RNA in its genome [526]. They are categorized by 16 types 
of surface hemagglutinin (HA or H) together with 9 types of neuraminidase (NA or N) 
glycoproteins [526]. Influenza A viruses are some of the most important viral pathogen 
responsible for regular outbreaks worldwide, causing morbidity and mortality in human and 
animals [527, 528]. The most recent global pandemic in 2009 was caused by the influenza A 
H1N1 strain and was associated with more than 100,000 deaths worldwide, especially in 
children, young adults, and pregnant women [529, 530]. Moreover, several lines of 
epidemiological evidence indicate that influenza viruses are commonly found in COPD 
exacerbations and are the most common viruses associated with severe exacerbations 
requiring hospitalization [260, 531, 532]. Aberrant pulmonary immune responses, including 
striking elevation of numerous cytokines and chemokines, often called a “cytokine storm,” 
has been well-documented during influenza virus infection in both humans and animal 
models [533-535]. Nevertheless, experimental studies linking this influenza-induced 




In this study, our main goal was to study whether an altered immune status in the lungs 
induced by either vaccinia virus or influenza A virus can change the susceptibility to 
emphysema in mice, using the intratracheal porcine pancreatic elastase model. 
 
5.3 Results 
5.3.1 Priming with vaccinia enhances the sensitivity to develop elastase-
induced emphysema in C57BL/6J mice 
To determine the effect of pre-exposure to vaccinia on the development of emphysema, we 
infected C57BL/6J mice by intranasal inoculation of two million vaccinia particles (Fig. 
5.1A). The control group was treated with an equal volume of PBS. Seven days after vaccinia 
inoculation, the mice received either PBS (control) or porcine-derived pancreatic elastase at 
doses of 1.5, 3 or 6 enzymatic units (U) by the intratracheal route. When the mice were 
sacrificed at day 21 post-elastase challenge, we evaluated the degree of pulmonary 
emphysematous changes by measurement of diffusion capacity, pressure-volume 
relationship, and histological assessment. Fig. 5.1B-D shows that vaccinia alone did not 
change any pulmonary function measurement at the harvest day. As expected, increasing the 
dose of elastase resulted in more emphysematous changes in the lung as seen by dose-
dependent decreases in DFCO, and increases in TLC, RV, and compliance. Vaccinia-infected 
mice who received 1.5 and 3 U of elastase showed augmented changes in all measurements 
compared to the mock-infected mice given the same dose of elastase. However, vaccinia did 
not show any effect with the 6U dose of elastase. Histological examination of the lungs 
supported the pulmonary function tests, showing that vaccinia alone did not cause any 
observable pathology in the lungs, but induced more pronounced elastase-induced airspace 
enlargement (Fig. 5.2A). By morphometric analysis, compared to 3U elastase-treated mice, 
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mice infected with vaccinia and followed by 3U elastase exhibited significant increases in 
mean linear intercept (Lm) compared to 3U elastase without the early vaccinia infection (Fig. 
5.2B).  
 
5.3.2 Intranasal vaccinia treatment alters pulmonary immune cell profiles  
We speculated that intranasal vaccinia treatment would change the pulmonary immune 
environment resulting in more susceptibility to elastase. C57BL/6J mice were either given 
vaccinia (2 x 106 pfu) or PBS, then all challenged with 3U elastase 7 days later. Then we 
harvested and analyzed the whole lung tissue for cellular profiles by flow cytometry at day 0, 
2, 7 or 14 post-elastase challenge (Fig. 5.3A). We analyzed for polymorphonuclear cells 
(PMNs, Ly6G+ CD11b+ Ly6C+), monocytes (CD11b+ CD64+ Ly6C+), dendritic cells 
(CD11b+ CD11c+ SiglecF-), macrophages (CD11b- CD11c+ SiglecF+), CD4+ T cells (B220- 
CD3+ CD4+), CD8+ T cells (B220- CD3+ CD8+),  T cells (gdTCR+), B cells (B220+ CD3-), 
NK cells (NKp46+ CD3- CD49b+), and NKT cells (NKp46+ CD3+ CD49b+). In term of 
myeloid populations (Fig. 5.3), vaccinia treated mice showed a much greater number of 
dendritic cells than mock treated animals at day 0 (7 days after vaccinia administration), with 
a gradual decrease over time. While there were more monocytes recruited into the lungs of 
vaccinia-treated mice at day 2 and day 7, the increases in number of macrophages seemed to 
be delayed and were not found significant until day 7 and day 14. However, vaccinia had no 
effect on the neutrophil count. Examining the lymphoid populations showed that vaccinia 
infected mice had greater numbers of CD4+, CD8+,  T cells, and NK cells on day 0 than 
PBS-treated mice. Although eventually there were decreases in the numbers of CD4+ and 
CD8+ T cells, the level of these cells in vaccinated mice remained significantly higher 
compared to control animals. In contrast, the elevated number of  T cells and NK cells 
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were only found in the lungs less than 7 days after elastase administration. There were slight 
increases in the number of NKT cells in vaccinia-treated mice from day 2 to day 7, but no 
differences in the number of B cells were detectable. 
 
5.3.3 Effect of vaccinia on the sensitivity of elastase-induced emphysema is 
time-sensitive 
Since the elevated number of immune cells peaked around 7 days after intranasal 
administration of vaccinia (the day of elastase challenge in the previous experiments), and 
then steadily declined after 7 days, we hypothesized that there was a critical period for the 
vaccinia effect on the alteration of elastase-induced emphysema. To test this proposition, we 
modified the treatment by giving vaccinia to C57BL/6J mice 21 days (instead of 7 days) 
prior to challenging with 3U elastase and observing the emphysema phenotypes at 21 days 
post-elastase challenge (Fig. 5.5). We found that, with this modified protocol, the effect of 
prior vaccinia infection on augmenting the severity of elastase-induced emphysema no 
longer existed. There were no differences in DFCO, TLC, RV, or compliance between 
vaccinia-treated or mock-treated animals (Fig. 5.5B-E).  
 
We then intratracheally instilled 3U elastase to C57BL/6J mice 7 days before intranasal 
infection with vaccinia and obtained the functional data on day 21 post-elastase instillation 
(Fig. 5.6). There were slight decreases in DFCO and increases in TLC in the mice who 
received vaccinia compared to the ones who did not.  However, these changes did not reach 
a significance level of 0.05. Only lung compliance was found to be significantly higher in 




5.3.4 Priming with vaccinia reduces the sensitivity to develop elastase-induced 
emphysema in BALB/cJ mice 
Since it is known that BALB/c and C57BL/6 mice exhibit distinct responses to viral 
infection [536] as well as dissimilar sensitivity to developing elastase-induced emphysema 
(Chapter 3), we repeated experiments in BALB/c mice. BALB/cJ mice were infected with 2 
x 106 pfu vaccinica by the intranasal route, and then instilled with either 1.5U, 3U or 6U of 
elastase seven days later. Twenty-one days after the treatment with elastase, animals were 
subjected to pulmonary function tests and their lung were collected to evaluate morphology 
(Fig. 5.7). Surprisingly, opposite results were obtained in the BALB/cJ strain, compared to 
C57BL/6 mice. Vaccinia-treated BALB/cJ mice who received 1.5 and 3 U elastase showed 
reduced degrees of emphysematous changes as observed by diminished TLC, RV, and 
compliance compared to mice without vaccinia who received the same dose of elastase.  
While all 10 BALB/cJ mice receiving 6U elastase were found dead within 48 hours after 
elastase administration, this mortality rate was significantly reduced to 40% in BALB/cJ pre-
infected with vaccinia. Similar to C57BL/6J mice, vaccinia alone had no detectable effect on 
pulmonary function measurements. These functional data were supported by the histological 
sections (Fig. 5.8). BALB/cJ mice given vaccinia developed less severe elastase-induced 
alveolar damage than mice with no infection. 
 
5.3.5 Pre-infection with influenza virus modifies the sensitivity to develop 
elastase-induced emphysema in BALB/cJ mice, but not in C57BL/6J mice 
Because influenza virus is much more relevant to COPD patients than vaccinia virus, we 
also evaluated the effect of pre-infection with influenza virus on the development of 
elastase-induced pulmonary emphysema in both C57BL/6J and BALB/cJ mice. We 
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inoculated C57BL/6J and BALB/cJ mice via the intranasal route with mouse adapted 
influenza A virus H1N1/PR8 (50 TCID50). All mock-infected mice received an equivalent 
volume of DMEM media. After 14 days of infection, either 3 units of porcine elastase or 
PBS was delivered to the mice via intratracheal route. The lung properties were measured 
and lung tissue was collected at day 21 post-elastase delivery. In contrast to vaccinia, 
influenza virus failed to enhance the severity of elastase-induced emphysema in C57BL/6J 
mice (Fig. 5.9). No significant differences were observed in DFCO, TLC, RV, or compliance 
between influenza-infected and mocked-infected mice in both PBS and elastase groups. 
However, similar to vaccinia, pre-exposure to influenza in BALB/cJ mice significantly 
attenuated the increases in TLC, RV, and compliance following the elastase insult (Fig. 5.10). 
Comparable degree of emphysematous lesions were confirmed by histological assessment 
between elastase-treated C57BL/6J mice who were either pre-infected with influenza or not, 
whereas airspace enlargement caused by elastase was less conspicuous in influenza-exposed 
BALB/cJ mice (Fig. 5.11). Of note, the lung tissue sections from BALB/cJ mice in the 
influenza/PBS group displayed a noticeable degree of peribronchiolar and perivascular 
lymphoid tissues (Fig .5.11B).  These changes were reflected by marginal drops in DFCO and 
TLC when compared to PBS/Vehicle control animals (Fig. 5.10B-C). 
 
5.4 Discussion 
Exacerbation from respiratory bacterial/viral infection is a major concern for 
COPD/emphysema management, because such infections can impair patients' quality of life, 
decrease their health status, accelerate the progression of diseases and lead to life-threatening 
complications [31]. Although emphysema per se can develop in a sterile alveolar 
inflammation environment, and there is no evidence showing that pathogens can initiate the 
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destruction of alveolar ultrastructure leading to emphysema, we have investigated whether 
these infections can change the inflammatory milieu sufficiently to affect the development of 
emphysema initiated by other stimuli. Most of the studies on exacerbation of COPD in 
animal models focused on how host defenses respond to cigarette smoke, the primary 
etiological factor of COPD. These studies examined how the infection burdens impacts the 
clearance of pathogens and how combined cigarette smoke, combined with infection, 
impacts pulmonary inflammation ([338, 537-539]). On the other hand, few studies have 
examined how infection can modulate the functional progression of emphysema. To date, 
only Foronjy et al. and Ganesan et al. showed that respiratory syncytial virus and Haemophilus 
influenzae infection could augment the severity of chronic cigarette smoke-induced 
inflammation and emphysema in the lungs [339, 341]. Here, we have studied the effect of 
viral infection on the development of elastase-induced emphysema. 
 
We first investigated the role of vaccinia virus on elastase-induced emphysema. Modified 
vaccinia virus Ankara (MVA) used in this study was originally adapted and derived by serial 
passage in chicken embryo fibroblast chicken [540]. During extended passage, MVA 
becomes a highly attenuated strain of vaccinia virus which contains multiple deletion and 
mutations in its genome compared to the parental strain, and it loses replication capacity in 
almost all mammalian cells, but it still contains some host immunomodulatory proteins 
found in wild-type orthopoxviruses, including complement control protein (virulence factor) 
[541-543]. We selected MVA vaccinia strain to use in this study because of its several 
advantages. First, it is safe to use in both humans and mice because of its defectiveness in 
propagation as seen by no detectable pathology in the lungs (Fig. 5.2, 5.8). Second, several 
investigations in both pre-clinical studies and clinical trials have used MVA vaccinia as a 
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target protein-expressing vector to develop vaccines for many cancers, including lung cancer 
which often co-exists with COPD/emphysema [523, 544-546]. Last, despite its loss of 
several factors during its long time passage, MVA retains its immunogeneticity, and its 
induction of immune responses remains potent and equivalent to a fully replicating vaccinia 
virus [547, 548]. Our data show opposite effects between C57BL/6J and BALB/cJ mice in 
the development of elastase-induced emphysema when the mice were pre-infected with 
vaccinia virus. It is well known that C57BL/6 display a Th1-biased immunity during 
infection [416, 417],  and vaccinia virus can induce strong IFN--producing Th1 responses 
as well as augmented NK cells [524]. In Chapter 3 and 4, we showed that there was an up-
regulation of IFN- expression following to elastase administration in C57BL/6J mice, and 
IFN--/- mice failed to develop emphysema induced by elastase. Also, we also identified 
marked increases of CD4+, CD8+ and NK cells that have the potential to produce IFN- 
shortly after elastase administration (Fig. 5.4). Collectively, we hypothesized that vaccinia 
virus elevated the level of IFN- which subsequently exacerbated the severity of emphysema 
induced by elastase. Conversely, BALB/c mice have considerably less ability to develop a 
Th1 response [549], and our data from Chapter 3 showed that the development of 
emphysema in BALB/cJ mice was more likely due to increased IL-17A production and 
MMP-producing alternatively activated macrophages, rather than IFN-. A previous study 
on vaccination and pulmonary fibrosis from our colleagues demonstrated that vaccinia 
reduced both Th17 and alternatively activated macrophages responses in the lungs post-
bleomycin exposure [525]. We reasoned that decreases in the induction of IL-17 and M2 




We also examined the effect of a more relevant viral infection on elastase-induced 
emphysema using the influenza A virus strain H1N1/PR8.  MVA vaccinia virus and PR8 
influenza virus are different in several important ways. MVA vaccinia virus contains a DNA 
genome, has a lack of replication capacity in most of murine cells, and has relatively low 
virulence so it can be used under laboratory conditions at biosafety level 1. Conversely, 
influenza virus has RNA as a genome, and it can infect and reproduce in several cell types 
along the respiratory tract including ciliated/non-ciliated bronchial cells, alveolar epithelial 
type I cells, type II cells, and alveolar macrophages. Infection subsequently leads to 
pathologies such as marked bronchitis, alveolitis and mucus cell metaplasia, and the virus 
require handling at biosafety level 2 [550, 551]. Of note, due to its relatively high 
pathogenicity, intranasal inoculation of influenza virus causes loss about 20% of body weight 
at day 7 after inoculation, and administration of elastase on that day leads to almost 100% 
mortality of mice within 48 hours. Thus, we adapted the protocol to give elastase to the mice 
14 days after this viral infection instead of the 7 days used with vaccinia. 
 
Our results showed that previous infection with influenza virus 14 days beforehand did not 
alter elastase-induced emphysema in C57BL/6J mice. PR8 influenza virus can infect and 
rapidly replicate in the lung after intranasal administration. The virus titers reached a peak at 
2-5 days post-inoculation and virus was cleared out by day 9 [552, 553]. The peak 
inflammatory cell infiltration together with the peak of IFN-  expression were found close 
to the time of peak viral load in the lung, and the levels of most inflammatory cytokines 
(including IFN-) return to baseline levels within one week post-infection [553, 554]. 
Previously, in Chapter 3, we proposed that the pathology of emphysema in C57BL/6J was 
mediated by IFN-, and this is consistent with the observed increased level of IFN- induced 
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by the vaccinia infection.  Perhaps most of the altered immune response from the viral 
infection might be so minimal at day 14 after infection, that it would have little effect on 
elastase-induced emphysema. 
 
On the other hand, a prior influenza virus infection did abrogate the development of 
elastase-induced emphysema in BALB/cJ mice. Similar to vaccinia virus, intranasal 
inoculation of influenza H1N1/PR8 was found to significantly decrease pulmonary IL-17A 
level in BALB/c mice [555]. Influenza virus could also infect alveolar macrophages and, by 
tracking macrophage dynamics with in vivo labeling of lung resident macrophages, it was 
shown that more than 90% of alveolar macrophages were depleted (due to a cell death 
mechanism) by day 7 after sublethal PR8 influenza infection in this strain of mice [556]. 
Although this study showed that replenishment of macrophages was completed by day 11, 
another study demonstrated that the function of alveolar macrophages isolated after 
resolution of influenza infection did not return to the pre-infection state [557]. 
Desensitization of intracellular mechanisms, such as the NF-B signaling pathway, was 
evident and sustained for several months even after viral clearance. We suspect that both a 
decline in IL-17 level and impaired function of alveolar macrophages in the lungs facilitated 
the lesser progressive emphysema induced by the acute elastase insult. 
 
Overall, one of the most important finding of this study is the opposite responses of prior 
respiratory infection on the development of emphysema in the two mouse strain studied. 
This finding suggests a complex interaction between host genetic predisposition and 
environmental factors in determining the susceptibility to emphysema. This might be part of 
the reason why not all smokers with different infection history and with different genetic 
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backgrounds are equally susceptible to cigarette smoke.  Since most of the studies on COPD 
exacerbation in animal models have been performed in only one genetically-identical animal 
strain (commonly the C57BL/6 strain), these published results thus might not be easily 
extrapolateable to humans. 
 
In summary, we conclude that prior viral infection can impact the pulmonary immune 
environment, and in turn can modulate the susceptibility to emphysema. This effect can 
manifest itself differently in different genetic backgrounds, but the exact mechanisms 
underlying this phenomenon need further study. 
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Figure 5.1 Effect of priming with vaccinia (1 week before) on pulmonary function and 
mechanics in elastase-induced emphysema in C57BL/6J mice. (A) Schematic of the 
experimental design showing pre-infection with vaccinia 7 days prior to elastase 
administration (B) DFCO (C) TLC (D) RV and (E) Crs of C57BL/6J mice on Day 21 after 
elastase. (n = 5-15 mice per group). Unpaired t-test analysis: N.S. = not significant, * = p < 
0.05, ** = p < 0.01, *** = p < 0.001 comparing vaccinated group to unvaccinated group at 





Figure 5.2 Effect of priming with vaccinia (1 week before) on histological assessment 
in elastase-induced emphysema in C57BL/6J mice. (A) Representative H&E-stained 
lung sections on day 21 post elastase administration from vaccinia-primed vs non-primed 
C57BL/6J mice given different doses of elastase or PBS. Original magnification x40. Scale 
bar = 500 m. (B) Quantitative morphometric assessment of airspace enlargement. (n = 9 






Figure 5.3 Effect of priming with vaccinia (1 week before) on granulocytes/myeloid 
cell populations in elastase-treated C57BL/6J mice. (A) Schematic of the experimental 
design showing either pre-infection with vaccinia or PBS 7 days prior to 3U elastase 
administration. Numbers of (B) Polymorphonuclear cells (C) Monocytes (D) Dendritic cells 
and (E) Macrophages per right lung of C57BL/6J mice on Day 0, 2, 7 and 14 after elastase. 
(n = 3). Unpaired t-test analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 comparing 






Figure 5.4 Effect of priming with vaccinia (1 week before) on lymphocyte 
populations in elastase-treated C57BL/6J mice. Numbers of (A) CD4+ T cells (B) CD8+ 
T cells (C)  T cells (D) B cells (E) NK cells and (F) NKT cells per right lung of C57BL/6J 
mice on Day 0, 2, 7 and 14 after elastase. (n = 3). Unpaired t-test analysis: * = p < 0.05, ** = 








Figure 5.5 Effect of priming with vaccinia (3 weeks before) on elastase-induced 
emphysema in C57BL/6J mice. (A) Schematic of the experimental design showing pre-
infection with vaccinia 21 days prior to 3U elastase administration (B) DFCO (C) TLC (D) 
RV and (E) Crs of C57BL/6J mice on Day 21 after elastase. (n = 5 mice per group). Two-
way ANOVA analysis: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 comparing elastase-
treated group to PBS control group. N.S. = no significant difference were observed between 












Figure 5.6 Effect of post-exposure with vaccinia (1 week after) on elastase-induced 
emphysema in C57BL/6J mice. (A) Schematic of the experimental design showing post-
infection with vaccinia 7 days after 3U elastase administration (B) DFCO (C) TLC (D) RV 
and (E) Crs of C57BL/6J mice on Day 21 after elastase. (n = 5 mice per group). Unpaired t-







Figure 5.7 Effect of priming with vaccinia on pulmonary function and mechanics in 
elastase-induced emphysema in BALB/cJ mice. (A) Schematic of the experimental 
design showing pre-infection with vaccinia 7 days prior to elastase administration (B) DFCO 
(C) TLC (D) RV and (E) Crs of BALB/cJ mice on Day 21 after elastase. (n = 5-15 mice per 
group). Unpaired t-test analysis: N.S. = not significant, * = p < 0.05, ** = p < 0.01 









Figure 5.8 Effect of priming with vaccinia on histological assessment in elastase-
induced emphysema in BALB/cJ mice. Representative H&E-stained lung sections from 
vaccinia-primed vs non-primed BALB/cJ mice given different doses of elastase or PBS on 





















Figure 5.9 Effect of priming with influenza virus (2 weeks before) on elastase-
induced emphysema in C57BL/6J mice. (A) Schematic of the experimental design 
showing pre-infection with influenza virus 14 days prior to 3U elastase administration (B) 
DFCO (C) TLC (D) RV and (E) Crs of C57BL/6J mice on Day 21 after elastase. (n = 3-6 
mice per group). Two-way ANOVA analysis: * = p < 0.05 comparing elastase-treated group 
to PBS control group. N.S. = no significant differences were observed between influenza-

















Figure 5.10 Effect of priming with influenza virus (2 weeks before) on elastase-
induced emphysema in BALB/cJ mice. (A) Schematic of the experimental design 
showing pre-infection with influenza virus 14 days prior to 3U elastase administration (B) 
DFCO (C) TLC (D) RV and (E) Crs of BALB/cJ mice on Day 21 after given elastase. (n = 3-
6 mice per group). Two-way ANOVA analysis: N.S. = not significant, * = p < 0.05, ** = p < 
0.01, *** = p < 0.001 comparing elastase-treated group to PBS control group. † = p < 0.05, 




Figure 5.11 Effect of priming with influenza virus (2 weeks before) on histological 
assessment of elastase-induced emphysema in C57BL/6J and BALB/cJ mice. 
Representative H&E-stained lung sections from influenza-infected vs non-infected (A) 
C57BL/6J and (B) BALB/cJ mice given 3U elastase or PBS on day 21 post elastase 























In the present study, we focused on the identification of immunological pathways that are 
involved in determining the susceptibility to emphysema in a mouse model of the disease. 
First, we compared the susceptibility to emphysema in two commonly used strains of mice, 
C57BL/6J and BALB/cJ, which have shown disparate phenotypic and immune responses in 
other disease models. We used pulmonary functional tests, lung mechanics, and lung 
histopathology to show that BALB/cJ mice were not only much more sensitive to 
pulmonary hemorrhage, edema, and alveolar tissue destruction, but also show an accelerated 
chronic progression of elastase-induced emphysema compared to C57BL/6J mice. This 
response to elastase by the BALB/cJ strain is consistent with the exacerbated phenotypes 
reported for other murine emphysema models, including chronic ozone and hookworm 
infection. We then showed how differences in the production of IFN-, IL-17A, and the 
activation status of macrophages between these two strains might contribute to the degree of 
pathology in the lung. While the resistant C57BL/6J strain had greater increases in the 
expression of IFN-, the sensitive BALB/cJ mice had a higher elevation of Th17-associated 
cytokine gene expression (IL-17A, IL-6, IL-1 and IL-18) and greater activation of 
macrophages (with both M1 and M2 markers), especially in the expression of the genes 
encoding the proteases MMP-2 and MMP-12. 
 
To clarify the significance of these cytokines and their activation, studies were conducted 
using mice carrying targeted genetic manipulation of several key genes. We showed that 
deficiency of either IFN- or IL-17A ameliorated the severity of elastase-induced 
emphysema. These results indicate a potential contribution of these cytokines/signaling 
pathways in the general development of emphysema. Also, the data suggest that different 
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pathways in the two strains of mice might primarily drive elastase-induced emphysema, 
specifically by IFN- in C57BL/6J mice and by IL-17A in BALB/cJ mice. 
 
Somewhat surprisingly, we found that systemic depletion of neutrophils or the lack of B and 
T lymphocytes in RAG-1-/- mice had no significant impact on the degree of elastase-induced 
emphysema. However, our data does suggest an important role for macrophages in the 
pathogenesis of elastase-induced emphysema. Mice deficient in key transcriptional regulators 
of alternative macrophage activation (i.e., STAT6 and STAT3) were moderately protected 
from elastase-induced emphysema. Given that BALB/cJ mice had a greater number of long-
lived macrophages in the BAL and higher expression of activation markers including matrix-
remodeling enzymes (MMP-2, MMP-12), these changes in macrophage activation might 
account for the BALB/cJ strain showing increased sensitivity to emphysema in both the 
acute and chronic disease stages.  
 
Our experiments also showed a potential role for the IL-33/ST2/MyD88 signaling pathway 
in the progression of elastase-induced emphysema. IL-33 is released during necrotic cell 
death or epithelial damage and has been shown to enhance the alternative activation of 
macrophages [488]. We observed increased IL-33 and ST2 expression after elastase injury, 
which is consistent with previous data from our laboratory showing elevated IL-33 protein 
in the lungs following elastase challenge. Blockade of this IL-33/ST2/MyD88 axis by using 
mice lacking either the ST2 receptor or the MyD88 adaptor protein had a significant impact 








Figure 6.1 Proposed model for the pathogenesis of elastase-induced emphysema and 
the effects of viral infection. The data from this study and other previous studies are 






Fig. 6-1 represents a mechanistic model for maintenance of progressive lung damage in 
elastase-induced experimental emphysema that summarizes the relevant signaling pathways 
supported by the data presented in this dissertation. This model places macrophages as the 
central effector cells, and their activation leads to the release of several extracellular matrix-
degrading proteases (such as MMP-2, MMP-12) that subsequently contribute to the 
progression of emphysema. The activation of these deleterious macrophages is in part via 
STAT6 and STAT3 phosphorylation and can be triggered and modulated by several 
mediators such as IL-33, IL-17A, and IFN-.  So with the initial acute elastase insult, there is 
damage of epithelial tissue, degradation of the extracellular matrix, and generation of cells 
undergoing necrotic and pyroptotic death, which serves to drive the release of the epithelial-
derived alarmin, IL-33. We hypothesize that IL-33 binds directly to the ST2/IL1RAP 
receptor on the surface of alveolar macrophages and activates them toward a protease-
secreting phenotype. Alternatively, IL-33 may bind to receptors on type 2 innate lymphoid 
cells (ILC2) causing them to release IL-13, which results in M2 activation of macrophages. 
These two modes of IL-33-meidated activation of macrophages are not mutually exclusive.  
In addition, lung macrophages also express the receptor for IL-17A. Elevated IL-17A, 
especially in BALB/cJ mice after elastase challenge, can enhance the production of MMPs 
by macrophages. The activated macrophages might also serve as autocrine sources of IL-6 
and IL-10, which in turn promote STAT3 phosphorylation and perpetuate their own 
activation. Lastly, MMP expression in macrophages might be induced by IFN- following 
the administration of elastase, particularly in C57BL/6J mice. Although MMPs were shown 
to be induced in alternatively activated macrophages in vitro, some studies have suggested 
that IFN-, primarily an inducer of classical macrophage activation, can indirectly stimulate 




This hypothesized schematic pathway is supported by several human and animal studies. 
Patients with COPD/emphysema and animals exposed to cigarette smoke often have 
elevations of IFN-, IL-17A, as well as activated macrophages in the lungs [160, 167, 169, 
181, 187, 464, 465, 475]. Overexpression of IFN- in the murine lung can induce MMP-12 
production leading to pulmonary emphysema [173]. Lung specific, transgenic mice 
overexpressing-IL-17A had more BAL macrophages, greater MMP-12 expression, and had 
exaggerated emphysema when exposed to cigarette smoke [187]. Conversely, either IFN- or 
IL-17A deficient mice exposed to cigarette smoke had fewer numbers of BAL macrophages, 
reduced expression of MMP-12, and developed a lesser degree of emphysema compared to 
wild-type controls [187, 511].  
 
The development, progression and severity of emphysema in humans is influence by a 
number of environmental factors.  To provide evidence that environmental factors impact 
progression in the elastase-induced experimental emphysema model (Fig. 6-1), we utilized 
two viral infection models: vaccinia and influenza A. Vaccinia virus was selected because it 
has been shown to induce IFN- production and alternative macrophage activation while 
decreasing IL-17 production [525]. Our study is the first to show how a prior infection can 
affect the development of elastase-induced emphysema. Interestingly, pre-infection with 
vaccinia virus resulted in differential effects on elastase-induced emphysema between 
C57BL/6J and BALB/cJ mice. In C57BL/6J mice, prior vaccinia virus amplified the 
elastase-induced emphysematous changes, possibly due to the induction of IFN- by 
vaccinia virus in Th1-biased C57BL/6J mice.  In contrast, in BALB/cJ mice vaccinia virus 
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prevented the development of emphysema, possibly due to the impaired production of IL-
17 following vaccinia infection. We confirmed these results by using influenza A virus, a 
virus that is more relevant to humans. Similar to the vaccinia virus results, pre-inoculation of 
influenza A virus could ameliorate the severity of elastase-induced emphysema in BALB/cJ 
mice. However, we did not observe the significant impact of infection with influenza A virus 
(14 days prior to elastase challenge) on the development of emphysema in C57BL/6J mice. 
This lack of effect may have been caused by the increased (14 day) length of time post-
infection when the mice were studied. 
 
Overall, these results show that the underlying mechanisms of elastase-induced emphysema 
are quite complex and involve several types of immune cells and mediators beyond the 
proteolytic activity of exogenously-administered elastase. As such, emphysema can be 
considered as a disease that results from the outcome of multiple hits originating from a 
variety of initiating factors (e.g. cigarette smoke), with upstream and downstream modulation 
by a complex combination of both genetic and environmental factors.  
 
An important finding from this thesis is that BALB/cJ mice are more sensitive to elastase-
induced emphysema than C57BL/6J mice.  This result is advantageous, since an 
understanding of the reasons for this differential sensitivity in the BALB/cJ strain might lead 
to mechanistic insights that could lead to new therapeutic interventions to delay or lessen the 
progression of emphysema.  Another important (and perhaps related) finding is the 
differential effect in the two mouse strains when infected with virus prior to an elastase 
insult.  Prior infection with vaccinia augmented the severity of the elastase-induced 
emphysema in C57BL/6J mice, but it significantly lessened the emphysematous outcome in 
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BALB/cJ mice.  The implications of this could be profound, since many studies often use 
only one genetically identical inbred mouse strain (particularly C57BL/6J mice) to study 
emphysema, and it is now quite reasonable to question whether such published observations 
can be generally extrapolated to what might happen in the context of human emphysema. 
Studies utilizing just a single mouse strain may in fact be representative of only single 
individuals or groups of genetically similar individuals, and likely would not reflect the 
diversity of responsiveness you might expect to exist within a heterogeneous population.  
Ultimately, the data presented here might provide some insight as to why not all smokers 
develop emphysema.  Furthermore, since many drugs have been shown to provide effective 
protection against emphysema in animal models, but have failed to translate successfully into 
the clinic, our results offer a possible explanation for this disparity.  Even if a therapy holds 
promise for certain individuals, it may not be generally useful across a genetically diverse 
population. 
 
A comment on the lung phenotyping approaches utilized in our mouse studies is also 
warranted here.  One of the essential steps in the study of emphysema is an unbiased and 
accurate quantitative assessment of emphysematous changes to the lung. Although a careful 
quantitation of airspace size (Lm) should be mandatory to properly characterize changes to 
lung structure, an increase in Lm by itself does not always implicate the destruction of 
alveolar walls, because Lm is also a function of lung volume [558].  Many published studies 
fail to consider how changes in lung volume can affect Lm, and most studies do not measure 
lung volumes. Thus, there is an ongoing dispute over the most appropriate morphometric 
quantitative analyses for emphysematous changes in animal models and in humans [293, 558, 
559]. Of importance, Lm is not used routinely to identify emphysema in humans. While most 
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investigators attempt to demonstrate emphysematous changes in animal models solely based 
on changes to Lm, one of the strengths of the studies presented here is the combination of 
quantitative assessments of histological sections used in conjunction with pulmonary 
function tests. The loss of alveolar walls (gas exchange surface area) and the subsequent loss 
of elastic recoil were quantified by DFCO measurements and lung P-V curves to demonstrate 
phenotypic physiological changes during the progression of emphysema. Indeed, DFCO is a 
functional test quite similar to what is more generally used in human subjects (DLCO). 
Accurate phenotyping in mice provides animal studies with more meaningful data that can 
then be used to better link potential disease mechanisms and therapeutic interventions 
discovered in the lab to changes in lung structure and function observed in the clinic.  
 
6.2 Limitations of the study 
Although the elastase-induced emphysema model resembles human emphysema in many 
ways, thereby providing a good opportunity to study the progressive nature of the disease, 
this model has several important limitations. The elastase model can be considered one of 
chronic sterile inflammation, originating from a single insult which initially causes acute lung 
injury but subsequently triggers a mild degree of chronic inflammation that eventually leads 
to progressive emphysema. Most of the sustained elevation of immune cells following 
elastase injury in the lung is attributable to macrophages. Neutrophils and lymphocytes are 
recruited only during the first week of injury and are quickly cleared from the lungs. After 
much experimentation we could find no convincing contribution of these cells beyond the 
acute phase of disease onset. However, it would be presumptuous to entirely rule out the 
importance of neutrophils and lymphocytes in human emphysema. In humans, the onset of 
emphysema may involve the repetition of insults that result in the accumulation of 
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inflammatory cells including neutrophils and lymphocytes in the lung parenchyma and 
alveolar space. And if there were a long-term presence of neutrophils and lymphocytes in the 
lungs of patients with emphysema, particularly during infections, these cells might play a 
bigger role in the development of human emphysema than what we can accurately study 
following an acute elastase insult in our animal model.  
 
To explore the immunological pathways involved in the pathogenesis of emphysema in 
Chapter 4, we utilized genetically-engineered mice with deletions of relevant immune genes. 
While knockout animal technology represents a valuable research tool, several concerns with 
such knockout mice should be addressed. One important drawback of using genetically 
engineered mice is that the absence of a specific gene itself might have some consequences, 
which affect either the expression or the function of other genes and could have secondary 
effects on the outcome of experiments and their subsequent interpretation. Also, redundant 
mechanisms might be activated to compensate for a specific gene deletion. Moreover, the 
mixed genetic background of the knockout mice may also impact the experimental results.  
Knockout mice were originally generated from 129/Sv embryonic stem cells, fused with 
C57BL/6J blastocysts, and then backcrossed for several generations onto the desired 
background strains. However, given the limitation of resources, it was not feasible to retrace 
the number of generations each of our knockout strains were backcrossed and thus how 
pure the present genetic background is. Furthermore, it should be noted that even ten 
generations of backcrossing might not be sufficient to adequately homogenize the genetic 
background, and thus sufficient backcrossing and colony maintenance represents a daunting 
task [560].  In this thesis we emphasize that there are different susceptibilities to emphysema 
between two strains of mice. However, if the knockout mice (particularly on the BALB/cJ 
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background) used in this study retained some degree of coding or regulatory content from 
other background strains, it might have a significant impact on our results. In practice, 
although often not achievable, it would be best to breed these genetically altered mice as 
heterozygous x heterozygous and use the littermate wild-types derived from the same parent 
strain that was originally used to backcross the mice as controls to avoid genetic background 
effects. Also, other approaches such as the recently described CRISPR/Cas9 knockout 
system and the targeting of specific cytokines or signaling pathways with neutralizing 
antibodies or specific inhibitors should be done to validate the results from conventional 
knockout animal experiments. 
 
6.3 Moving forward: Future directions 
While this dissertation has yielded several interesting results, there are many outstanding 
issues to be addressed. 
 
(i) Contribution of macrophages to the development of emphysema. In this study, 
we identified a role for macrophages as key effector cells in the pathogenesis of emphysema. 
This speculation was based on data showing that macrophages can produce several tissue 
degrading enzymes. In addition, a deficiency of either STAT6 or STAT3, which can alter the 
activation of macrophages, offered some degree of protection from elastase-induced 
emphysema. However, these observations do not truly verify the contribution of 
macrophages, since these enzymes can also be produced by other cell types.  Also, the 
STAT6-/- mice and Cre-Lyz/STAT3fl/fl mice we used for our studies do not lack these genes 
only in macrophages, but also in other cell types, which could act separately from 
macrophage activation. Other approaches, such as the depletion of macrophages, are 
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necessary in order to confirm the role of macrophages. Previous data by Dr. Daniel Lagassé, 
a former graduate student in our group, showed that the increasing number of macrophages 
in the lung following elastase treatment resulted from the proliferation of CD11c+ alveolar 
macrophages residing in the lung, rather than from blood monocytes recruited from the 
peripheral circulation. This result adds the possibility of using transgenic mice containing the 
diphtheria toxin receptor gene under the CD11c promoter (CD11c-DTR mice) as an 
alternative way to deplete alveolar macrophages.  
 
Although we have paid much attention here to alternatively activated macrophages, 
classically activated or regulatory macrophages might also play important roles in 
emphysema. There have been many studies looking at the activation status of macrophages 
in human COPD/emphysema. Some investigators have shown a predominance of M1 
macrophages, whereas others have described the presence of M2 macrophages or 
macrophages that display a mix of the M1 and M2 phenotypes. One issue that further 
complicates this issue of macrophage activation is the inconsistent use of the markers used 
to characterize these cells across a number of these studies. Furthermore, M2 macrophages 
can be subdivided into several (not yet standardized) subtypes. A new concept of regulatory 
macrophages, distinct from classically and alternatively activated macrophages has also been 
proposed [561]. It is critical to this field to standardize the characterization of these cell types 
in order to provide consistency among investigators. A better understanding of macrophage 
heterogeneity in the pathogenesis of emphysema may reveal a better molecular target to 




Matrix metalloprotease-12 (MMP-12) is mainly produced by macrophages and is believed by 
many to account for the major matrix destruction in the lungs of mice. This hypothesis is 
based on several studies showing an association between the expression of lung MMP-12 
and the severity of emphysema in experimental rodents. Unfortunately, although MMP-12 
inhibitors have been developed, none of them have been successfully shown to be beneficial 
for treating emphysema in humans. This might result for several reasons. (i) There have been 
controversial reports in humans questioning whether MMP-12 is actually up-regulated in 
COPD patients [562]. (ii) MMP-12 in rodents has a pro-inflammatory effect, whereas MMP-
12 in humans is not necessarily pro-inflammatory and actually inhibits neutrophil 
recruitment in certain scenarios. In general, it seems unlikely that the inhibition of one 
specific enzyme could be used as a broad-spectrum therapy to treat emphysema. A more 
realistic approach to treat emphysema might be to take advantage of the plasticity of 
macrophages to reprogram or shift their polarization status to a more beneficial phenotype. 
 
(ii) Source of IL-17A. Our data showed a role of IL-17A in modulating the function 
of macrophages and determining the extent of elastase-induced emphysema. However, data 
obtained from RAG-1-/- in our model would seem to suggest that the critical source of IL-
17A is not T cells - normally the primary source of IL-17A. So which cells might be 
producing this cytokine in response to elastase injury? Other cell types now shown to secrete 
IL-17A include type 3 innate lymphoid cells (ILC3s), NK cells, monocytes, and even alveolar 
macrophages [525, 563]. For example, Song et al. showed that IL-17A produced by alveolar 
macrophages can be mediated by allergic challenges [563]. We speculate that elevated IL-17A 
in our model might be coming from either alveolar macrophages or ILC3s. However, this 




(iii) Significance of IL-33/ST2 and type 2 cytokines. One of the important findings 
in this dissertation is the significant role of the IL-33/ST2 axis in elastase-induced 
emphysema. Although IL-33 can stimulate activation markers in macrophages by itself [564], 
it is also well known to be able to amplify the alternative activation of macrophages by 
eliciting IL-13 secretion from ILC2s. It would be interesting to investigate whether the 
production of IL-13 by ILC2, as induced by IL-33, plays any role in the elastase-induced 
emphysema model. Even though we did not observe an increased expression of IL-13 in the 
lung after elastase administration, it is important to note that this effect was only shown at 
the mRNA level in the whole lung, and not in isolated cells or at the protein level.  In 
addition, there are relatively few ILC2 cells in the lungs, so changes in their expression of IL-
13 might be masked by changes in other more abundant cell types. Moreover, although we 
have emphasized an important contribution of IFN- and IL-17A, we have not entirely ruled 
out roles for type 2 cytokines (IL-4, IL-5 and IL-13). Indeed, we also observed an elevated 
expression level of IL-4 and IL-5 in response to elastase challenge at certain time points, so 
these cytokines might still play some role in the pathologic mechanism. . 
 
Another unknown pertains to what forms of IL-33 are involved during elastase-induced 
emphysema. IL-33 is constitutively expressed particularly in Type II epithelial cells of the 
mouse lung as a 30 kDa full-length nuclear protein. After cellular injury, IL-33 can be 
released to the extracellular space where it is subjected to cleavage by several proteolytic 
enzymes into a variety of highly bioactive forms [565]. Given the fact that there are a 
number of proteases present in the alveolar space after elastase injury, it would be important 
to determine which enzymes are involved in the cleavage of pro-IL-33 and which bioactive 
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forms of IL-33 play the most important role in our model. Furthermore, the IL-33 receptor, 
ST2, also has two isoforms: a membrane-bound receptor form (known as ST2L) and a 
soluble ST2 form (sST2). The soluble ST2 form lacks the transmembrane domain and is 
proposed to be a decoy receptor with no intrinsic signaling ability. This raises the question 
whether the neutralization of IL-33 by administration of sST2 could possibly serve as a 
therapeutic intervention in emphysema. 
 
(iv) Role of viral infection. Our data also show that the prior exposure to viruses can 
alter the severity of elastase-induced emphysema. However, the mechanisms underlying this 
effect are unclear, and it warrants further study. The levels of IFN- and IL-17A and the 
function of macrophages (including MMP-12 expression) need to be assessed following viral 
inoculation and elastase administration. Further experiments using knockout mice (e.g. IFN-
-/- or IL-17A-/-) and/or neutralizing antibodies should be performed to further clarify the 
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